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Abstract
Pediatric and adult diseases characterized by lung hypoplasia or dysplasia are an epidemiological 
relevant issue, involving important morbidity and mortality rates. The understanding of the complex 
process of lung development, regulated by several genetic, chemical and physical determinants, 
has clinical relevance since it can open new perspectives in the treatment of these lung diseases 
as well as modulation of lung repair. Regardless of the advanced knowledge of normal lung growth, 
there are several possible regulators and determinants that need to be investigated. Therefore, the 
main aim of the present dissertation was to discover novel physiological regulators of normal lung 
morphogenesis, expecting to contribute for the development of new strategies for lung diseases, 
namely for fetal lung hypoplasia, in context of congenital diaphragmatic hernia (CDH).
Using different laboratorial approaches, namely histological, molecular, and functional studies, 
the role of glycoprotein 130 (gp130) family of cytokines and renin-angiotensin system (RAS) was 
evaluated throughout fetal lung development, in rat model of either normal and hypoplastic (the 
nitrofen-induced CDH model) lung development..
In this thesis, it was demonstrated that interleukin 6 (IL-6) and leukemia-inhibitory factor (LIF) are 
constitutively expressed during fetal lung development and they have a physiological role on pul-
monary branching mechanisms. Indeed, cytokines signaling through gp130 homodimers (IL-6 and 
IL-11) stimulate lung branching, whereas cytokines acting in a gp130 heterodimer receptor (LIF, 
oncostatin M) inhibit lung growth. It was also established that there is a local and physiologically 
active RAS during lung morphogenesis. In fact, all RAS components are constitutively expressed in 
the lung throughout gestation and angiotensin II (ANG II), the physiologically active peptide of RAS, 
induces a stimulatory effect on lung branching, mediated by type 1 (AT1) receptor of ANG II, through 
p44/42 and Akt phosphorylation. 
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After the description of these two new physiological regulators/modulators of fetal lung growth, 
gp130 family of cytokines and RAS, their role in pulmonary hypoplasia, in the CDH context, were 
assessed. First of all, it was showed that hypoplastic fetal lung has the intrinsic ability to regulate its 
growth and to recover from growth retardation through a way that resembles the catch-up growth 
phenomenon. Moreover, IL-6 might be involved in the mechanisms underlying this phenomenon. 
Finally, the discovery of RAS as a new regulator of fetal lung growth allowed the establishment of 
an antagonist of type 2 (AT2) receptor of ANG II (PD-123319) as a putative antenatal therapy for 
pathologies characterized by fetal lung hypoplasia, such as CDH. In vivo, in nitrofen-induced CDH 
model, antenatal PD-123319 treatment improved the key determinants of mortality associated with 
CDH, namely lung hypoplasia and pulmonary hypertension, and also improved lung function and 
survival, without maternal or fetal deleterious effects.
In summary, in this thesis, according to the proposed aims, two novel physiological regulators of 
fetal lung development were identified: gp130 family of cytokines and local lung RAS. Moreover, 
we demonstrated that fetal lung has the intrinsic ability to regulate its growth and proposed a 
model for regulation of correct lung size and growth. Nonetheless, future studies are necessary 
to clarify this regulatory loop and the mediators (afferent arms, sensors, efferent arms) involved 
on this hypothetic feedback mechanism of compensatory growth. Finally, we established that 
selective inhibition of AT2 receptor is a putative antenatal therapy for pathologies characterized by 
lung hypoplasia, such as CDH, which open perspectives for future pre-clinical studies.
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Resumo
As doenças pulmonares pediátricas ou do adulto, que cursam com hipoplasia ou displasia 
pulmonar, associam-se a elevadas taxas de morbilidade e mortalidade. A compreensão dos 
mecanismos complexos do desenvolvimento pulmonar, regulados por determinantes genéticos, 
químicos e mecânicos, apresenta relevância clínica ao permitir o desenho de novas abordagens 
terapêuticas que mimetizem o normal crescimento e maturação pulmonares, bem como a rege-
neração pulmonar. Nos últimos anos, o conhecimento sobre desenvolvimento pulmonar normal 
muito ter evoluído. Contudo, são vários os fatores de crescimento e reguladores que permane-
cem por esclarecer. Assim, nesta dissertação investigaram-se novos reguladores fisiológicos 
da morfogénese pulmonar, procurando contribuir para o desenvolvimento de novas estratégias 
terapêuticas para as doenças pulmonares, nomeadamente a hipoplasia pulmonar fetal, no con-
texto da hérnia diafragmática congénita (HDC).
No modelo animal do rato, quer em animais controlo quer no modelo de HDC induzida pelo 
nitrofeno, a função da família das citocinas da glicoproteína 130 (gp130) e do sistema renina-
angiotensina (SRA) foi avaliada ao longo do desenvolvimento pulmonar fetal. Diferentes técnicas 
laboratoriais foram utilizadas, nomeadamente estudos histológicos, moleculares e funcionais. 
Os nossos resultados demonstraram que a interleucina 6 (IL-6) e o fator inibidor da leucemia (LIF) 
são constitutivamente expressos ao longo do desenvolvimento pulmonar fetal e desempenham um 
papel fisiológico nos mecanismos de ramificação pulmonar. Assim, a IL-6 e a IL-11, cujos recetores 
são homodímeros da gp130, estimulam a ramificação pulmonar. Por sua vez, o LIF, a oncostatina 
M, que sinalizam via heterodímeros de gp130, inibem o crescimento pulmonar. Para além disso, 
foi também descrita a presença de um SRA local e fisiologicamente ativo durante a morfogénese 
pulmonar. Na verdade, todos os componentes do SRA são expressos no pulmão em todas as ida-
des gestacionais estudadas e a angiotensina II (ANG II), o peptídeo fisiologicamente ativo deste sis-
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tema, estimula a ramificação pulmonar, via recetor de tipo 1 (AT1) e a fosforilação da p44/42 e Akt.
Uma vez descritos estes dois novos reguladores/moduladores do crescimento pulmonar fetal, a 
família das citocinas da gp130 e o SRA, o seu papel na hipoplasia pulmonar fetal, no contexto da 
HDC, foi avaliado. Foi possível demonstrar que o pulmão fetal hipoplásico apresenta capacidade 
intrínseca para regular o seu crescimento e recuperar do atraso de crescimento por um mecanis-
mo similar ao clássico fenómeno de catch-up growth. A IL-6 revelou-se como um dos mediado-
res envolvidos nos mecanismos subjacentes a este fenómeno. Finalmente, a descoberta do SRA 
como um novo regulador do crescimento pulmonar fetal permitiu apresentar o PD-123319, um 
antagonista específico do recetor de tipo 2 da ANG II (AT2), como um potencial alvo terapêutico 
para patologias caraterizadas por hipoplasia pulmonar fetal, das quais a HDC é um exemplo. No 
modelo de HDC induzida pelo nitrofeno, in vivo, a administração materna antenatal de PD-123319 
melhorou os determinantes chave associados a esta patologia, nomeadamente a hipoplasia e 
hipertensão pulmonares, e melhorou a função pulmonar e a taxa de sobrevida, sem aparentes 
efeitos deletérios maternos ou fetais.
Em resumo, nesta tese, de acordo com os objetivos inicialmente estabelecidos, foram identi-
ficados dois novos reguladores fisiológicos do desenvolvimento pulmonar fetal: a família das 
citocinas da gp130 e o SRA pulmonar. Foi, também, demonstrado que o pulmão fetal apresenta 
capacidade intrínseca para regular o seu crescimento e foi proposta a existência de um modelo 
de regulação do crescimento pulmonar. Contudo, estudos futuros são necessários a fim de se 
clarificar este hipotético mecanismo de regulação do crescimento e os seus mediadores (vias 
aferentes, sensor e vias eferentes). Por fim, a apresentação do recetor AT2 como um potencial 
alvo terapêutico antenatal para patologias caraterizadas por hipoplasia pulmonar, tais como a 
HDC, promove o desenvolvimento de estudos pré-clínicos futuros.
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General Introduction
1. Normal Lung Development
The human lung is a vital organ, which is able to achieve a final gas diffusion surface of 70 
m2 in area by 0.1 mm in thickness in young adulthood. In this way, it is capable of supporting 
systemic oxygen consumption ranging between 250 and 5500 mL/min, and it can accommodate 
pulmonary blood flow rising from 4 to 40 L/min, at rest and during maximal exercise, respectively 
[Warburton et al., 2000].
Histological and anatomically, lung is a very complex organ. The lung consists of two ex-
tensively branched, tree-like systems - the airways and the vasculature - that develop in a co-
ordinated way in order to generate millions of alveolar gas exchange units [Morrisey & Hogan, 
2009; Shi et al., 2009]. The complexity of lung morphogenesis is immediately evident from the 
multiple cell types that comprise the lung, all present in appropriate numbers and sites to sup-
port respiration [Maeda et al., 2007].  Regarding cell types, different authors point to more than 
40 specific types of cells are differentiating during lung development, either in airway or vascular 
structures, derived of the same epithelial or mesenchymal common precursors. The lung epithe-
lium composition changes significantly along the proximal-distal axis and the differentiation of 
airway epithelium follows a centrifugal pattern. In proximal pseudostratified airway epithelium, 
there are three major cell components, ciliated columnar cells, basal and mucous (goblet) cells. 
Regarding distal columnar epithelium, there are pulmonary neuroendocrine cells (PNEC), Clara 
and alveolar cells. Regarding alveolar surface, its majority is covered by flattened type I alveolar 
epithelial cells (AECI) or pneumocytes. Indeed, type I pneumocytes covered 95% of the surface 
area of the alveolar wall. The other 3% of the alveolar surface is covered by rounded cells, type 
II alveolar epithelial cells (AECII) or pneumocytes. Regarding the pulmonary mesenchyme, it is 
composed by several specialized cell types, including fibroblasts, myofibroblasts, parabronchial 
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Figure 1. Overview of lung development: stages, structure, characteristic events and major molecular mediators. Human lung development has 
been divided in six different stages: embryonic (4 to 7 weeks), pseudoglandular (5 to 17 weeks), canalicular (16 to 26 weeks), saccular (24 to 38 
weeks), alveolar (36 weeks – 7 years) and microvascular stages (birth to 2-3 years). The braces are representing the duration of each stage of human 
lung development. The duration of rat lung stages are also depicted [11 to 12.5 days post-conception (dpc); 12.5 to 18.5 dpc; 18.5 to 19.5 dpc; 19.5 
to 22 dpc; and 7 to 35 postnatal days, respectively]. In opposition to human, in rat, the alveolar stage is all a postnatal phenomenon.
and vascular smooth muscle cells, endothelial cells, vascular pericytes, and chondrocytes in 
large airways [Morrisey & Hogan, 2009; Shi et al., 2009; Cardoso & Lü, 2006]. 
Anatomically, in humans the right lobe is trilobed and the left is bilobed, with 23 genera-
tions of airway branching (in opposition to mouse and rat lung that consist of right four lobes and 
one left lobe). Thus, the bronchial tree of the human lung has more than 105 conducting and 
107 respiratory airways, with a matching capillary network developing in close apposition to the 
alveolar surface [Correia-Pinto et al., 2010; Maeda et al., 2007].
Classically, although a continuous process, lung development has been divided in six different 
stages: embryonic, pseudoglandular, canalicular, saccular, alveolar and microvascular stages (Figure 1). 
The embryonic stage is characterized by formation of the respiratory primordium that giving 
rise to the main bronchi (left and right), and also by the tracheoesophageal septation. In human, 
this process occurs about day 26 after conception (4th week of gestation), whereas in mice and rats 
begins at 9.5 and 11 days post-conception (dpc), respectively [Cardoso & Lü, 2006; Warburton et 
al., 2005; Copland & Post, 2004]. During embryo development, following gastrulation, the definiti-
ve endoderm undergoes complex morphogenetic movements that ultimately lead to the formation 
of the primitive gut tube [Chuang & McMahon, 2003]. The foregut is the most anterior (cranial) 
region of this tube, while the midgut and hindgut are located at progressively more posterior (cau-
dal) regions of the embryo. The mammalian lung formation initiates with the emergence of a small 
diverticulum, the respiratory diverticulum or laryngotracheal groove, from the ventral-lateral aspect 
of the foregut endoderm, which then invade the surrounding splanchnic mesoderm [Chuang & 
McMahon, 2003]. The proximal portion of the laryngotracheal groove gives rise to the larynx and 
trachea, whereas the distal portion gives rise to the left and right mainstem bronchial buds, which 
in turn give rise to the left and right lobar branches of the bronchial tree. Interestingly, the trachea 
and lungs originate from the same endoderm layer, like the thyroid, esophagus, stomach, liver, and 
pancreas. Thus, early on gestation, several factors needs to regulate the commitment of specific 
regions of the foregut into development of specific organs. Expression of transcription factors or ma-
rkers characteristic of specific organs are observed along the anterior-posterior axis of the foregut 
tube before formation of each organ [Maeda et al., 2007]. 
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EMBRYONIC
CANALICULAR
ALVEOLAR
Respiratory primordium 
appears as a ventral 
diverticulum of the
foregut and it branches giving 
rise to the main bronchi; 
Tracheoesophageal septation.
MAJOR MOLECULAR MEDIATORS:
TTF-1, FOXA2, GATA-6, SOX2, 
FGF-10,  BMP-4, SHH, RA
MAJOR MOLECULAR MEDIATORS:
FOXJ1, FOXA2, TTF-1, GATA6, SOX2, VEGF, 
RA, glucocorticoids, sex hormones
MAJOR MOLECULAR MEDIATORS:
Elastin, PDGF, RA, VEGF, 
angiopoietins, ephrins
Formation of respiratory 
bronchioles and alveolar ducts; 
Increase of capillary bed; 
Epithelial and mesenchymal
differentiation;
Surfactant production starts.
Alveologenesis: 
establishment of  
secondary septa and 
alveolar formation.
PSEUDOGLANDULAR
SACCULAR
MICROVASCULAR
MATURATION
MAJOR MOLECULAR MEDIATORS:
FGF-10, SPRY2, SHH, BMP-4, 
TGF-β, WNT family, EGF, PDGF, RA, 
extracellular matrix components 
MAJOR MOLECULAR MEDIATORS:
TTF-1, FOXA2, VEGF, glucocorticoids, 
sex hormones
MAJOR MOLECULAR MEDIATORS:
VEGF, angiopoietins, ephrins
Formation of airways and 
blood vessels up to a 
pre-acinar level.
Formation of small 
terminal sacs 
(primitive alveoli);
Further maturation of 
the vasculature and 
surfactant system.
Septum maturation and 
capillary remodeling from 
double into a single 
capillary layer.
LUNG
DEVELOPMENT
STAGES
2/3 YEARS
7 YEARS
38
36
26
24
17
16
7
5
4
Weeks Days
HUMAN
1
3
5
2
4
BIRTH
6
11
18.5
19.5
22
12.5
RAT
40
35
BIRTH
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The pseudoglandular stage occurs, in human, between 5 to 17 weeks of gestation (12.5 
to 18.5 dpc in rat) and it is characterized by development of the hierarchical pattern of all pre-
acinar airways (until terminal bronchioles) and blood vessels [Morrisey & Hogan, 2009]. During 
the pseudoglandular stage occurs the first sixteen generations of branching that are stereoty-
pically reproducible (genetically predetermined). The remaining seven generations, the last of 
which lead into the alveoli, occurring in other stages, appears to follow a more random-appearing 
distribution [Metzger et al., 2008; Maeda et al., 2007; Shi et al., 2007; Warburton et al., 2000]. 
Further step in lung development is production of cartilage, which can already be found around 
the main bronchi before 10 weeks after conception [Correia-Pinto et al., 2010]. 
The canalicular stage comprise the period between 16 and 26 weeks in humans (18.5 to 
19.5 dpc in rat). The cranial part of the lung develops relatively faster than the caudal part, resul-
ting in partial overlap between this stage and the previous stage. This stage is characterized by 
further expansion of respiratory tree in diameter and length, division of terminal bronchioles into 
respiratory bronchioles and alveolar ducts, and an increase of capillaries number leaning against 
the epithelium, marking the beginning of the prospective gas-exchange region. Moreover, the pul-
monary epithelium differentiates into AECI (cells of thinned air-blood barrier) and AECII (surfactant 
producers) and surfactant production starts at the end of this stage [Correia-Pinto et al., 2010; Shi 
et al., 2009]. Pulmonary surfactant is a complex mixture of about 90% phospholipids (PLs) and 
10% proteins that function to decrease the surface tension at the alveolar air-liquid interface, there-
fore stabilizing and maintaining the alveoli in an open position that prevents alveolar collapse. The 
PLs, mainly phosphotidylcholine, are assembled in the endoplasmic reticulum and the Golgi appa-
ratus of AECII and are packaged in lamellar bodies until exocytosis [Gower & Nogee, 2011; Osanai 
et al., 2006]. Regarding surfactant proteins (SP), there are four types synthesized by AECII (SP-A, 
B, C and D). SP-A and SP-D are hydrophilic proteins that regulate surfactant secretion and support 
immune responses in the lung. On the other hand, SP-B and SP-C are hydrophobic proteins that 
allow proper functioning of surfactant, with SP-B interacting with calcium ions and SP-C enhancing 
the movements of PLs molecules that keeps the surfactant properties [Gower & Nogee, 2011; 
Whitsett & Weaver, 2002]. The importance of surfactant for perinatal survival is further supported 
by the findings that inherited disorders of surfactant metabolism cause lethal respiratory distress in 
mature infants after birth [Gower & Nogee, 2011; Maeda et al., 2007].
The canalicular stage is also characterized by mesenchymal cells differentiation and intersti-
tial tissue decrease. The major source for these lung mesenchymal cells is lateral splanchnic me-
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soderm. However, about 30% of the vascular smooth muscle cells as well as some mesenchymal 
cells outside the blood vessel walls are derived from mesothelial cells [Shi et al., 2009; Que et al., 
2008]. Lung mesenchyme development is crucially influenced by signals from the epithelium and 
the pleura that, in concert, appear to maintain a balance of differentiated and proliferating multipo-
tent progenitors while the lung grows [Weaver et al., 2003].
The saccular (terminal sac) stage begins at about 24 weeks in human pregnancy (19.5 
to 22 dpc in rat). There is again a partial temporal overlap between this stage and the previous 
stage, since in first 2 weeks of this stage, proximally are occurring saccular specific phenome-
na, whereas distally are taking place yet canalicular phenomena. In this stage, the terminal or 
acinar tubes narrow and give rise to small terminal sacs or primitive alveoli. There is substantial 
thinning of the interstitium that it results from apoptosis as well as ongoing differentiation of me-
senchymal cells. The capillaries also grow rapidly in the mesenchyme surrounding the primary 
alveoli to form a complex double network. Indeed, the airspaces are smooth-walled transitory 
ducts and saccules with primary septa, which are thick and are tightly associated with a dou-
ble capillary network. Furthermore, during this period, preparation for the real alveolarization 
starts by deposition of elastic fibers at the localizations where future secondary septa will form. 
Additionally, at this stage, the alveolar epithelial cells are more clearly differentiated into mature 
squamous AECI, providing close apposition between pulmonary blood vessels and the respira-
tory epithelium, and secretory surfactant AECII, with further maturation of the surfactant system 
occurring. These factors are determinant to support relatively inefficient gas exchange, but su-
fficient to maintain the life of prematurely born neonates [Correia-Pinto et al., 2010; Morrisey & 
Hogan, 2009; Copland & Post, 2004].
The alveolar stage begins around 36 weeks of pregnancy in human, and continues pos-
tnatally at least up to 7 years of age, giving rise to about 300 million alveoli. In opposition, in 
rodents (mouse and rat), perhaps the most extensively studied laboratory species for lung de-
velopment, the alveolar stage is all a postnatal phenomenon (7 to 35 postnatal days) [Shi et al., 
2009; Zoetis & Hurtt, 2003]. During alveolarization the sacs are subdivided by the ingrowth of 
ridges or crests known as secondary septae. In fact, the establishment of secondary septa within 
terminal sacs is the key step for differentiation of the saccules into alveoli, and the increase of 
airway surface area. The alveologenesis involves a complex interaction between airway epithelial 
cells, vascular endothelial cells, and myofibroblasts that migrate to the proper position within 
nascent alveolar septa, and synthesize and deposit of elastin [Correia-Pinto et al., 2010; Morrisey 
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& Hogan, 2009]. The trans-section of these newly formed interalveolar walls (secondary septa) 
demonstrates a doubled capillary layer separated by a sheet of connective tissue. This structure 
does not yet correspond to the adult morphology characterized by thin interalveolar septa, in 
which a capillary monolayer occupies almost the whole space of the septum. Therefore, these 
structures will undergo more restructuring, the microvascular maturation [Correia-Pinto et al., 
2010; Morrisey & Hogan, 2009; Copland & Post, 2004].
The microvascular maturation stage is a postnatal stage characterized by septum ma-
turation and formation of the mature interalveolar wall, a functional respiratory membrane that 
consists of endothelial cells tightly associated with the flattened AECI, which favors optimal gas 
exchange [Correia-Pinto et al., 2010; Roth-Kleiner & Post, 2003]. Thus, two additional proces-
ses occur: the thinning out of the secondary septa; and the maturation of the capillary bed. 
Thinning of the interstitial tissue involves cells apoptosis in the postnatal lung mesenchyme. 
Simultaneously, occur capillary remodeling from double capillary layer into a single capillary 
layer [Schittny et al., 1998].
Lung development is a highly orchestrated process directed by mesenchymal (vessels)-
epithelial interactions which control and coordinate the temporal and spatial expression of mul-
tiple regulatory factors required for proper lung formation [Correia-Pinto et al., 2010]. In the next 
sections current knowledge about airway branching morphogenesis, vasculature development 
and regulation of lung development will be detailed.
1.1 Branching morphogenesis
Once the primary lung buds have formed, they extend into the surrounding mesenchyme and be-
gin the process of branching morphogenesis, generating a complex tree-like structure [Morrisey 
& Hogan, 2009]. The branching morphogenesis results from three distinct local processes that 
are repeatedly in different combinations: domain branching, planar bifurcation, and orthogonal 
bifurcation [Metzger et al., 2008; Warburton et al., 2008]. Domain branching is responsible for 
the formation of the main secondary branches and it involves the orderly sprouting of new buds 
at specific distances from the tip of a stalk and at positions around the circumference that are 
either dorsal/ventral or medial/lateral relative to the axis of the parent stalk [Morrisey & Hogan, 
2009]. The other two processes are related to the bifurcation of the tip. They are called planar 
and orthogonal bifurcation, depending on the axis along which the two new buds are formed. 
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Planar bifurcation subsequently generates the tertiary and later-generation branches, whereas 
orthogonal bifurcation results in the formation of three-dimensional branching of the airways. 
The importance of mesenchymal-epithelial tissue interactions for lung development has been 
known for several decades. Each tissue compartment produces unique sets of growth factors and 
other signaling molecules, which signal in a paracrine manner between the epithelium and the 
mesenchyme. Their expression must be well coordinated as at some sites they need to enhance 
cell proliferation (at the edge of the growing lung buds), while at other sites they have to inhibit cell 
division (at branching points). The exact mechanisms responsible for regulation of lung bud bran-
ching are not completely understood. However, the current model suggests that lung buds undergo 
repetitive cycles of four processes: lung bud position and elongation, cessation of outgrowth, expan-
sion of the tip, and bifurcation [Morrisey & Hogan, 2009; Metzger et al., 2008]. At the molecular 
level, these processes result from a dynamic change in relative activity of fibroblast growth factor 
10 (FGF-10), fibroblast growth factor receptor 2IIIb (FGFR2IIIb), sprouty 2 (SPRY2), sonic hedgehog 
(SHH), and bone morphogenetic protein 4 (BMP-4) [Correia-Pinto et al., 2010; Morrisey & Hogan, 
2009; Metzger et al., 2008]. It has been proposed that high SHH signaling and low FGF-10 signa-
ling occurs where branching is not supposed to proceed. In opposition, where a branch emerges, 
SHH is locally suppressed by patched receptor (PTC) and hedgehog interacting protein (HIP), which 
re-establish FGF-10 signal. FGF-10 induces the dynamic expression of its inhibitor SPRY2 as bran-
ches extend. As the bud elongates towards the mesenchymal source of FGF-10, SPRY2 begins to be 
synthesized at the most distal tip until it reaches maximal expression and almost abrogates FGF-10 
expression, thus determining interbranch length. Proximally, bud outgrowth is regulated by SHH 
signaling. BMP-4 is also an important factor that appears to enhance lung branch tip outgrowth ac-
cording together with FGF-10. FGF-10 is shown stimulating BMP-4 expression (Figure 2) [Morrisey 
& Hogan, 2009; Cardoso & Lü, 2006; Warburton et al., 2005].  
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Figure 2. Current model of molecular events involved in lung bud position and elongation, cessation of outgrowth, expansion of the tip and 
bifurcation [from Warburton et al., Pediatr Res, 2005]. A. FGF-10 distal mesenchyme expression induces chemotaxis of the bud tip toward the FGF-
10 source. Heparan sulfate is important for FGF-10 function. B. BMP-4 enhances bud tip branching according together with FGF-10. FGF-10 induces 
BMP-4 epithelial expression, whereas the BMPs binding proteins gremlin (GRE) and noggin (NOG) repress BMP-4 expression. C. SHH inhibits 
FGF-10 expression at the branch tip and, simultaneously, HIP inhibits SHH which re-establish FGF-10 signal. D. Lung bud position and elongation: 
FGF-10, BMP-4 and SHH promote the balance between chemotaxis and proliferation resulting in bud induction versus inhibition of bud outgrowth. E. 
Cessation of outgrowth and expansion of the tip: interbranch length may be determined by arrest of bud outgrowth by concerted action of SPRY2 and 
SHH. FGF-10 mesenchymal gradient induces SPRY2 epithelial gradient as branches extend, thus inhibiting epithelial outgrowth. In proximal regions 
of lung bud, SHH mediates branching suppression by inhibiting FGF-10 expression in the peripheral mesenchyme. F. Lung bud bifurcation: Wingless 
(WNT) signaling propels fibronectin (FN) deposition between the branch tips, leading to epithelial cleft formation. Dickkopf 1 (DKK1) inhibits WNT 
signaling away from the cleft, with consequent lower deposition of FN where the cleft does not have to occur.
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1.2 Development of Pulmonary Vascular System
Pulmonary vascular system is divided into pulmonary and bronchial circulations. The pul-
monary arteries supply the intrapulmonary structures and regulate gas exchange. The bronchial 
system is the nutrient and oxygen supplier of the lung. All intrapulmonary structures are drained 
into the pulmonary veins, whereas the hilar structures drain into the bronchial veins and then to 
the azygos system [Hislop, 2005; Hislop, 2002].
The vascular development takes place during all stages of lung development and important 
alterations of the three-dimensional structure of the capillary network lay the foundation for alveola-
rization [van Tuyl et al., 2005]. Even in the early stages of lung development vascular connections 
are well established, with the development of the central bronchial arteries during the embryonic 
period. By the end of the pseudoglandular stage, preacinar bronchi are formed and are accompa-
nied by the pulmonary and bronchial arteries. During the canalicular stage of lung development, 
the distal circulation develops and there is a marked growth in capillary network which gets closer 
to the pulmonary epithelium. Thus, the canalicular stage is also known as the vascular stage 
[Copland & Post, 2004; Warburton et al., 2000]. In the saccular phase capillaries are evident 
around the saccules.  In the alveolar phase the secondary septa contain a capillary bilayer. During 
the microvascular maturation the vasculature development is completed with the formation of sin-
gle capillary networks [Copland & Post, 2004].
The pulmonary vasculature develops within the splanchnic mesoderm via two simultaneous pro-
cesses, vasculogenesis and angiogenesis [Fisher & Summer, 2006; Hislop, 2002; Gebb & Shannon, 
2000]. Vasculogenesis is characterized by in situ new vessels formation from precursors (angio-
blasts). The angioblasts or endothelial cell precursors are present in mesoderm since early stages of 
lung development. Thus, these mesodermal cells trans-differentiates into endothelial cells, proliferate, 
and organize into vessels [Warburton et al., 2000]. Angiogenesis is the process of new vessels for-
mation from extension of pre-existing ones. In this process, differentiated endothelial cells proliferate, 
sprout from previously formed vessels, and form new vascular structures [van Tuyl et al., 2005].
Several studies about pulmonary vasculature development suggest that the large central 
pulmonary arteries are formed by angiogenesis from the aortic sac, whereas the capillary plexus 
around the distal endoderm (lung periphery) is generated by vasculogenesis [Morrisey & Hogan, 
2009; Anderson-Berry et al., 2005; Hislop, 2002]. Moreover, a fusion process is necessary to 
connect angiogenic and vasculogenic vessels, the main pulmonary trunks with the peripheral 
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vasculature [Morrisey & Hogan, 2009; deMello & Reid, 2002]. Communication between the 
two respective vascular networks rarely occurs in the mid-pseudoglandular stage, but a gradual 
increase in communication progresses until a complete vascular circuit is achieved by the begin-
ning of the terminal sac stage [Schwarz et al., 2009; deMello et al., 2002]. Nonetheless, ques-
tions regarding the process of pulmonary vascular morphogenesis remain. For instance, Parera 
et al suggested distal angiogenesis as the mechanisms for lung vasculature development [Parera 
et al., 2005]. Recently, Schwarz et al also defended that initial pulmonary vessel formation occur-
ring within the mesenchyme is predominately angiogenic [Schwarz et al., 2009].
Regarding molecular regulation of pulmonary vasculature development, it has only recently 
begun to be elucidated. It has been demonstrated that cell-extracellular matrix and cell-cell inte-
ractions as well as growth factors and transcription factors are involved in vascular development 
[Copland & Post, 2004]. Specifically, members of the vascular endothelial growth factor (VEGF) 
[Yamamoto et al., 2007; Healy et al., 2000], the angiopoietin [Hato et al., 2009] and the ephrin 
[Vadivel et al., 2012] families appear to be key players in the control of pulmonary vascularization. 
Moreover, it is now consensual that lung vascular development requires epithelial-mesenchymal 
interactions [Crivellato, 2011; Gebb & Shannon, 2000]. For instance, VEGF is expressed in the de-
veloping epithelium, whereas their cognate receptors (Flk-1, fetal liver kinase 1; Flt-1, FMS-like tyro-
sine kinase 1) are expressed in and direct the emergence of developing vascular capillary networks 
within the mesenchyme [Correia-Pinto et al., 2010; White et al., 2007; Warburton et al., 2005]. 
Furthermore, there is growing evidence for reciprocal interactions between airways and blood 
vessels that are critical for normal lung development [Crivellato, 2011]. For instance, hepatocyte 
growth factor (HGF) produced by the endothelial cells positively regulates the proliferation of the 
endoderm [Yamamoto et al., 2007]. Ephrin B2 expressed by the microvasculature is critical for lung 
alveolization and secondary septae formation [Vadivel et al., 2012; Wilkinson et al., 2008]. On the 
other hand, it was demonstrated that ablation of lung epithelium impairs lung vascular cells develo-
pment [Sarah et al., 2000]. Moreover, VEGF inhibition in neonatal rats leads to arrested alveolar de-
velopment, suggesting that inhibition of vascular growth itself may directly impair lung development 
[Thébaud et al., 2005; van Tuyl et al., 2005; Compernolle et al., 2002; Healy et al., 2000; Jakkula 
et al., 2000]. In contrast, addition of VEGF to early mouse embryonic lung explants markedly sti-
mulates epithelial as well as vascular morphogenesis, playing an important role in matching the 
epithelial-capillary interface during lung morphogenesis [Del Moral et al., 2006; Compernolle et al., 
2002]. Interestingly, recently Lazarus et al uncovered that vasculature also determines stereotypy 
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of epithelial branching morphogenesis. Indeed, vascular ablation perturbed branching stereotypy, 
inducing overall flat lung morphology, and also led to a high frequency of ectopic branching. This 
role of the vasculature was independent of perfusion, flow or blood-borne substances [Lazarus et 
al., 2011]. Thus, airway and vascular development are intimately linked processes and the disrup-
tion of one system has severe consequences on the development of the other. 
1.3 Regulation of Lung Development
The lung development is a highly predetermined program, orchestrated by finely integrated and 
mutually regulated networks of several controlling factors, namely: i) genetic factors (transcription fac-
tors, growth factors, hormones, their receptors and intracellular signaling components, extracellular 
matrix (ECM) components and intercellular adhesion molecules); ii) mechanical stimuli, including 
Lung 
Development 
Regulation 
Genetic 
Factors 
Mechanical 
Stimuli 
Chemical 
Factors  
Transcription factors 
Growth factors 
Hormones 
ECM components 
Intra-thoracic space 
Fetal breathing movements 
Peristaltic airway contractions 
Lung fluid 
Hypoxic environment  
Calcium concentration 
Figure 3. Overview of lung development regulation. The lung development is a complex morphogenetic process, involving genetic factors, 
mechanical stimuli and chemical factors.
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intra-thoracic space, fetal breathing movements, peristaltic airway contractions and lung fluid; and iii) 
chemical factors such as relative hypoxia and calcium concentration (Figure 3) [Correia-Pinto et al., 
2010; Shi et al., 2009; Warburton et al., 2005]. 
The role and the interplay between major molecular mediators of lung morphogenesis will 
be reviewed in following sections. 
1.3.1 Genetic Factors
Several transcription factors, growth factors, hormones, their receptors and intracellular 
signaling components have been described as crucial players involved in normal lung develop-
ment. These genetic factors are programmed to be expressed at the correct time, place and dose 
to induce and control orderly airway and vasculature development.
1.3.1.1 Transcription Factors
Numerous transcription factors and their binding sites have been characterized and as-
sociated with the regulation of lung specific genes. For instance, several transcription factors 
play a specific part in differentiation of the epithelium and mesenchyme into specific cell types. 
Nonetheless, the principles that govern the design and evolution of transcriptional networks 
operating during lung formation and function have just begun to be understood [Maeda et al., 
2007]. In the following sections the main transcription factors involved on lung morphogenesis 
will be briefly reviewed.
Thyroid-specific Transcription Factor 1
The thyroid-specific transcription factor 1 (TTF-1) also known as Nkx2 marks the region 
from which lung buds arise and is one of most important genes in lung development. Indeed, 
the earliest known step in the development of the respiratory system (the trachea and lungs) is 
the establishment of a localized domain of TTF-1 expression in the ventral wall of the anterior 
foregut. Thus, TTF-1 is the earliest known marker associated with commitment of endodermal 
cells to pulmonary and thyroid cell lineages, appearing before formation of the definitive lung 
[Maeda et al., 2007]. Abrogation of Ttf1 in mice results in full absence of distal airway branches, 
while two main bronchial stems are still formed, suggesting lung development is arrested at a 
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very early stage [Cardoso & Lü, 2006]. Null mutation of Ttf1 is also associated with defects in 
tracheoesophageal septum development [Morrisey & Hogan, 2009]. Furthermore, TTF-1 also 
influences perinatal lung maturation, regulating the expression of genes critical for respiratory 
adaptation at birth [Maeda et al., 2007]. 
Forkhead Box Proteins
Forkhead box proteins (FOX) are a family of more than 50 transcription factors sharing a win-
ged helix deoxyribonucleic acid (DNA) binding domain, and play important roles in the regulation 
of the expression of genes involved in cell growth, proliferation, differentiation. Members of FOX 
proteins have differential expression patterns in lung during development [Maeda et al., 2007]. 
FOXA2 or hepatocyte nuclear factor 3β (HNF-3β) is expressed in cells believed to be pro-
genitors of respiratory epithelial cells and has a major role in the regional specification of foregut 
endoderm. Foxa2 knockout (KO) presents a severe early embryonic lethal phenotype with complete 
failure of the primitive foregut to close into a tube and, therefore, absence of the lungs [Sasaki & 
Hogan, 1993]. Later in lung development, FOXA2-binding sites have been found in the promoter 
regions of several lung-specific genes, such as SP-A, B, C, D and Clara cell-secretory protein (CCSP) 
[Warburton et al., 2000; Bohinski et al., 1994]. Thus, the FOXA2 is expressed in an overlapping pat-
tern with TTF-1 in respiratory epithelial cells and appears to cooperate with the TTF-1 to determine 
pulmonary epithelial cell lineage fates [Maeda et al., 2007; Warburton et al., 2000].
FOXF1 has been involved in the regulation of mesenchymal-epithelial interactions. Indeed, 
it is expressed in the splanchnic mesenchyme in close apposition to endoderm, suggesting its 
role in mesenchymal-epithelial interaction during lung and gastrointestinal tract morphogene-
sis. Foxf1 KO is lethal before the gastrulation whereas Foxf1 heterozygote presents severe lung 
malformations and is associated with tracheoesophageal septum anomalies [Morrisey & Hogan, 
2009; Maeda et al., 2007; Mahlapuu et al., 2001].
Regarding FOXJ1, also known as hepatocyte nuclear factor-3/forkhead homologue 4 
(HFH-4), this transcriptional factor is critical in the establishment of right-left asymmetry and in 
the development of the ciliated cells. In fact, defects of FOXJ1 results in failure of cilia formation 
and left-right asymmetry that is integral part of the body plan and necessary for normal forma-
tion and localization of intrathoracic and intra-abdominal organs [Alten et al., 2012; Maeda et 
al., 2007; Zhang et al., 2004].
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A/TGATA/G -Binding Transcription Factor
GATA-6, a member of the GATA family of zinc finger transcriptional factors, which bind DNA con-
sensus sequence A/TGATA/G, is expressed in respiratory epithelial cells throughout lung morphoge-
nesis [Maeda et al., 2007]. GATA-6 has been implicated in pulmonary endoderm specification. Later 
in development, GATA-6 also influences epithelial cells differentiation, sacculation and alveolarization 
of the lung [Zhang et al., 2008]. Interestingly, expression of a dominant negative Gata6 in mouse respi-
ratory epithelial cells inhibited lung differentiation in late gestation and decreased surfactant proteins. 
On the other hand, increased activity of GATA-6 inhibited alveolarization and perturbed pulmonary 
function [Maeda et al., 2007; Yang et al., 2002; Koutsourakis et al., 2001]. 
Sex determining region Y- Box
A number of sex determining region Y-box (SOX) genes are expressed in the developing 
lung, including SOX2, -4, -9, -11, and -17 [Maeda et al., 2007]. 
Regarding SOX2, it is involved in tracheoesophageal septation. As respiratory diverticulum 
caudally grows, the single foregut tube begins to separate into two - a dorsal esophagus that leads 
into the stomach and a ventral trachea that connects to the lung buds, by the tracheoesophageal 
septum formation [Morrisey & Hogan, 2009]. A greatest SOX2 expression is observed dorsally 
in the future esophagus while TTF-1 expression marking the future trachea is greatest ventrally. 
This patterning also depends on signals from the surrounding mesenchyme. Null mutations of 
Sox2 lead to defects in tracheoesophageal septum development including tracheoesophageal 
fistula and esophageal atresia [Morrisey & Hogan, 2009; Que et al., 2006]. Recently, it was also 
demonstrated that SOX2 is required for maintenance and differentiation of PNEC, Clara, ciliated, 
and goblet cells [Tompkins et al., 2009; Tsao et al., 2009;].
Semaphorins, Eyes absent and Six Transcription Factors
Recently, other transcription factors have been described to be important for lung development.
To date, more than 20 types of semaphorins (Sema) have been identified and they have diver-
se functions in many physiological processes [Arese et al., 2011]. Sema3A is a neural guidance 
cue that also mediates cell migration, proliferation and apoptosis, and inhibits branching morpho-
genesis. It was demonstrated that Sema3A modulates distal pulmonary epithelial cell development 
and lung morphogenesis. Indeed, genetic deletion of Sema3A induces septae thickness, alveolari-
zation reduction and significant perinatal lethality [Becker et al., 2011].
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The evolutionarily conserved homeodomain transcription factor Six1 (homologous to 
Drosophila sine oculis gene) and its canonical coactivator Eyes absent 1 (Eya1) synergistically 
control organ-specific progenitor cell proliferation and survival and are critical regulators of em-
bryonic development, namely of kidney, muscle and inner ear development [Farabaugh et al., 
2012; Li et al., 2003]. Recently, it was demonstrated that Six1 and Eya1 are important coordi-
nators of pulmonary epithelial, mesenchymal and vascular morphogenesis. These transcription 
factors are expressed at the distal epithelial tips of branching tubules as well as in the surroun-
ding distal mesenchyme. Six1 and Eya1 ensure the proper level of proliferation and differen-
tiation along the proximodistal axis of epithelial, mesenchymal and endothelial cells, and they 
are critical upstream coordinator of SHH-FGF-10 signaling during embryonic lung development. 
Indeed, Six1 and Eya1 deficient lungs are severely hypoplastic, with reduced epithelial bran-
ching, increased mesenchymal cellularity and severe defects in the smooth muscle component 
of the bronchi and major pulmonary vessels [El-Hashash et al., 2011a; El-Hashash et al., 2011b].
1.3.1.2 Growth Factors
Growth factors and their signal pathways play important regulatory roles in lung morphogenesis. 
Many of them also play important roles in lung pathologies and lung repair mechanisms [Warburton 
et al., 2000]. Some authors defense that early formation of the airways is mainly controlled by trans-
cription factors, whereas later division of airways is influenced by growth factors [Hislop, 2002].
Fibroblast Growth Factor Family
In vertebrates, the FGF family is composed by 22 members that have functions on cell prolife-
ration, differentiation and migration during organogenesis [Itoh & Ornitz, 2011; Ornitz & Itoh, 2001]. 
The developing lung expresses FGF-1, -2, -7, -9, -10, and -18, and FGF family have been shown to be 
important for the formation of secondary septae [Correia-Pinto et al., 2010; Weinstein et al., 1998]. 
FGF-10 has proven to be absolutely necessary for lung development. Indeed, mice deficient 
for Fgf10 present lung agenesis [Ohuchi et al., 2000]. On the other hand, FGF10 overexpression 
perturbs pulmonary morphogenesis and induced cystic lung malformations [Hashimoto et al., 
2012a; Gonzaga et al., 2008]. FGF-10 is expressed in the distal mesenchyme at sites where epithe-
lial buds will emerge and it was shown to induce chemotaxis of the distal lung epithelium. FGF-10 
and its high affinity receptor FGFR2IIIb (present on epithelial cells) are mediators of fundamental 
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epithelial-mesenchymal interations during lung development [Weaver et al., 2000]. Furthermore, 
FGF-10 plays a pivotal role in maintaining epithelial progenitor cell proliferation and regulates the 
formation of multiple mesenchymal lineages during lung development, namely alveolar smooth 
muscle cell formation and vascular development [Ramasamy et al., 2007]. 
Regarding FGF-9, during early pulmonary development, it is expressed in epithelium and 
mesothelium, becoming later restricted to the mesothelium. Mesothelial- and epithelial-derived 
FGF-9 have distinct functions in the regulation of lung development. Mesothelial FGF-9 is pri-
marily responsible for regulating mesenchymal proliferation and differentiation, and it has been 
suggested that maintains a FGF-10 progenitor population. On the other hand, epithelial FGF-9 
primarily affects epithelial branching [Yin et al., 2011]. Thus, embryos lacking Fgf9 present me-
senchymal hypoplasia, epithelial branching decrease and, by the end of gestation, hypoplastic 
lungs [Weaver et al., 2003; Colvin et al., 2001]. 
Concerning to FGF-7 (or keratinocyte growth factor), it is expressed by mesenchymal pul-
monary cells and mediates epithelial-mesenchymal interactions by binding to FGFR2IIIb. FGF-7 
overexpression in pulmonary epithelium has been related with abnormal morphogenesis similar 
to cytadenomatoid malformation [Simonet et al., 1995]. 
At the moment there are four subtypes of FGFR described, which bind members of the FGF 
family with varying affinity. FGFR1, 2, and 3 encode two receptor isoforms that are generated by 
alternative splicing, and each binds a specific repertoire of FGF ligands. FGFR2IIIb is mainly ex-
pressed in epithelium and binds four known ligands (FGF-1, FGF-3, FGF-7, and FGF10), which are 
primarily expressed in mesenchymal cells [Ornitz & Itoh, 2001]. This receptor has a key role during 
lung development. In fact, mice deficient for Fgfr2IIIb present agenesis and dysgenesis of multiple 
organs, including the lungs [Peters et al., 1994].
Sprouty Family
In vertebrates have been identified 4 SPRY homologs and all share a cysteine-rich region. 
SPRY family plays an important role in regulation of lung branching morphogenesis. Indeed, this 
family is a FGF-inducible signaling antagonist and also an inhibitor of other tyrosine kinase signaling 
pathways such as epidermal growth factor (EGF) [Hashimoto et al., 2012b; Tefft et al., 2002].
SPRY2 has a critical role in branching morphogenesis. It is expressed at the distal tips of the 
embryonic lung epithelial branches and is down-regulated at sites of prospective bud formation. 
SPRY2 high expression at the bud tip induces bud outgrowth arrest and tip splitting event must 
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occur [Sutherland et al., 1996]. Recently, it was demonstrated that in embryonic day 14 and 16 
lungs, SPRY2 was expressed both in epithelial and peripheral mesenchymal cells [Hashimoto et 
al., 2012b]. Mouse Spry2 KO presents increase of lung branching morphogenesis and enhanced 
expression of specific lung epithelial differentiation markers [Tefft et al., 2002]. On the other hand, 
SPRY4 is predominantly expressed throughout the distal lung mesenchyme. SPRY4 inhibits endo-
thelial cells proliferation and negatively regulates angiogenesis [Tefft et al., 2002].
Sonic Hedgehog Pathway
SHH signaling is crucial for lung branching morphogenesis regulation, since the temporos-
patial restriction of FGF-10 expression by SHH appears to be essential to initiate and maintain 
lung branching [Jia & Jiang, 2006]. Indeed, Shh null mutant presents lung hypoplasia [Pepicelli 
et al., 1998]. Epithelial SHH expression is also a mesenchymal differentiation signal. Moreover, 
SHH expression is locally suppressed at branch tips by the induction of its PTC receptor and HIP. 
These proteins assist local FGF signaling where branching is stereotypically programmed to take 
place [Zhang et al., 2010; Chuang & McMahon, 2003]. The activation of PTC by SHH induces the 
glioblastoma (GLI) transcription factors (GLI1, GLI2 and GLI3). There are expressed in distinct but 
overlapping domains in lung mesenchyme and the highest expression registered at the distal tips. 
Experiments with Gli KO are indicating that these transcription factors may be effectors of other 
signaling pathways besides SHH [Maeda et al., 2007; Motoyama et al., 1998].
SHH pathway has also been implicated in tracheoesophageal septation. In fact, Shh and 
Gli1/Gli3 null mutants also present defects in tracheoesophageal septum development, inclu-
ding tracheoesophageal fistula and esophageal atresia [Morrisey & Hogan, 2009].
Transforming Growth Factor Beta Family
The transforming growth factor beta (TGF-β) superfamily of cytokines regulates important 
organogenesis events, such as cell proliferation, differentiation and death. This superfamily can 
be divided into three subfamilies: TGF -β  , BMP and activin. These TGF-β ligands bind to their cog-
nate receptors on the cell surface and activate downstream cytoplasmatic effectors, the Smads 
(homologous genes of Drosophila mothers against decapentaplegic) proteins, which translocate 
into the nucleus and modulate target gene expression [Shi et al., 2009]. 
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TGF- β
There are three TGF-β isoforms (TGF-β1, -β2, and -β3) in mammals. All of them plus 
TGF- β type I and type II receptors, though differentially distributed, are expressed during lung 
development. In early mouse embryonic lungs, TGF-β1 is expressed in the distal mesenchyme 
underlying branching points, whereas TGF-β2 is localized in distal epithelium, and TGF-β3 is 
expressed in proximal mesenchyme and mesothelium [Bragg et al., 2001; Millan et al., 1991].
Endogenous autocrine/paracrine TGF-β signaling via TGF-β type II receptors negatively regulates 
lung morphogenesis by keeping cell cycle in G1 arrest [Zhao et al., 1996]. On the other hand, TGF-β 
signaling via TGF-β type I receptors is responsible for the formation of branch points and localized 
deposition of ECM components [Heine et al., 1990]. Embryonic lung organ and cell cultures as well 
as KO models has demonstrated that finely regulated and correct physiologic concentrations and tem-
porospatial distribution of TGF-β1, 2, and 3 are essential for normal lung morphogenesis and defense 
against lung inflammation [Zhao J et al., 1999; Serra et al., 1994]. Indeed, mice lacking Tgfb1 develop 
normally but die within the first month or two of life of aggressive pulmonary inflammation. On the 
other hand, Tgfb2 KO die in utero of severe cardiac malformations, whereas Tgfb3 mutants die, during 
the neonatal period, of lung dysplasia and cleft palate [Kaartinen et al., 1995; Serra et al., 1994].
BMPs 
BMPs, with more than 20 family members, have been shown to regulate many developmen-
tal processes including lung development [Correia-Pinto et al., 2010; Hogan, 1996]. Indeed, BMPs 
may play multiple roles in lung development. 
BMP-3, -4, -5 and -7 as well as type I BMP receptors are expressed during lung development 
[Bellusci et al., 1996; Takahashi & Ikeda, 1996]. Signaling through BMP receptors has been involved 
on promotion of respiratory identity in the foregut. In fact, type I BMP receptors promote tracheal 
formation via repression of SOX2 and it restricts the site of lung bud initiation [Domyan et al., 2011].
Regarding BMP-4, its expression was detected in pulmonary epithelium, with maximal ex-
pression at branch tips and in the adjacent mesenchyme [Bellusci et al., 1996]. The exact roles 
of BMP-4 in lung development remain controversial. BMP-4 has been described as responsible 
for epithelial proliferation suppression, mediator of branch extension and determinant of branch 
points [Weaver et al., 2000; Bellusci et al., 1996]. More recently, however, BMP-4 was considered 
a branching stimulator [Warburton et al., 2005; Bragg et al., 2001]. Nonetheless, overexpression 
of Bmp4 at distal budding epithelium induces epithelial proliferation decrease, lung hypoplasia and 
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distended terminal buds [Bellusci et al., 1996]. FGF-10 is able to induce BMP-4 expression in lung 
epithelium, acting in concomitance during lung bud outgrowth. In opposition, BMP-4 effects are ne-
gatively modulated by BMPs binding proteins, gremlin and noggin [Hyatt et al., 2004; Weaver et al., 
2003; Weaver et al., 2000]. Furthermore, BMP signaling is also important in lung vasculogenesis 
and angiogenesis. In fact, mutations of BMP type II receptor and changes in the expression level 
of gremlin are associated with primary pulmonary hypertension [Costello et al., 2008; Lane et al., 
2000]. Since KO for Bmp4 and BMP-specific Smads cause early embryonic lethality, their functions 
in lung development in vivo still need to be further defined. Nonetheless, it is known that null mu-
tations of Bmp4 and noggin lead to defects in tracheoesophageal septum development, including 
tracheoesophageal fistula and esophageal atresia [Morrisey & Hogan, 2009; Que et al., 2006.
Wingless Signaling Pathway
In mouse, Wingless (WNT) growth factor family consists of 19 secreted ligands that interact with 
10 known frizzled (FZ) receptors and either one of two single-span membrane proteins, the low-density-
lipoprotein receptor-related proteins (LRP) 5 and 6 [Tamai et al., 2000]. WNT proteins have been grouped 
into two classes, canonical (WNT1, WNT3, WNT3a, WNT7a, WNT7b, WNT8) and noncanonical (WNT4, 
WNT5a, WNT11), according to signal transduction. The canonical pathway involves the WNT binding to 
FZ receptors and, consequently, the inhibition of β -catenin phosphorylation mediated by glycogensyntha-
se kinase-3β (GSK3β). Hypophosphorylated and stable β-catenin accumulates in the cytoplasm, after 
which it translocates to the nucleus and interacts with members of TCF/LEF (T Cell Factor/Lymphoid 
Enhancer Factor) transcription factors, activating transcription of TCF/LEF target genes [Chuang & 
McMahon, 2003]. Non-canonical pathways consist of the PCP (Planar-Cell-Polarity (PCP)-like pathway), 
or JNK/AP1 (c-Jun NH(2)-terminal kinase/activating protein 1), and of the PKC/CaMKII/NFAT (Protein 
Kinase C/Calmodulin kinase II/Nuclear Factor of Activated T cells) dependent transduction [Pongracz & 
Stockley, 2006]. Moreover, there are two classes of secreted WNT antagonists described: sFRP (secreted 
Frizzled-related Proteins) and DKK (Dickkopf) [Warburton et al., 2005].
WNT ligands and other components of WNT signaling pathway (β-catenin, FZ, TCF/LEF) have 
been demonstrated to be expressed during lung development. Indeed, studies of the expression 
pattern of several WNT proteins suggest that WNT signaling can originate from the epithelium and 
mesenchyme and can target both tissues in an autocrine/paracrine fashion [Pongracz & Stockley, 
2006]. WNT signaling is also important for the normal lung morphogenesis. However, the different 
results obtained with interference of the WNT signaling cascade (WNT, β-catenin, DKK) makes it 
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difficult to pinpoint the nature of WNT signaling in lung development [Correia-Pinto et al., 2010]. 
WNT7b, for instance, is expressed in the lung epithelium with highest expression in the distal 
region [Pongracz & Stockley, 2006]. In mice, null mutation of Wnt7b results in markedly hypoplas-
tic lung and perinatal lethality due to respiratory failure, associated with decrease of mesenchymal 
cells proliferation and type I pneumocytes differentiation [Rajagopal et al., 2008; Shu et al., 2002]. 
Regarding WNT5a, a ligand for WNT noncanonical pathway, WNT5a have been demonstrated to 
have a pivotal role in directing the essential coordinated development of pulmonary airway and vas-
culature. Some authors defense that WNT5a functions during alveolarization, in opposition to WNT 
canonical pathway, which is more important in earlier lung development [Loscertales et al., 2008]. In 
fact, Wnt5a KO present overexpansion of distal airways, thickened intersaccular interstitium, delayed 
lung maturation and, consequently, respiratory failure [Li et al., 2002]. Lungs of Wnt5a KO animals 
also present an increase of FGF-10, SHH and BMP-4 expression, which suggests that WNT5a may in-
teract with other essential signaling pathways for lung morphogenesis [Yin et al., 2011; Li et al., 2005]. 
Interestingly, constitutive activation of WNT canonical pathway in embryonic lung epithe-
lium makes these cells transdifferentiate into intestinal epithelial lineages [Okubo & Hogan, 
2004]. Therefore, an appropriate level of WNT signaling in the right place at the right time is 
essential for normal lung organogenesis [Shi et al., 2009].
Furthermore, WNT signaling pathway has an important role in cleft formation via induction 
of fibronectin deposition where the splitting must occur. Impaired WNT pathway by DKK (a po-
tent and specific inhibitor of WNT action that is also endogenously secreted by the distal lung 
epithelium) display altered branching, characterized by unsuccessful cleft formation, enlarged 
terminal buds and decrease of fibronectin deposition [de Langhe et al., 2005]. Thus, fibronectin 
is a downstream target of WNT signaling.
Epidermal Growth Factor Family
EGF family consists of EGF, TGF-α and amphiregulin. The members of this family act via 
EGF receptor (EGFR). The mRNA of EGF family members is synthesized in the mesenchyme, 
whereas the EGF proteins are expressed in epithelium. Moreover, EGFR is expressed in lung epi-
thelium. Therefore, EGF ligands are produced in the lung mesenchyme and act on epithelium. 
[Warburton et al., 2000; Ruocco et al., 1996]. 
Regarding the role of EGF family on lung morphogenesis, several studies have demonstrated 
that EGF signaling positively modulates lung morphogenesis and cytodifferentiation [Warburton 
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et al., 2000]. In fact, Egfr null mutation provokes a 50% reduction in branching morphogenesis 
and a neonatal pulmonary lethal phenotype [Miettinen et al., 1997]. Moreover, an in vivo study 
established that maternal treatment with EGF could promote lung morphogenesis and increase 
the surfactant levels in premature fetal lung [Ma et al., 2009].
Platelet-Derived Growth Factor Family
Platelet-derived growth factor (PDGF) family consists of four different peptides: PDGF-A, 
PDGF-B, PDGF-C and PDGF-D, which form homo or heterodimers to be active. The PDGF receptors, 
tyrosine kinase receptors, are of two types: PDGFR-α and PDGFR-β. After binding of PDGF dimers, 
these receptors dimerize and may combine to generate homo or heterodimers (PDGFR-αα, αβ, 
ββ), which have different affinities towards the four PDGFs [Warburton et al., 2000]. The PDGF-AA 
and PDGF-BB homodimers and PDGFR are present in embryonic mouse lung and have an impor-
tant role in alveologenesis [Lau et al., 2011; Shi et al., 2009; Warburton et al., 2000]. PDGF-AA is 
a leading factor in alveolarization. Pdgfa homozygous null mutant mice are perinatally lethal, their 
lungs present lack of alveolar smooth muscle cells, reduction of elastin fibers deposition in the lung 
parenchyma, and alveolar hypoplasia [Boström et al., 2002]. On the other hand, PDGF-B is crucial 
for vascular growth and integrity during the alveolar stage [Lindahl et al., 1997].
Insulin-like Growth Factor Family
The insulin-like growth factor (IGF) family consists of two ligands (IGF-I and IGF-II), six IGF 
binding proteins (IGFBPs 1-6) and two receptors (IGF1R and IGF2R). All members of this family 
are expressed during lung development. IGF-I is expressed in lung mesenchyme, IGF-II in epithe-
lium, IGF1R presents ubiquitous expression and IGF2R is restricted to pulmonary mesenchyme 
[Retsch-Bogart et al., 1996; Maitre et al., 1995]. The IGFBPs are differentially regulated during 
lung development and they may play a role in mediating temporospatial IGF signaling, particu-
larly the regulation of cellular proliferation rates [Warburton et al., 2000]. KO for IGF signaling 
components do not have a gross defect in primary branching morphogenesis per se, but the 
lungs are hypoplastic [Liu et al., 1993; DeChiara et al., 1990]. Nonetheless, it is likely that IGF 
signaling may play a key role in facilitating signaling by other peptide growth factors involved in 
lung morphogenesis. Indeed, IGF1R signaling function is required for both the mitogenic and 
transforming activities of the EGF receptor [Warburton et al., 2000]. 
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Moreover, Han et al described a possible role for IGF1R during human and rat pulmonary angio-
genesis and vasculogenesis. Inhibition of IGF1R signal induced loss of endothelial cells and mesen-
chymal cell apoptosis. These observations suggest a role of IGF family of growth factors, acting throu-
gh the IGF1R, as survival factors during normal human lung vascular development [Han et al., 2003].
Pulmonary Neuroendocrine Factors
It has been demonstrated that pulmonary neuroendocrine products, in addition to chemo-
reception function, have a role in regulation of lung growth and maturation. The earliest PNEC 
are the first cell type to differentiate within the primitive airway epithelium and can be identified 
in humans at 8 weeks of gestation. This observation has lead to speculation that PNEC play 
some role during fetal lung development [McGovern et al., 2010]. In fact, PNEC synthesize 
and secrete a number of peptides that exhibit pulmonary growth factor activity, namely gastrin-
releasing peptide (GRP, the mammalian equivalent of bombesin) and ghrelin [Cutz et al., 2007; 
Santos et al., 2006; Van Lommel et al., 2001].
Regarding GRP, its expression and of its cognate receptor is maximal during the pseugo-
glandular and canalicular stages [Wang et al., 1996]. It has been demonstrated that GRP stimu-
lates branching morphogenesis and lung maturation both in vitro and in vivo [Warburton et al., 
2000; Emanuel et al., 1999; Aguayo et al., 1994; Sunday et al., 1990].
Concerning ghrelin, a strong growth hormone secretagogue, it is expressed in PNEC 
throughout fetal lung development, reaching a maximal expression during pseudoglandular sta-
ge [Santos et al., 2006; Volante et al., 2002]. Moreover, it was demonstrated that ghrelin mater-
nal administration attenuates pulmonary hypoplasia in fetuses with nitrofen-induced congenital 
diaphragmatic hernia (CDH) [Santos et al., 2006].
1.3.1.3 Hormones
Retinoic Acid
Studies in animal models and humans have revealed that disruption of signaling by retinoic 
acid (RA), the biologically active form of vitamin A, is associated with developmental abnorma-
lities, including defects in the respiratory system, range from lung hypoplasia to bilateral lung 
agenesis, and defects in tracheoesophageal septum development, including tracheoesophageal 
fistula [Chen et al., 2010; Gallot et al., 2005; Malpel et al., 2000]. 
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Retinoids are involved in different stages and phenomena of lung morphogenesis. Moreover, 
dynamic and differential spatiotemporal expression patterns are present for RA receptors (RAR 
α, β and g) and retinoic acid receptor X receptors (RXR α, β and g) during lung development 
[Gallot et al., 2005]. RA is involved in formation of lung primordium as well as distal bud outgro-
wth. RA acts as a major regulatory signal integrating the WNT and TGF-β pathways in the control 
of FGF-10 induction in the foregut mesoderm. In fact, the activation of WNT signaling required for 
the emergence of the primordial lung is dependent of local repression of DKK-1 by endogenous 
RA. Furthermore, RA regulates the expression of genes involved in distal bud outgrowth, such as 
FGF-10 and SHH [Chen et al., 2010; Gallot et al., 2005].
RA pathway is also involved in differentiation status of the epithelial cells and distal me-
senchyme, occurring during the canalicular stage [Cardoso & Lü, 2006; Weaver et al., 2003]. 
Additionally, RA together with glucocorticoids regulates the synthesis of surfactant. Retinoids 
have been also involved in promoting alveolization, inducing formation of secondary septae. 
In fact, alveolar septation is associated with decrease of retinyl ester storage and production 
of more biologically active molecules such as RA [Gallot et al., 2005; Malpel et al., 2000]. 
Nonetheless, the three RAR play distinct roles at different times during alveoli development. For 
instance, RAR-β seems to be a negative factor in the regulation of alveologenesis in the perinatal 
period, which suggests that RA signaling via RAR-β restricts the number of alveoli being formed 
during lung morphogenesis. On the other hand, RAR-g is a positive factor in the regulation of 
this process and RAR-α is needed for the proper number of alveoli to develop after the perinatal 
period in mice. In fact, Rarβ gene mutants mice develop too many alveoli and Rarg  gene mu-
tants fail to correctly form alveoli and show a lower number of alveoli compared to wild-type mice 
[Gudas, 2012; Gallot et al., 2005].
Steroid Hormones
Steroid hormones, namely sex hormones and glucocorticoids, have a relevant role in lung 
morphogenesis.
More than thirty years ago, a higher incidence of respiratory distress syndrome (RDS) was repor-
ted in male versus female preterm neonates (1.7:1). Moreover, although surfactant therapy has been 
successful in decreasing the mortality rate associated to RDS in both sexes, male neonates affected by 
RDS continue to present a higher incidence of morbidity [Seaborn et al., 2010]. Thus, the role of sex 
hormones in lung development mechanisms, namely androgens and estrogens, has been studied. 
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Fetal lung is not only passively exposed to circulating sex hormones but also has the capability 
to synthesize and inactivate them, and to modulate their action. Indeed, testosterone, androste-
nedione and estradiol are expressed in canalicular, saccular, and alveolar stages of mouse lungs 
of both sexes, whereas dihydrotestosterone is detected only in male lungs [Boucher et al., 2010]. 
During the fetal period, estrogenic effects could be perceived as antagonistic to those of an-
drogens. Nonetheless, since both sex hormones are involved in lung morphogenesis, a balance in 
their levels must be kept to ensure proper lung development and maturation [Seaborn et al., 2010].
Concerning androgens, they have been implicated in a dual role during lung development: i) 
positive regulators in early branching morphogenesis in both sexes; ii) negative regulators responsi-
ble for the observed delay in male lung maturation [Provost et al., 2004; Levesque et al., 2000]. In 
human, rodents and rabbit, the peak in plasma testosterone level occurs several weeks before lung 
maturation and, in fact, the surge of surfactant synthesis occurring at mid–late gestation is delayed 
in males and is linked to androgen levels. In addition to their delaying effects on AECII maturation, 
androgens stimulate proliferation and fetal lung growth [Seaborn et al., 2010].
On the other hand, estrogens have positive effects on surfactant production during fetal 
development, enhancing the number of AECII and phospholipid content, and stimulating the ex-
pression of SP-A and SP-B [Seaborn et al., 2010]. Moreover, estrogens positively modulate alveolo-
genesis during the neonatal period [Carey et al., 2007]. Indeed, estrogens enhance expression of 
VEGF in primary cultures of fetal lung cells and they have been associated with the sex dimorphism 
observed in rodent alveologenesis, namely more alveoli and alveolar surface area, per body mass, 
in females than in males [Seaborn et al., 2010; Trotter et al., 2009]. Both estrogen receptor α 
(ERα) and β (ERβ) are expressed in fetal lung and are required for the alveoli development, and 
they regulate alveolar size and number in a nonredundant manner [Seaborn et al., 2010]. 
Interestingly, lung fluid is also regulated to some extent by sex hormones, with androgens 
stimulating and estrogens decreasing the activity of the cystic fibrosis transmembrane conduc-
tance regulator [Seaborn et al., 2010].
Regarding glucocorticoids, they have a relevant role on perinatal lung maturation, regulating 
the expression of critical genes for respiratory adaptation at birth. Indeed, antenatal glucocorticoi-
ds have been widely used for 40 years to stimulate maturation of preterm fetal lungs and improve 
neonatal lung function [ACOG, 2011; Roberts & Dalziel, 2006; Grier & Halliday, 2004]. Stimulation 
of the pulmonary surfactant system has been regarded as the most important effect of antenatal 
glucocorticoids. These hormones/drugs regulate enzymes in AECII that stimulate surfactant lipid syn-
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thesis and subsequent release of surfactant. Moreover, glucocorticoids alter production of surfactant 
proteins. In addition to this effect on surfactant synthesis, they also induce lung architectural changes, 
accelerating morphologic development and cytodifferentiation of both types of alveolar cells (AECI 
and AECII). Furthermore, glucocorticoids enhance fetal lung antioxidant enzymes, including catalase, 
glutathione peroxidase and two superoxide dismutases, and lung fluid absorption, inducing the epi-
thelial sodium channel and the membrane protein sodium/potassium ATPase [Maeda et al., 2007; 
Grier & Halliday, 2004]. Interestingly, in spite of the use of glucocorticoids to induce lung maturation, 
they appear to inhibit secondary septation (alveolarization) and vascular development [Bourbon et al., 
2009; Morrisey & Hogan, 2009; Maeda et al., 2007; Grier & Halliday, 2004].
1.3.1.4 Extracellular matrix components and intercellular adhesion molecules
ECM components include the interstitial matrix and the basement membrane, which has 
multiple functions, such as cells support and anchorage, formation of a tissue scaffold, and 
regulation of intercellular communication. The ECM has an important role in the mediation of 
epithelial-mesenchymal cell matrix interactions. Interstitial matrix is composed of polysacchari-
des and fibrous proteins that fill the intercellular spaces, while basement membranes are sheet-
like depositions of ECM on which epithelial cells rest. The most important protein components 
of ECM are laminins, nidogen, type IV collagen, elastin, fibronectin, proteoglycans, tenascin 
and SPARC (secreted protein, acidic and rich in cysteine) [Smits et al., 2010; Shi et al., 2009; 
Warburton et al., 2000].
ECM components are differentially expressed during lung morphogenesis. Absence or inhibition 
of epithelial cells interactions with the basement membrane results in failure of normal lung develo-
pment [Hilfer, 1996]. Apart from its supportive role of tissue architecture, ECM also plays an active 
role in modulation of cell proliferation and differentiation during lung development [Shi et al., 2009]. 
Laminins are a family of glycoproteins implicated in cell adhesion, migration, proliferation 
and differentiation during tissue development. Laminins are composed of three chains, one central 
(α) and two laterals (β and g) that are linked by disulfide [Warburton et al., 2000]. Until to date five 
α, three β and three g chain isoforms have been described. This suggests that their combination 
can lead to many variants of laminin [Nguyen & Senior, 2006]. At least ten laminin variants partici-
pate in a temporospatial fashion during lung development [Warburton et al., 2000]. In lung explant 
culture, α1 chain isoform laminin has been shown to be important for lung branching morphoge-
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nesis and bronchial smooth muscle cell formation [Schuger et al., 1997]. Moreover, mutation of α5 
chain isoform results in a lethal phenotype during fetal life and lung presents poor lobe septation 
and bronchiolar branching, suggesting that laminin α5 is essential for normal lobar septation in 
early lung development, and alveolarization and maturation in late lung development [Nguyen et 
al., 2005; Nguyen et al., 2002; Warburton et al., 2000]. Until the moment, the mechanisms res-
ponsible for the lung phenotypes in mice with laminin mutations are unknown, but it is clear that 
multiple laminin isoforms are crucial for lung development and those different laminin isoforms 
exhibit specific, non-overlapping functions [Nguyen & Senior, 2006].
Nidogen is a constituent of the basement membranes that forms a link between laminin and 
collagen IV. It is actively synthesized by mesenchymal cells during fetal lung development, which 
suggests that nidogen has a key role in the organization of the basement membrane [Warburton et 
al., 2000; Dziadek, 1995]. Although inhibition of the interaction of nidogen with laminin affects the 
progression of lung development in vitro, null mutation of nidogen does not have significant impact 
on lung formation [Dong et al., 2002; Dziadek, 1995; Ekblom et al., 1994].
Collagen IV is a key structural component of all basement membranes. The basement 
membranes of fetal lung present several collagen IV isoforms and these are critical for structural 
lung integrity. However, the specific role of collagen IV molecules during lung morphogenesis 
remains still to be fully elucidated [Suki et al., 2005; Warburton et al., 2000].
Elastin, a cross-linked polymer of soluble tropoelastin monomers, is a critical and prominent 
structural component of the pulmonary ECM. It plays a role in the elastic characteristics of the lung, 
namely property of recoil to the vascular, conducting airway, and terminal airspace compartments 
[Smits et al., 2010; Mariani et al., 1997]. Elastin deposition in the primary septa appears to have a 
spatially instructive role inasmuch as the specific sites of elastic fiber formation correspond precisely 
to the location of future buds. Moreover, elastin also plays a fundamental role in the control of budding 
of secondary septa and it is necessary for proper development of alveoli [Shi et al., 2007; Warburton 
et al., 2000; Mariani et al., 1997].
Fibronectin seems to play an important role in branching morphogenesis by accumula-
ting at clefts, specific points that do not branch [Sakai et al., 2003]. The treatment of developing 
lung rudiments with anti-fibronectin antibody inhibits branching morphogenesis, while fibronec-
tin supplementation promotes lung branching [Sakai et al., 2003; Roman et al., 1991].
Proteoglycans are deposited within the ECM during early embryonic lung branching mor-
phogenesis. They function as flexible structures in the organization of the basement membrane and 
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may also play an important role as a reservoir for growth factors, water and cations [Warburton et 
al., 2000]. Perlecan is a major proteoglycan in the basement membrane and it has also been invol-
ved in the control of smooth cell proliferation and differentiation [Roediger et al., 2009; Warburton 
et al., 2000]. Moreover, both heparan sulfate and chondroitin sulfate proteoglycans are required for 
lung branching, since FGF-10 signaling is mediated by those proteoglycan [Warburton et al., 2005; 
Shannon et al., 2003; Izvolsky et al., 2003]. It was already demonstrated that the inhibition of pro-
teoglycan synthesis or treatment with heparitinase severely affects lung branching [Warburton et al., 
2005; Toriyama et al., 1997]. In fact, disruption of proteoglycans synthesis results in lung malforma-
tion, respiratory distress and neonatal death [Thompson et al., 2010].
Anti-adhesive glycoproteins of the ECM are SPARC and tenascin. SPARC has a wide dis-
tribution in the basement membrane during lung morphogenesis [Warburton et al., 2005]. 
Inhibition studies of SPARC interactions demonstrate branching impairment [Strandjord et al., 
1995]. On the other hand tenascin, namely tenascin C, presents a spatiotemporal distribution 
in the developing lung either in epithelium or mesenchyme, and it has a regulatory role during 
branching morphogenesis [Lambropoulou et al., 2009; Kaarteenaho-Wiik et al., 2001; Jones & 
Jones, 2000]. In fact, some authors defense that tenascin C promotes the penetration into the 
surrounding mesenchyme and the branching of the growing airways [Roth-Kleiner et al., 2004].
1.3.2 Mechanical stimuli 
Physical forces exerted on the developing fetal lung are an important regulator of this process, 
namely intra-thoracic space, fetal breathing movements, peristaltic airway contractions and lung 
fluid. Conditions that induce decrease of intra-thoracic space, such as thoracic tumors or CDH, 
lead to pulmonary hypoplasia as result of lung compression [Copland & Post, 2004].
Fetal breathing movements, resulting from episodic diaphragmatic contractions, are a 
feature of normal fetal life that can be observed as early as 10 weeks of gestation [Copland & Post, 
2004]. These movements cause cyclic fluctuation of intratracheal pressure during fetal life and 
they are required for cell cycle kinetics regulation as well as for biochemical differentiation of Clara 
cells, type I and type II pneumocytes [Shi et al., 2007; Inanlou et al., 2005]. Experimentally, when 
fetal breathing movements are disrupted either mechanically, by transecting the fetal cervical spinal 
cord above phrenic motoneurons, or genetically, in the myogenin null mouse that lacks normal 
skeletal muscle fibers, lung hypoplasia occurs, namely decrease of lung weight and DNA content 
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compared to control animals [Copland & Post, 2004; Tseng et al., 2000; Liggins et al., 1981]. 
Spontaneous and coordinated peristaltic airway contractions are rhythmic narrowings 
of the airways, caused by contractions of the surrounding airway smooth muscle cells. These 
contractions produce a pulsatile distal-driven movement of lung liquid, which might cause an 
expansion of the end lung buds, thereby stretching the epithelial layer lining the buds [Schittny et 
al., 2000]. These peristaltic contractions have been shown to play an important role in embryo-
nic lung branching morphogenesis [Jesudason et al., 2005].
Concerning lung fluid and its intraluminal hydraulic pressure, in utero the lung is a hydrau-
lic, fluid-filled system. This lung fluid has two sources: amniotic fluid and secretions of the epithelial 
cells into the airway lumen, which are osmotically driven by active chloride secretion, through 
chloride channels. This gives rise to a continuous forward flow of lung liquid that drains into the 
amniotic fluid. The larynx and nasopharynx, where the partial occlusion of the vocal cords acts as 
a one way valve, generate back pressure to partially inflate the growing lungs and maintains an 
intraluminal hydraulic pressure of approximately 1.5 cm water in the airways [Shi et al., 2007]. This 
physiological circulation of lung fluid filling the air spaces is critical to lung development. In fact, if 
it is disturbed lung growth and maturation is impaired. For instance, excess fluid drainage during 
fetal life or decrease of fluid pressure, due to oligohydramnios or premature rupture of the mem-
branes, are associated with lung hypoplasia [Shi et al., 2007; Wilson et al., 2007; Copland & Post, 
2004]. In opposition, prenatal tracheal occlusion increases luminal pressure and expansion and, 
consequently, enhances the rate of branching but negatively affects epithelial cell differentiation 
[Unbekandt et al., 2008; Wilson et al., 2007; Flecknoe et al., 2000]. Similar to effects on airway 
branching, lung distention has also been shown to play a critical role in coordinating angiogenesis 
during lung development [Tschumperlin et al., 2010; Cloutier et al., 2008].
Taken together, these observations demonstrate the importance of mechanical forces for 
proper lung development. Mechanotransduction, that is meaning the conversion of mechanical 
forces into biochemical signals, appears to be related with stimulation of gene expression of gro-
wth factors and their receptors. However, the mechanisms by which pressure is sensed have not 
yet been determined, but stress-activated ion channels, stress-induced activation of protein tyro-
sine kinases and ECM-integrin-cytoskeletal pathways have received the most attention [Morrisey 
& Hogan, 2009; Copland & Post, 2007; Liu & Post, 2000].
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1.3.3 Chemical factors 
The fetus develops in physiological hypoxic environment of the uterus. Several studies 
have shown that the low-fetal oxygen environment is beneficial for embryo development and for car-
diovascular and kidney organogenesis [Rajatapiti et al., 2010; Chen et al., 1999; Yue & Tomanek, 
1999; Loughna et al., 1998]. Only recently, it has studied the influence of oxygen on fetal lung 
development. In vitro studies have shown that hypoxia positively regulates lung branching morpho-
genesis [McGovern et al., 2010; Gebb & Jones, 2003]. Indeed, a low-oxygen environment (1.5% 
or 3% versus 21% of oxygen) enhances the rate of branching of both distal lung epithelium and 
vasculature, and increase VEGF and tenascin C expression [Rajatapiti et al., 2010; van Tuyl et al., 
2005; Gebb & Jones, 2003].  Only a study, using whole lung organ culture, did not find significant 
branching acceleration under hypoxic condition [Shinkai et al., 2005]. Moreover, the relevance of 
oxygen in lung development is demonstrated by hypoxia-inducible factor 2α (HIF-2α). HIF-2α is an 
oxygen-regulated transcription factor expressed in endothelial and type II pneumocytes, which ex-
pression increases toward the end of gestation. In vivo experiments with newborn mice expressing 
an AECII conditional mutant of Hif2α revealed that HIF-2α is a key regulator of alveolar maturation 
and the production of phospholipids. In fact, these newborns are born alive but quickly succumb 
to respiratory distress and their lungs present dilated alveoli covered with enlarged, aberrant AECII 
and a diminished number of AECI. Furthermore, the AECII lack two crucial enzymes involved in the 
metabolism of glycogen into surfactant lipids [Huang et al., 2012].
Lung development occurs in a hypercalcaemic environment (free ionized plasma cal-
cium concentration [Ca2+]o of the fetus is higher than of the adult). Recently, Finney el al de-
monstrated that the extracellular calcium-sensing receptor (CaR), which monitored [Ca2+]o, is 
expressed in fetal mouse lung epithelium. Moreover, it was demonstrated that CaR expression 
is developmentally regulated, with an expression peak at 12.5 dpc and a subsequent decrease 
by 18 dpc, after which the receptor is absent [Finney et al., 2008]. Using a lung explant culture 
model, it was verified that lung branching morphogenesis is sensitive to [Ca2+]o. High levels of 
[Ca2+]o, found in fetal plasma, induce suppressive effects on lung branching morphogenesis and 
stimulates lung expansion by increasing fluid secretion into the lumen of the developing lung. 
Thus, fetal [Ca2+]o, acting through a developmentally regulated CaR, is an important extrinsic 
factor that modulates the intrinsic lung developmental program and prevents hyperplastic lung 
disease in utero [Finney et al., 2008; Wilson, 2008]. 
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2. Glycoprotein 130 Family of Cytokines
The gp130 dependent family of cytokines or interleukin-6 (IL-6) family of cytokines is a group 
of functionally and structurally related proteins that comprises IL-6, IL-11, leukemia inhibitory factor 
(LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), and cardio-
trophin-like cytokine (CLC) [White & Stephens, 2011; Heinrich et al., 2003]. Recently, IL-27 and 
neuropoietin (NP) had been also added to this cytokines family [White & Stephens, 2011; White 
& Stephens, 2010; Murakami et al., 2004]. These cytokines are grouped in same family, since all 
exert their action by the bind to plasma membrane receptor complexes containing the common 
signal transducing receptor chain gp130. This is the characteristic that unify these cytokines on the 
same biochemical family [Carbia-Nagashima & Arzt, 2004; Heinrich et al., 2003]. However, each 
cytokine interacts with a specific receptor that is a complex of receptor subunits. Classically, these 
subunits are characterized as α chains (ligand-specific and non-signalling: IL6Rα, IL11Rα and 
CNTFRα) and chains with transduction signal functions (gp130, LIFR and OSMR). According to the 
cytokine, its receptor is composed by different combinations of these subunits.  Thus, the receptor 
complex for gp130 family of cytokines consists of (i) gp130 homodimers with a ligand-specific α 
chain for IL-6 and IL-11; (ii) gp130 heterodimers (gp130/LIFR) without specific α chain for LIF and 
OSM; (iii) or gp130 heterodimers with a ligand-specific α chain (CNTFRα) for CNTF and CLC or α 
chain-like for CT-1 ) [White & Stephens, 2011; Murakami et al., 2004; Heinrich et al., 2003]. Until 
the moment, the α chain recruited by CT-1 has not been characterized [White & Stephens, 2011]. 
Interestingly, human OSM has the exceptional capability to recruit two different receptor comple-
xes, gp130/LIFR heterodimers (type I OSM receptor) and gp130/OSMR (type II OSM receptor), 
while mouse OSM binds to gp130/OSMR only (Figure 4) [White & Stephens, 2011; Murakami et 
al., 2004; Heinrich et al., 2003]. Regarding the new members of this cytokines family, NP was 
also reported to utilize CNTFRα/gp130/LIFR tri-partite receptor complex [Derouet et al., 2004], 
however recent studies demonstrated that NP signaling is not mediated by LIFR signaling [White 
& Stephens, 2010]. On the other hand, IL-27 engages a gp130/WSX-1 (IL27Rα) heterodimeric 
receptor complex [Pflanz et al., 2004].
After activation of the specific receptor complex, signal transduction involves the activation 
of Janus kinase (JAK) and the subsequent recruitment of signal transducers and activators of 
transcription (STAT) proteins, mainly STAT3 and, to a lesser extent, STAT1 [Heinrich et al., 2003; 
Tanaka & Miyajima, 2003]. STAT1 has been shown to be induced by IL-27 [Takeda et al., 2003]. 
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Alternatively, gp130 cytokine family can also initiate cell signaling via other signaling pathways, 
including the mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3 kinase (PI3K) 
cascades [Mihara et al., 2012; Carbia-Nagashima & Arzt, 2004; Heinrich et al., 2003].
The gp130 dependent family of cytokines activates target genes involved in differentiation, 
survival, apoptosis and proliferation [Heinrich et al., 2003]. Therefore, these cytokines  regulate 
a variety of complex biological processes, including hematopoiesis, immune response, inflam-
mation, mammalian fertility, liver and neuronal regeneration, myocardial development, pituitary 
proliferation, bone homeostasis, adipocyte differentiation and function, and embryonic develop-
ment [Mihara et al., 2012; Fujio et al., 2011; White & Stephens, 2011; Carbia-Nagashima & Arzt, 
2004; Heinrich et al., 2003].
IL-6 OSM
IL-11
LIF CT-1
CNTF
CLC
OSM
GP130 LIFR
OSMR
GP130
GP130
GP130
GP130
FAMILY OF 
CYTOKINES 
GP130
HOMODIMERS
GP130
HETERODIMERS
Figure 4. Illustration of receptors of gp130 family of cytokines. IL-6 and IL-11 receptors are gp130 homodimers, whereas LIF, CT-1, CNTF, CLC and OSM 
receptors are gp130/LIFR heterodimers. Human OSM receptor could also be a different receptor complex, a gp130/OSMR heterodimer.
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Absence of common gp130 signal transducer in gp130 KO mice causes embryonic lethality 
and animals are not viable, exhibiting disrupted placental architecture, hypoplastic development 
and a decrease in fetal liver hematopoiesis [Fasnacht & Müller, 2008; Wang et al., 2003], and 
highlighting a role for gp130 signaling during development. Conditional gp130 KO mice, where 
gp130 was inactivated by conditional gene targeting after birth, exhibited neurological, cardiac, 
hematopoietic, immunological, hepatic, and pulmonary defects, confirming the widespread im-
portance of gp130 signaling. Regarding lung, it was demonstrated that a conditional gp130-
mutant mice develop lung emphysema with increasing age [Betz et al, 1998]. Furthermore, lung 
epithelial cell-specific gp130 deficient mice established a role for gp130 signaling in the repair of 
the bronchiolar epithelium following injury, influencing epithelial cell migration, density, and sha-
pe [Fasnacht & Müller, 2008; Kida et al., 2008]. Moreover, LIFRα deletion (a receptor subunit 
part of the receptor complexes for LIF, CNTF, CT-1, CLC and OSM) also causes perinatal death 
with multiple defects [Fasnacht & Müller, 2008; Wang et al., 2003; Betz et al, 1998; Ware et al., 
1995]. On the other hand, mice lacking individual members of gp130-type cytokines displayed 
milder phenotype than expected which is most likely due to the similarity and redundancy of do-
wnstream events induced by gp130-dependent cytokines [Fasnacht & Müller, 2008]. In fact, as 
these cytokines share gp130 as a common signal transducer, they present redundant biological 
activities even though they also exhibit specific biological activities [Carbia-Nagashima & Arzt, 
2004; Heinrich et al., 2003]. Moreover, considering that gp130 is ubiquitously expressed, the 
time and place at which gp130 functions in vivo appears to be mainly determined by expression 
of the respective specific receptor chains and the cytokines themselves, which synthesis and 
release are spatially and temporally restricted [Carbia-Nagashima & Arzt, 2004].
In the following sections the roles of classic cytokines of this family will be briefly reviewed.
 
2.1 Interleukin-6
IL-6 is a pleiotropic cytokine with important roles on acute inflammatory response, infection, 
haematopoiesis, cell growth, differentiation, survival, apoptosis and proliferation [Mihara et al., 2012; 
Heinrich et al., 2003; Dame & Juul, 2000]. The α chain ligand-specific of IL-6 receptor is widely 
distributed in developing human fetuses, which suggest an IL-6 nonhematopoietic role in the develop-
ing fetus [Dame & Juul, 2000]. Indeed, IL-6 signaling has been involved embryonic submandibular 
gland development [Melnick et al., 2001] and lung maturation [Jobe & Ikegami, 2001]. Regarding 
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this point, it has been proved that IL-6 promotes fetal lung maturation by inducing SP synthesis and, 
consequently, it improves lung mechanics and gas exchange [Jobe & Ikegami, 2001; Shimoya et al., 
2000]. Moreover, IL-6 also plays an important modulatory role in lung angiogenesis, a fundamental 
process in fetal lung morphogenesis [McClintock & Wagner, 2005]. In opposition, in adult mice, it has 
been demonstrated that IL-6 is a main causative agent of emphysema, via induction of apoptosis in 
the lung [Ruwanpura et al., 2011]. 
 
IL-6 KO mice present impaired hematopoiesis, defects in acute phase protein synthesis, compro-
mise of the bactericidal and antiviral response, and defects in liver regeneration and bone homeosta-
sis [Bluethmann et al., 1994; Poli et al., 1994].
2.2 Interleukin-11
IL-11, acting either alone or in synergy with other cytokines, is capable of stimulating me-
gakaryopoiesis, thrombopoiesis, myelopoiesis and lymphopoiesis in vitro. Other activities of IL-11, 
outside of the hematopoietic system, include inhibition of adipogenesis, induction of hepatocyte 
production of acute phase proteins, induction of neuronal differentiation, and as a potential re-
gulator of cartilage and bone function [White & Stephens, 2011; Suga et al., 2004; Zheng et al., 
2001; Davidson et al., 1997]. Growing evidence indicates an important role of IL-11 in epithelial 
tissue biology and epithelial regeneration. In fact, IL-11 has been found to have mucosal protecti-
ve effects in the setting of mucosal injury. These effects have been investigated most thoroughly 
in the gastrointestinal tract, where IL-11 stimulates proliferation and differentiation of intestinal 
cells and prevent apoptosis of epithelial cells. Consequently, IL-11 protects small intestinal cells 
following cytoablative treatments, reduces experimental mucositis, and ameliorates injury in 
models of inflammatory bowel disease [Opal et al., 2003; Dickinson et al., 2000]. IL-11 has 
also been shown to improve survival after thoracic irradiation [Wang et al., 2006; Zheng et al., 
2001]. Furthermore, IL-11 attenuates nephrotoxic nephritis [Lai at al., 2001] and it decreases 
severity of acute necrotizing pancreatitis in mice [Shimizu et al., 2000]. Regarding the lung, IL-11 
is produced by a variety of structural cells (fibroblasts, epithelial cells, human airway smooth 
muscle cells) and eosinophils in response to a variety of stimuli [Zheng et al., 2001; Minshall et 
al., 2000]. Actually, IL-11 induces tissue fibrosis and is over-expressed in asthma context, while 
inhibits antigen-induced inflammation. This suggests that IL-11 acts as a healing cytokine in 
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the asthmatic airway and in other tissues. Interestingly, IL-11 provides protective effects against 
oxidant-mediated injury in fetal and adult lung [Waxman et al., 2003; Waxman et al., 1998].
Despite all these IL-11 functions, mice deficient in IL-11Rα only present female sterility 
[Robb et al., 1998].
2.3 Leukemia Inhibitory Factor
LIF is a multifunctional glycoprotein cytokine that regulates many cellular responses such as 
proliferation, differentiation and survival in different cellular types [Heinrich et al., 2003; Metcalf, 
2003; Auernhammer & Melmed, 2000]. Indeed, LIF displays several biological activities ranging 
from the classic hematopoietic and inflammatory actions to effects on blastocyst implantation, 
kidney development, neural development, bone cell metabolism, adipocyte lipid transport and 
energy homeostasis, muscle satellite cell proliferation, heart hypertrophy, retinal vascularization 
and endocrine actions [McColm et al., 2006; Kurdi et al., 2005; Metcalf, 2003; Auernhammer 
& Melmed, 2000]. LIF deficient animals are born normal and they only exhibit female sterility 
due to defective blastocyst implantation, postnatal growth retardation and hematopoiesis defects 
[Pichel et al., 2003; Betz et al., 1998].
During fetal development, LIF expression was already described in the ureteric bud [Plisov 
et al., 2001], skin, skeletal muscle, heart, brain, liver and gut [Robertson et al., 1993] supporting 
a role for this cytokine in the normal development of several organ systems. For instance, LIF 
has an inhibitory effect in fetal kidney development [Bard & Ross, 1991] as well as in embryonic 
stem cells [Williams et al., 1988].
Regarding the lung, numerous lung structural cell types express LIF and the LIFR, sugges-
ting previously unrecognized roles for this cytokine in lung biology [Knight, 2001]. Several studies 
have investigated LIF’s role in the pathophysiology of different lung diseases, such as acute 
respiratory distress syndrome [Jorens et al., 1996], asthma [Xiong et al., 2007], chronic airway 
inflammation [Knight, 2001] and inflammation induced by tobacco [Jorens et al., 1996]. It was 
already described that LIF, with IGF-I, regulates lung maturation. In fact, absence of LIF in addi-
tion to IGF-I null mutant mice aggravates pulmonary immaturity and mice die due to respiratory 
failure. LIF/IGF-I double deficient embryos present lung hypoplasia and defective differentiation 
of the alveolar epithelium and vasculogenesis [Moreno-Barriuso et al., 2006; Pichel et al., 2003].
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2.4 Oncostatin M
OSM is closely related structurally, genetically and functionally to LIF. In fact, it has been 
suggested that OSM and LIF evolved by gene duplication relatively recently [Tanaka & Miyajima, 
2003]. OSM can modulate a variety of biological processes and has some functional overlap with 
LIF, such as growth regulation, differentiation, gene expression, and cell survival. However, OSM 
is also a unique cytokine that plays an important role for various biological systems. These spe-
cific OSM effects appear to be mediated by specific oncostatin receptor (gp130/OSMR) [White 
& Stephens, 2011; Tanaka & Miyajima, 2003].
Regarding these OSM specific functions, OSM modulates growth of malign and benign cells 
either positively (endothelial-like, hematopoietic, Sertoli and Leydig cells) or negatively (solid tissue 
tumor cells, normal mammary and breast epithelial cells,) depending on the target cells [Tanaka 
& Miyajima, 2003; Grant et al., 2001; Miyajima et al., 2000; Hara et al., 1998]. OSM plays some 
important roles in the hematopoiesis [Tamura et al., 2002a], liver development [Morikawa et al., 
2005; Kinoshita & Miyajima, 2002], nervous system development [Morikawa et al., 2005], testis 
morphogenesis [Teerds et al., 2007], inflammatory responses namely in fibroblasts, endothelial 
cells, and lung epithelial cells [Morikawa et al., 2005; Tamura et al., 2002b], and tissue remode-
ling [Znoyko et al., 2005]. Regarding the lung, OSM is a potent mediator of lung inflammation and 
extracellular matrix accumulation, and is up-regulated in patients with idiopathic pulmonary fibrosis 
and scleroderma [Mozaffarian et al., 2008]. 
Despite all OSM functions, OSMR-deficient mice develop normally, presenting alterations in 
hematopoiesis as well as liver regeneration [Tanaka et al., 2003]. OSM-deficient mice exhibit a 
reduction in responses to mechanical and thermal stimuli [Morikawa et al., 2005]. Interestingly, 
OSM overexpression is deleterious during mouse development [Tanaka & Miyajima, 2003].
During fetal life, OSM is expressed in hematopoietic tissues (bone marrow, liver, thymus 
and spleen) and in choroid plexus, and limb [Tamura et al., 2002a]. After birth, it is detectable 
in other organs, such as lymph node, bone, heart, kidney, small intestine, skin, nasal cavity, 
and lung [Morikawa et al., 2005; Tamura et al., 2002b]. In the lung, the signals are detected in 
alveolar epithelium and bronchiolar epithelium [Tamura et al., 2002b]. The OSMR/gp130 recep-
tor complex is widely expressed on a variety of cell types, including epithelial cells, fibroblasts, 
chondrocytes, hepatocytes, and some neurons [Mozaffarian et al., 2008].
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2.5 Cardiotrophin-1
CT-1 was recently discovered substance, which affects most of organ systems. Firstly, it 
was demonstrated that CT-1 is expressed at high levels in the myocardium during the cour-
se of cardiogenesis and supports embryonic cardiomyocyte survival and hypertrophy [White & 
Stephens, 2011; Jougasaki, 2010; Stejskal & Ruzicka, 2008]. In cardiovascular system, CT-1 
also plays an important cardioprotective effect on myocardial damage [Ruixing et al., 2007], 
is overexpressed in individuals with heart failure [Talwar et al., 2000] and hypertensive heart 
disease [López et al., 2007], and it has been proposed as prognostic factor in these pathologies 
[Jougasaki, 2010; Stejskal & Ruzicka, 2008].
It was already demonstrated that CT-1 is expressed in adult heart, skeletal muscle, liver, 
lung, kidney, dorsal root ganglia, ovary, colon, prostate and testis as well as in fetal heart, kid-
ney and lung [White & Stephens, 2011; Jougasaki, 2010; Stejskal & Ruzicka, 2008; Zhou et al., 
2003]. This CT-1 expression pattern suggests that it exerts pleiotropic actions in other organ 
systems, namely hypertrophic and cytoprotective actions [Jougasaki, 2010]. Indeed, CT-1 is a 
hepatocyte survival factor and is involved in liver regeneration [Iñiguez et al., 2006], is a potent 
regulator of signaling in adipocytes [Zvonic et al., 2004], plays an important role in the pathophy-
siology of atherosclerosis [Ichiki et al., 2008], has relevant anti-inflammatory effects namely  in a 
model of endotoxin-induced acute lung injury [Pulido et al., 1999], decreases pulmonary arterial 
pressure in a hypoxic pulmonary hypertension model [Nomura et al., 2003], is important in 
normal motoneuron development [Pennica et al., 1996] and regeneration of the skeletal muscle 
[Nishikawa et al., 2005], induces osteoclast differentiation and activation [Richards et al., 2000], 
and promotes photoreceptor survival [Song et al., 2003]. Furthermore, CT-1 has been related 
with chronic asthma, contributing to airway wall thickening through reduction of apoptosis rates 
and induction of hypertrophy of airway smooth muscle cells [Zhou et al., 2003].
2.6 Ciliary Neurotrophic Factor
CNTF is a 22-kDa nonsecreted cytosolic cytokine synthesized by Schwann cells in the pe-
riphery and by neurons and astrocytes centrally that was originally identified for its role in the 
differentiation and/or survival of different neuronal cell types [White & Stephens, 2011; Rezende 
et al., 2009; Sango et al., 2008; Ozog et al., 2004]. Its specific receptor, CNTFRα, is located on 
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neuronal cell membranes and CNTF seems to be released only by damaged cells [Vlotides et al., 
2004]. CNTF expression and synthesis are dramatically increased by trauma, inflammation and 
ischaemia [Stanley et al., 2000]. Indeed, CNTF acts as a lesion factor, preventing neuronal cell 
death and facilitating axonal regeneration after nerve injury [Sango et al., 2008]. Furthermore, 
CNTF significantly delays cell death in models of photoreceptor degeneration [Wahlin et al., 
2000], and form a part of the feedback loop regulating the hypothalamo-pituitary-gonadal axis 
[Stanley et al., 2000]. Interestingly, this cytokine is suggested to be anti-diabetogenic, since it 
improves peripheral sensitivity to insulin, reduces insulin secretion, adiposity, and body weight 
[Rezende et al., 2009; Ahima et al., 2006]. In addition, CNTF promotes the survival of rat 
pancreatic islets, albeit not affecting its differentiation [Rezende et al., 2009]. However, CNTF 
deficient mice exhibit only very mild neuronal problems as gradual loss of motoneurons, resul-
ting in minor muscle weakness [Takahashi et al., 1994; Masu et al., 1993]. In opposition, mice 
deficient in CNTFRα display profound motoneuron deficits and die perinatally due to inability to 
suckle, suggesting that additional cytokine signal through CNTFRα and compensate for the loss 
of CNTF in CNTF deficient mice [Elson et al., 2000; DeChiara et al., 1995].
It was already described that CNTF is widely expressed in the adult brain, heart, lung, liver, 
kidney and testis, in addition to preferential expression in the sciatic nerve [Ohta et al., 1996]. 
Regarding embryonic development, CNTF is specifically expressed in rat pineal gland and eyes 
[Hata et al., 2002].
2.7 Cardiotrophin-like cytokine
CLC [also known as novel neurotophin-1/B cell-stimulating factor-3 (NNT-1/BSF- 3)] is a newly 
identified gp130-related cytokine with highest homology to CNTF and CT-1 [Forger et al., 2003; 
Uemura et al., 2002]. CLC can be actively secreted from cells due to complex formation with the 
soluble type I cytokine receptor cytokine-like factor-1 (CLF-1) or soluble CNTFR (sCNTFR) [Vlotides et 
al., 2004; Forger et al., 2003]. Interestingly, mice with a targeted deletion of the clf gene exhibit a phe-
notype similar to CNTFRα KO mice [Alexander et al., 1999]. Thus, CLC/CLF-1 composite cytokine is 
a second ligand for CNTFRα [Elson et al., 2000]. 
CLC is mainly expressed in secondary lymphoid organs, such as lymph nodes and spleen, 
but has also been detected in numerous other organ systems including bone marrow, ovary, 
placenta, pituitary, liver, kidney, colon, heart, lung and pancreas [Vlotides et al., 2004; Senaldi 
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et al., 1999]. During development, CLC is expressed in lung, kidney, brain, tooth, epithelia and 
skeletal muscles. In the lung, CLC is expressed faintly in distal airway epithelium whereas CLF is 
strongly expressed in distal and proximal epithelia [de Bovis et al., 2005]. This CLC expression 
pattern suggests important biological roles in cellular functions. 
CLC has been shown to act as a potent neurotrophic factor, B cell stimulatory agent [Senaldi 
et al., 2002; Senaldi et al., 1999] and neuroimmunoendocrine modulator of corticotroph func-
tion [White & Stephens, 2011; Vlotides et al., 2004; Elson et al., 2000]. Indeed, CLC supports 
the survival of embryonic motor and sympathetic neurons [Forger et al., 2003; Elson et al., 
2000; Senaldi et al., 1999] and induces astrocyte differentiation of fetal neuroepithelial cells 
[Uemura et al., 2002]. CLC/CLF-1 complex also promotes mesenchymal to epithelial conversion 
and nephrogenesis [Schmidt-Ott et al., 2005].
2.8 Interleukin-27 and Neuropoietin
Recently, IL-27 and neuropoietin were also included in the gp130 dependent family of 
cytokines. IL-27 is important in immune response regulation since it has broad inhibitory effects 
on Th1, Th2, and Th17 subsets of T cells [Jankowski et al., 2010]. Moreover, it has been described 
that IL-27 is involved in processes such as neuronal growth, bone maintenance, cardiac deve-
lopment, angiogenesis regulation and intestinal epithelial barrier protection [Diegelmann et al., 
2012; White & Stephens, 2011; Villarino et al., 2004]. 
Regarding neuropoietin, it has been characterized as a regulator of central nervous sys-
tem development, with the ability to induce neuroepithelial cells differentiation into astrocytes 
[White & Stephens, 2011; White & Stephens, 2010; Derouet et al., 2004]. Moreover, neuropoietin 
was shown to inhibit adipogenesis and to have ability to modulate insulin sensitivity [White & 
Stephens, 2010].
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3. Renin-Angiotensin System
Since the first identification of renin by Tigerstedt and Bergmann in 1898, the renin-angio-
tensin system (RAS) has been extensively studied. The RAS is classically known as an endocrine 
system regulating blood pressure, electrolyte and fluid homeostasis [Paul et al., 2006; Lavoie & 
Sigmund, 2003]. This classical RAS consists of several key components, namely angiotensinogen 
(the hepatic derived precursor), two critical enzymes, renin (secreted from the juxtaglomerular 
apparatus of the kidney) and angiotensin-converting enzyme (ACE, pulmonary-bound metallopro-
teinase), whose sequential actions produce the decapeptide angiotensin I and the physiologically 
active octapeptide, angiotensin II (ANG II), respectively. ANG II operates on two G protein-coupled 
receptors, the ANG II type 1 (AT1) and type 2 (AT2) receptors [Goyal et al., 2011; Paul et al., 2006].
AT1 receptor has been described to be expressed during both fetal and postnatal life, while 
AT2 receptor expression is almost solely in the fetus and dramatically decreases after birth, being 
restricted to a few organs and at low levels, such as brain, adrenal, heart, kidney, myometrium 
and ovary [de Gasparo et al., 2000; Morrell et al., 1996; Shanmugam et al., 1996]. Indeed, an 
increase of AT2 receptor expression during adult life has been only observed under pathological 
conditions, such as vascular injury, myocardial infarction, heart failure, renal failure, brain isch-
aemia, skin wounds and sciatic or optic nerve transsection [Kaschina & Unger, 2003]. 
ANG II has an important role in vascular tone regulation and it is one of a growing number of 
peptide hormones that have been involved in cellular growth and apoptosis regulation [Lemarié & 
Schiffrin, 2010; Paul et al., 2006]. An opposite action of AT1 and AT2 receptors has been shown both 
in vitro and in vivo studies. Whereas AT1 mediates the vasoconstrictor and growth promoting effects of 
ANG II, AT2 has been shown to mediate vasodilator effects, to exert inhibitory effects in cell prolifera-
tion, growth and hypertrophy, and to promote apoptosis [Lemarié & Schiffrin, 2010; Chassagne et al., 
2000]. For instance, AT2-mediated actions that counteract AT1 effects have been described on endo-
thelial [Stoll et al., 1995] and vascular smooth muscle cells proliferation [Akishita et al., 1999], heart 
hypertrophy [Inagami & Senbonmatsu, 2001], phosphatidylinositol hydrolysis in rat skin fibroblasts 
[Gyurko et al., 1992], and fetal kidney development [Yosypiv, 2011]. The dual actions of ANG II on its 
receptors, i.e. this broader and functional antagonism between AT1 and AT2 receptors, with respect to 
tissues growth, could be physiological interpreted as a basis of a RAS homeostasis at the tissue level. 
This mechanism might control organ development, differentiation and remodeling, for instance, in 
cases where excessive growth, induced by growth factors, needs to be controlled.
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The signaling pathways of the AT1 receptor include classical G-protein-coupled cascades lead-
ing to activation of MAPK and PI3K/Akt cascades, and JAK/STAT pathway [Stoll & Unger, 2001]. 
The elucidation of the nature of AT2 signaling remains enigmatic and still is a matter of intense 
research efforts. However, while ANG II via AT1 receptors mediates their growth actions through 
kinases activation, a hallmark of AT2 signaling on growth suppressing actions appears to be more 
related with the activation of specific phosphatases causing protein dephosphorylation. These 
phosphatases can lead to the inhibition of MAPK [namely extracellular signal-regulated kinases-1 
and -2 (ERK1/2 or p44/42) and JNK], PI3K/Akt and STAT pathways, and activation of p38 kinase 
and nuclear factor (NF)-κβ [Lemarié & Schiffrin, 2010; Yosypiv, 2011; Stoll & Unger, 2001]. The 
stimulation of the AT2 receptor may involve two other mechanisms: activation of bradykinin/ nitric 
oxide/ cyclic guanosine 3’,5’-monophosphate pathway, and stimulation of phospholipase A2 and 
release of arachidonic acid [Lemarié & Schiffrin, 2010].
The current view of the RAS had to be expanded significantly by more recent findings that 
increased complexity of the system. Exciting new concepts, such as the identification of new 
peptides [ANG (1-7)] [Santos et al., 2000], new enzymes (serine protease chymase, ACE-2) 
[Arakawa & Urata, 2000; Donoghue et al., 2000], novel receptors (AT4) [Swanson et al., 1992], 
and signal transduction pathways involved [Sayeski & Bernstein, 2001; de Gasparo et al., 2000], 
have been derived from recent studies.
Moreover, the introduction of the local tissue RAS concept, not requiring hormone secre-
tion into the systemic circulation, also has changed our view of the RAS. This local RAS concept 
was based on findings of RAS components in unlikely places (for instance, the presence of renin 
in the brain) where the endocrine actions of the system could not explain the findings [Kaparianos 
& Argyropoulou, 2011; Paul et al., 2006]. The definition of local RAS requires that all components 
necessary for the biosynthesis of the biologically active peptide, ANG II, as well as receptors for 
this product, are present within the tissue. Furthermore, the biologically active product needs to be 
regulated within the tissue, independently of the systemic circulation [Carey & Siragy, 2003].
The first local RAS was described on kidney [Yosypiv, 2011; Gomez et al., 1988]. In this 
sequence, during the last two decades, evidences have demonstrated the presence of functional 
local RASs with autocrine/paracrine/intracrine actions in several other organs or systems, such 
as nervous system and sensory organs, heart, blood vessels, adrenal glands, reproductive tract, 
digestive organs, skin, adipose tissue, and lymphatic organs [De Mello & Frohlich, 2011; Vaajanen 
& Vapaatalo, 2011; Leung, 2007; Paul et al., 2006; Engeli et al., 2000]. If there is a common de-
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nominator for the physiological role of these local systems, it is the preservation of a homeostasis, 
at the tissue level, between opposing effects mediated by the RAS, such as growth promotion (via 
AT1) and inhibition (via AT2). The dual actions of ANG II on its receptors can be considered as a 
basis for this balance [Paul et al., 2006]. Regarding the cardiac RAS, for instance, the predominant 
physiological role appears to be the maintenance of an appropriate cellular milieu balancing stimuli 
inducing and inhibiting cell growth and proliferation, as well as mediating adaptive responses to 
myocardial stress, for example, after myocyte stretch [De Mello & Frohlich, 2011; Paul et al., 2006]. 
Moreover, it has been also demonstrated that local ANG II formation and its tissue-specific 
effects on growth and differentiation are extremely important for embryonic and fetal development 
[Paul et al., 2006; Hu et al., 2004; Morrell et al., 1996; Shanmugam et al., 1996; Grady et al., 
1991]. The different RAS components were already described to be widely expressed on extraem-
bryonic fetal tissues, as chorion, decidua and placenta, and in different developing organs, display-
ing specific spatial and temporal distribution during gestation, which suggest a possible role for 
ANG II in organogenesis [Leung, 2007; Paul et al., 2006; Morrell et al., 1996; Shanmugam et al., 
1996]. Indeed, ANG II has already been demonstrated as an important modulator of fetal kidney, 
heart, vasculature, adrenal gland, liver and brain development [Yosypiv, 2011; Paul et al., 2006]. 
Regarding lung morphogenesis, there is some evidence that lung expresses ACE as well as 
AT1 and AT2 receptors during fetal development. In rat, ACE expression was observed in endothe-
lium of hilar pulmonary arteries since 15 dpc, whereas AT1 mRNA was expressed by non-epithe-
lial undifferentiated mesenchyme on 17 dpc [Morrell et al., 1996] and AT2 mRNA was expressed 
in pulmonary artery since 15 dpc and in bronchi and trachea since 17 dpc [Shanmugam et al., 
1996]. Interestingly, ANG II has been demonstrated to potentiate the mitogenic effect of EGF 
[Norman et al., 1987] and increase expression of PDGF [Grady et al., 1991; Naftilan et al., 1988], 
both positive regulators of branching morphogenesis. Furthermore, it is also well known that 
the maternal administration of angiotensin converting-enzyme inhibitors (ACE-I) or angiotensin 
receptor-antagonists (ARA) against hypertension, during gestation, induces several congenital 
anomalies, such as oligohydramnios, intrauterine growth retardation, hypocalvaria, renal dyspla-
sia, renal failure, pulmonary hypoplasia and death. In addition to the oligohydramnios induced 
by these pharmacological drugs, other underlying mechanism for lung hypoplasia development 
still remains unknown [Walfisch et al., 2011; Quan, 2006; Cooper et al., 2006].
Although the widespread expression and functions of RAS components either during fetal or 
adult life, the AT1 receptor KO phenotype is only characterized by ex utero survival rate decrease, 
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low body weight gain, hypotension, and abnormal kidney morphology [Kaschina & Unger, 2003]. 
On the other hand, AT2 receptor KO phenotype revealed subtle deficiencies, such as impaired 
drinking responses to water deprivation, increased vasopressor responses to injection of ANG II, re-
duced body temperature, spontaneous movements and exploratory behavior [Stoll & Unger, 2001; 
Akishita et al., 1999; Hein et al., 1995]. Indeed, histological sections of heart, kidney, brain, aorta, 
adrenal, lung, spleen, ovary, uterus, pancreas, eye, skeletal muscle and blood did not reveal any 
differences in morphology between non-mutant and hemizygous or homozygous AT2 mutant mice 
[Hein et al., 1995]. However, it is necessary to stress that the KO approach may induce a pheno-
type that is a mixture of both lack of receptor function and compensatory events and mechanisms 
during development and later life [Stoll & Unger, 2001].
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4. Congenital Diaphragmatic Hernia
Severe respiratory failure in the newborn remains a main cause of neonatal death. Among 
the causes of severe respiratory failure in the newborn, CDH remains the most life threatening 
[Gosche et al., 2005]. 
In the history of Medicine, the earliest recordings of diaphragmatic hernia comes from 
Hippocrates (460-370 BC), who declared that it was caused by traumatic perforations, with en-
suing herniation of abdominal viscera into the thoracic cavity, and subsequent death [Coar, 1822]. 
On the other hand, the first CDH description occurred only in 1679 by Lazarus Riverius, as an 
incidental postmortem finding in 24 years-old man [Riverius, 1679]. The first pediatric case of CDH 
was recorded in 1701 by Sir Charles Holt, who described the clinical and postmortem findings of 
an infant with 2 months-old with CDH [Holt, 1701].
Actually, CDH is considered a severe developmental anomaly, with a mean incidence of 1:2.500 
live births, which etiology remains poorly understood [Keller et al., 2010; van den Hout et al., 2009; 
Gosche et al., 2005]. This congenital anomaly is characterized by a diaphragmatic defect that allo-
ws intra-thoracic herniation of abdominal organs and consequently maldevelopment of the alveoli 
and pulmonary vessels. The diaphragmatic defect may differ in its localization, dimensions and type 
and, consequently, it associates to different degrees of pulmonary hypoplasia and clinical severity. 
In humans, four types of diaphragmatic defects can be recognized: a posterolateral or Bochdalek 
type, an anterior Morgagni type, a central hernia or septum transversum type, and diaphragmatic 
eventration type (an incomplete diaphragmatic muscular consolidation). The Bochdalek hernia is the 
most common diaphragmatic defect (about 70% of the cases) [van Loenhout et al., 2009]. Since the 
diaphragmatic closure on the right side occurs earlier than the left, it occurs on the left side in 85-90% 
of cases, which is the form that is associated with worse prognosis. CDH occurs in 13% of cases on 
the right side and only 2% are bilateral [Rottier & Tibboel, 2005; Gallot et al., 2005].
The clinical presentation of CDH infants is very heterogeneous and the outcome of new-
borns is sometimes quite surprising. At one extreme of the spectrum of the disease there are 
newborns minimally affected with excellent prognosis after surgical correction of the diaphrag-
matic defect. At the opposite, there are severe CDH cases with multiples associated anomalies, 
which determine a poor prognosis that could even result in fetal demise. In the middle range, 
they are found CDH classic infants with severe pulmonary hypoplasia and PH that require in-
tensive and sophisticated treatment in addition to the straightforward surgical diaphragmatic 
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correction. These newborns represent the greatest challenge for those caring CDH infants, be-
cause if they survive to the critical neonatal period, lung will growth progressively and resolution 
of increased vascular resistance will occur with good long term prognosis. 
4.1 CDH Etiology
Classically, CDH has been explained based on 4 different theories: i) the diaphragmatic 
malformation is linked to abnormal adjacent lung development, due to the absence of critical 
signals emanating from adjacent lung; ii) the diaphragmatic defect is secondary to abnormal 
muscle innervations by the ipsilateral phrenic nerve; iii) the diaphragmatic hernia is secondary 
to atypical myotube formation, resulting in a fragile diaphragm that could rupture during the fetal 
life; iv) CDH formation is due to an abnormal or delayed closure of the pleuroperitoneal canal 
secondary to blockage by the intestine returning into the abdominal cavity [Gosche et al., 2005]. 
A fifth most recent theory, proposed by Babiuk et al suggests that the amuscular mesenchymal 
component of the pleuroperitoneal fold, likely derived from the somatopleure, is defective and 
does not provide a full foundation for the formation of diaphragmatic musculature. Thus, the 
error arises from an amuscular mesenchymal malformation [Babiuk et al., 2003]. 
Regardless of the theories that explain the CDH embryonic origin, its molecular dynamics 
and genetic defects are yet unknown. It probably results from genetic predisposition and/or envi-
ronmental factors. Among environmental factors, the study of the vitamin A deficiency effects in 
humans and teratogenic animal models suggest that the retinoid signaling pathway is important in 
CDH etiology [Clugston et al., 2010; van Loenhout et al., 2009; Kling & Schnitzer, 2007; Mey et al., 
2003; Thébaud et al., 1999]. Regarding the genetic factors, the possible involvement of different 
genes in CDH has been suggested by the analysis of both chromosomal abnormalities (found in 
10-30% of human infants with CDH) and transgenic mice. There are a lot of genes whose dele-
tion has been associated with true diaphragmatic defects, such as: Chicken ovalbumin upstream 
promoter-transcription factor II (COUP-TFII), retinoid receptors RARα and β type, retinal dehydro-
genase (RALDH) 1, 2 and 3, Stimulated by retinoic acid gene 6 homolog (STRA6), Wilm’s Tumor 
1 (Wt1),  Slit3, Roundabout (ROBO1), Glypican-3 (GPC3), Fibulin-4 (FBLN4), collagen, Delta-like 
3, the Lunatic Fringe and other Notch pathway factors. On the other hand, there are other genes 
that are associated with defects in the diaphragmatic muscle fibers, such as Fog2 (Friend of GATA 
2), GATA4, Pax3, HGF and c-Met, Grb2-associated binding 1 (Gab1), Lysyl oxidase (Lox), Single-
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minded homolog 2 (Sim2), Myogenic differentiation 1 (MyoD) and dystrophin, and fibrillin-1 (FBN1) 
[reviewed by Brady et al., 2011; Klaassens et al., 2009; Holder et al., 2007]. 
It is necessary to stress that CDH can occur as an isolated defect or may have other coe-
xistent congenital defects, or it may even be a part of syndromes with complex malformations. 
In fact, in about 10-20% of affected fetuses, CDH is associated with a chromosomal abnormality, 
mainly trisomy 18, trisomy 13, and Pallister- Killian syndrome (mosaicism for tetrasomy 12p) 
[Holder et al., 2007]. CDH presents frequent association with other defects, mainly cardiac, 
renal and skeletal, and multiple malformation syndromes (e.g., Fryns syndrome, de Lange’s 
syndrome, and Marfan syndrome) [Holder et al., 2007].
One inquisitive aspect in the CDH patophysiology is the presence of bilateral pulmonary hypo-
plasia from early stages of lung development.  Actually, it is well established that the diaphragmatic 
defect is independent, as well as previous or simultaneous to the pulmonary hypoplasia [Babiuk & 
Greer, 2002]. Thus, convincing evidences suggest that there being a common mechanism under-
lying the pathogenesis of CDH that targets primordial diaphragm and lung development in parallel. 
This highlights the hypothesis that an insult occurs in a critical point of the embryonic development, 
affecting other organs than diaphragm, like the lung and even the heart. Interestingly, from animal 
studies, it has been demonstrated that fetal lung hypoplasia in CDH results from complex dynamic 
processes that can be divided in early and late gestational determinant, according to the dual-hit 
hypothesis [Keijzer et al., 2000]. In this hypothesis the pathogenesis of pulmonary hypoplasia 
in CDH is explained by two developmental insults. The first insult occurs early in development 
(early determinants), before diaphragm development take place, and appears to be secondary to 
molecular disturbances. This early insult affects both lungs equally during pseudoglandular and 
canalicular stages of lung development. The second insult (late determinants) occurs after the 
establishment of the diaphragmatic defect. It seems to be primarily related to mechanical factors, 
mediated by visceral thoracic herniation, and affect essentially later stages of lung development of 
the affected side [Keijzer et al., 2000]. Thus, it results in greater impairment of the development of 
the ipsilateral lung than of the contralateral one.
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4.2 CDH Pathophysiology
CDH was originally regarded as an anatomic disease (solely related to the diaphragmatic 
defect) and, consequently, a surgical emergence. It was believed that the postnatal respiratory 
insufficiency and failure was secondary to lung compression induced by the herniated organs into 
the thorax, often including small intestine, colon, stomach and more rarely the spleen and liver, 
pancreas, adrenals and kidneys. Thus, the surgical reduction of the hernia and the defect closure 
allowed lung re-expansion [Deprest & De Coppi, 2012; Chinoy, 2002]. 
However, during 90th years, the knowledge of CDH pathophysiology progressed and it became 
clear that lung hypoplasia, abnormal arteriolar muscularization and consecutive persistent pulmonary 
hypertension (PH) associated with this disorder were the key determinants of mortality [Luong et al., 
2011; Keller et al., 2010; van den Hout et al., 2009]. Contradictory results about lung maturity and 
surfactant status in CDH have been published [van Tuyl et al., 2003; Thébaud et al., 2001; Keijzer 
et al., 2000], but one of the most recent studies performed with human CDH fetuses demonstrated 
that surfactant maturation is not delayed [Boucherat et al., 2007]. In this way, CDH treatment has 
evolved to the concept of physiological emergence [Luong et al., 2011; Masumoto et al., 2009]. It was 
demonstrated that early surgery repair is associated with unfavorable changes in lung compliance 
and gas exchange. Thus, several authors have advocate and shown benefit to delayed surgical repair 
of CDH, after clinical stabilization [Deprest & De Coppi, 2012; Masumoto et al., 2009; Charlton et 
al., 1991]. In our days, initial therapy is directed toward hemodynamic stabilization and respiratory 
support. This awareness results in improvement in therapeutics, like pulmonary vasodilators (inha-
led nitric oxide), sophisticated ventilation strategies (high frequency oscillatory ventilation) and extra 
corporeal membrane oxygenation (ECMO) [de Buys Roessingh & Dinh-Xuan, 2009; Bartlett, 2005]. 
Despite the improvements in understanding CDH pathophysiology and advances in neonatal 
care, in the most severely affected subset of CDH newborn, the prognosis remains poor, with a morta-
lity and morbidity rates that remains exceedingly high [Luong et al., 2011; Keller el al., 2010; van den 
Hout et al., 2009; Colvin et al., 2005]. Reports of the CDH mortality rate range from 32 to 62%, with 
some specialized tertiary care centers achieving survival rates of 70% or more [DeKoninck et al., 2011; 
Stege et al., 2003]. Unfortunately, there is significant long-term morbidity among survivors, mainly 
pulmonary (including bronchopulmonary dysplasia, asthmatic symptoms and recurrent respiratory 
tract infections) and gastrointestinal (reflux disease, oral aversion, and growth problems) [Rocha et al., 
2011; Peetsold et al., 2009; Bagolan & Morini, 2007].
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4.3 CDH Animal Models
Since the etiology and pathogenesis of CDH and its associated anomalies are still largely 
unknown, several animal models have been proposed to study CDH. The animal models avail-
able to study CDH include: i) surgical models in the rabbit and sheep; ii) teratogen-induced 
models in the rat and mouse; iii) and genetic (KO) mouse models [van Loenhout et al., 2009; 
Kling & Schnitzer, 2007; Clugston et al., 2006].
Surgical models are based on a surgical intervention making a diaphragmatic defect in 
fetal rabbits and sheep. Two variants of the surgical CDH animal model exist. The first consists 
in surgically creation of diaphragmatic defect and position of abdominal bowel into the chest, in 
fetal lamb and rabbits. The second model consists in inflation of a balloon in the thoracic cavity 
of fetal lambs [van Loenhout et al., 2009]. Surgical animal models are useful in investigating 
interventional therapies, such as the corticosteroids administration, in utero repair of the dia-
phragmatic defect and tracheal occlusion [Bratu et al., 2001]. Unfortunately, the diaphragmatic 
defect is created relatively late in gestation and certain pulmonary changes seen in human CDH 
might have occurred prior to this time. Therefore, these surgical models are less instructive in 
studying the etiology and pathogenesis of CDH, as well as the other associated anomalies (such 
as cardiac anomalies) [van Loenhout et al., 2009].
Regarding the teratogenic animal models, CDH can be induced by administration of 
a pan-RAR antagonist (BMS493) or RALDH2 inhibitors, such as 2,4-dichlorophenyl-p-nitro-
phenylether (nitrofen; an herbicide), 4-biphenyl carboxylic acid (BPCA; a breakdown product of 
a thromboxane-A2 receptor antagonist), bisdiamine (an inhibitor of alcohol dehydrogenase), or 
SB-210661 (a benzofuranyl urea derivative developed for inhibiting 5-lipoxygenase) [Clugston et 
al., 2010; van Loenhout et al., 2009; Kling & Schnitzer, 2007; Mey et al., 2003; Thébaud et al., 
2001; Thébaud et al., 1999; Tasaka et al., 1992].
The nitrofen model is the most extensively used for the study of CDH. This model is based 
in its administration to pregnant dams on 9.5 dpc when normal lung and diaphragm development 
are just about to begin. Originally, nitrofen was used as an herbicide and, in spite of the extensive 
use of nitrofen in agriculture, its teratogenetic effects have never been shown to play a role in hu-
man CDH. In toxicology screens in adult rats, no apparent problems were observed. However, the 
nitrofen administration during midgestation to pregnant dams causes developmental anomalies 
that reasonably replicate the major abnormalities and the pathophysiology described in human 
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CDH [van Loenhout et al., 2009; Montedonico et al., 2008; Kling & Schnitzer, 2007]. In fact, in this 
model, the specific location and extent of the diaphragmatic defects are very comparable, but also 
the similarities in the CDH-associated anomalies, including lung hypoplasia and PH, and cardiovas-
cular and skeletal defects, are impressive too [van Loenhout et al., 2009; Migliazza et al., 1999a; 
Migliazza et al., 1999b; Tenbrinck et al., 1990]. Therefore, the nitrofen-induced CDH model is one 
of the best to investigate the etiology, pathogenesis and therapeutic options in CDH.
Although the mechanism by which nitrofen induces the diaphragmatic defect and lung 
hypoplasia remains to be elucidated, recent evidences suggest the involvement of abnormali-
ties linked with the retinoid signaling pathway in this model and also in human CDH etiology 
[Montedonico et al., 2008; Kling & Schnitzer, 2007; Gallot et al., 2005; Greer et al., 2003]. The 
first evidence that CDH could be connected to perturbations in the retinoid signaling pathway 
was obtained already in 1941 by Andersen, who described diaphragmatic hernias in embryos of 
pregnant rats on a vitamin-A-deficient diet [Andersen, 1949]. This effect of maternal vitamin A 
deficiency was confirmed by Wilson et al in 1953 [Wilson et al., 1953]. Moreover, CDH and lung 
hypoplasia have been also described in RARα and β compound KO, as well as in mice with the 
deletion of the RXR ligand activation domain [Kling & Schnitzer, 2007; Mascrez et al., 1998]. 
One clinical study demonstrated the presence of decreased plasma levels of retinol and retinol-
binding protein in human CDH, suggesting a possible deterioration of retinol transport across the 
placenta [Major et al., 1998]. Furthermore, CDH has been observed in patients with deletions 
on the 15q chromosome, which contains the encoding gene for cellular retinoic acid binding pro-
tein (CRABP1) [van Loenhout et al., 2009; Holder et al., 2007; Major et al., 1998]. Additionally, 
administration of RA to nitrofen-treated lung explants demonstrated an increase in lung growth 
and partially rescued the hypoplasia [Montedonico et al., 2006]. In vivo, exogenous administra-
tion of retinoids (vitamin A or RA) improves lung growth and maturation, increases fetal survival 
and decreases the incidence of CDH, in the nitrofen-induced CDH model [Montedonico et al., 
2006; Baptista et al., 2005; Babiuk et al., 2004; Thébaud et al., 1999]. Regarding this teratogen 
model, it was already demonstrated that nitrofen inhibits RALDH2, a key enzyme responsible for 
the conversion of retinal to retinoic acid [Mey et al., 2003]. 
Besides the retinoid signaling pathway, another pathway implicated in CDH is the thyroid 
hormone signaling pathway. Nitrofen, triidothyronine (T3) and thyroxine (T4) have similar chemi-
cal structures. Therefore, it is possible that nitrofen influences both diaphragm formation and 
lung development by interfering with thyroid hormone homeostasis [van Loenhout et al., 2009; 
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Brandsma et al, 1994]. Nonetheless, a clear relation between the thyroid signaling pathway and 
lung or diaphragm defects has not been demonstrated so far.
In summary, although the nitrofen model appears to be the best model available since the 
timing of the developmental insult is similar to that in humans, a large disadvantage is that the 
significance of the potential teratogenic effects of nitrofen in rodents has never been demonstrated 
in humans. Moreover, although increasing evidence of the etiology of CDH points towards a dis-
turbance in the retinoid signaling and/or thyroid signaling pathways, the nitrofen model has not 
resolved the pathogenesis of CDH [van Loenhout et al., 2009].
Concerning genetic models, the use of KO mice technology allowed linking several expected 
and unexpected genes to CDH. Indeed, several reports of diaphragmatic defects in genetically en-
gineered mutant mice have been described, introducing potential genetic models for the study of 
CDH. Diaphragmatic defects have been observed in Wt1 null-mutant mice, in RARα and β2 double 
null-mutant mice, in MyoR and capsulin double null-mutant mice, in mice with COUP-TFII condition-
ally inactivated in mesenchyme tissues, in single null mutant mice for Gli2 and Gli3 as well as the 
double mutant, in Slit3 null mutant mice, in Fog2 mutant mice, in Gata4 KO mice, and in PDGFRα 
null mice models [van Loenhout et al., 2009; Clugston et al., 2006]. However, translation to the 
CDH human situation has not been made for all these genes. Moreover, the observed phenotype in 
CDH is so variable that it is potentially not due to a single gene mutation, but the result of multiple 
gene mutations. The different genes involved in different signaling pathways that have been shown 
to be important for normal embryonic development might be involved. 
4.4 CDH Clinical Approach
CDH prenatal diagnosis, which occurs in at least two out of three cases, is possible from 
routine obstetric screening from 15 weeks of gestation [DeKoninck et al., 2011]. The magnetic 
resonance imaging (MRI) is indicated for fetal differential diagnosis with other birth defects. After 
confirmation of prenatal diagnosis of CDH is necessary ruling out chromosomal abnormalities/
malformations. In fact, the presence of chromosomal abnormalities and/or other structural 
malformations, which occurs in around 40%, is associated with a worse prognosis, with mortality 
exceeding 90% [Deprest et al., 2011; Stege et al., 2003]. In these cases, several authors propose 
the medical termination of pregnancy. In the other cases, it is necessary stratify the prognosis 
[reviewed by Doné et al., 2008]. In addition to the chromosome and/or other malformations are 
52 Looking for Novel Physiological Regulators of Lung Development
several prognostic factors that have been proposed for follow-up of CDH fetuses, including the 
upper versus lower position of the left hepatic lobe, the right lung area to head circumference ra-
tio (LHR), gestational age at the time of prenatal diagnosis, the presence of polyhydramnios, the 
lung area to thorax transverse area ratio, the stomach in intra-thoracic position, side and size of 
the defect, the hypoplasia degree of the abdominal cavity, the left ventricular hypoplasia degree, 
the impedance of the left pulmonary artery, the acceleration time to right ventricular ejection 
time ratio, and the evaluation of fetal lung volumetry by 2D ultrasound, 3D or MRI [reviewed 
by Gucciardo et al., 2008]. However, many of these possible prognostic factors have not been 
universally accepted. The two prognostic factors that have obtained more consistent results are 
the LHR (expressed as a function of what is expected in a gestational aged control; observed /
expected LHR) [Alfaraj et al., 2011; Jani et al., 2009; Jani et al., 2007] and liver position [Mayer 
et al., 2011; Knox et al., 2010].
Based upon in these parameters, CDH fetuses can be now prenatally stratified into low and 
high-risk groups. The low-risk fetuses should be managed expectantly during pregnancy [DeKoninck 
et al., 2011; Mayer et al., 2011]. In opposition, for the high-risk fetuses (i.e. fetuses which prognosis 
is predictably poor with postnatal treatment available), the consensus is that something needs to 
be done before birth in order to total or partially revert the fetal lung hypoplasia. Hence, antenatal 
therapies that promote fetal lung growth remain an appealing approach to improve survival of high-
risk CDH fetuses [Deprest & De Coppi, 2012]. 
Regarding fetal surgical interventions, such as open fetal repair of the diaphragmatic defect and 
fetoscopic endoluminal tracheal occlusion (FETO), it is recognized that might improve lung growth. 
However, these techniques are invasive, technically demanding, limited by the maternal and fetal 
risks, and its efficacy is still not determined, with controversial results in survival and morbidity rates 
[Jani et al., 2009; Harrisson et al., 2003]. Recently, a brasilian group described in a randomized 
controlled trial with 41 patients that FETO improves neonatal survival in cases with isolated severe 
CDH [Ruano et al., 2012]. Moreover, the FETO consortium demonstrated that FETO in severe CDH 
is associated with a high incidence of spontaneous preterm premature rupture of membranes and 
preterm delivery, but a substantial improvement in survival. In fact, survival rate increased in severe 
cases with leftsided CDH from 24.1% to 49.1%, and in right-sided CDH from 0% to 35.3% [Jani et al., 
2009]. Subsequently, a randomized trial comparing expectant management during pregnancy and 
FETO, followed by standardized neonatal care (TOTAL, the Tracheal Occlusion to Accelerate Lung 
growth-trial) has been set up and is currently underway [DeKoninck et al., 2011]. 
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At the same time, less invasive approaches such as antenatal pharmacological treatment 
to stimulate lung growth before birth and to treat PH are also under investigation [Luong et al., 
2011; Santos et al., 2006; Baptista et al., 2005; Thébaud et al., 1999].  For instance, Santos et 
al described that maternal administration of ghrelin attenuates pulmonary hypoplasia in nitrofen-
induced CDH model [Santos et al., 2006]. Furthermore, Luong et al demonstrated recently that 
antenatal sildenafil treatment attenuates PH in experimental CDH [Luong et al., 2011. However, 
until the moment, any of the above strategies had resulted in significant clinical impact. 
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Aims and Thesis Layout
Pulmonary development is a complex process involving two different cellular phenomena, growth 
and maturation. The growth process occurs through fundamental cross-talk interactions between 
epithelial and mesenchymal tissues, airway and vasculature, involving a multitude of effectors in-
cluding growth factors, hormones, extracellular matrix interactions, and mechanical stimuli. During 
the last decades, the regulating mechanisms of lung growth have been unraveled. However, regar-
dless of the advanced knowledge of normal lung growth, there are several possible regulators and 
determinants that need to be investigated.
Lung pathologies are an epidemiological relevant issue. Indeed, there are several pediatric and 
adult diseases characterized by lung hypoplasia or dysplasia, involving important morbidity and 
mortality rates, around the world. The understanding of the effectors and lung growth regulatory 
mechanisms has clinical relevance since it can open new perspectives in the treatment of these 
lung diseases as well as modulation of lung repair. 
The present dissertation was developed according to this rationale: to clarify novel physiologi-
cal regulators of normal lung morphogenesis, expecting to contribute for the development of 
new therapeutic or preventive strategies for lung diseases. For someone who is a resident of 
Gynecology and Obstetrics, an especial interest in congenital lung diseases is natural.  Moreover, 
since long, our lab has focused research on the pathophysiology and development of potential 
prenatal therapeutics for CDH. 
Thus, the following specific aims were pursued in this thesis:
i. To investigate the role of inflammatory cytokines, namely gp130 family of cytokines, on fetal lung growth;
ii. To study the existence and functional relevance of a local RAS during fetal lung development;
iii. To demonstrate the intrinsic ability of fetal lung to regulate its growth and to investigate possi-
ble effectors responsible for this mechanism;
iv. To establish new therapeutic strategies for fetal lung hypoplasia, in context of CDH.
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The present PhD thesis is organized into nine different chapters. In Chapter I, just before 
the Aims and Thesis Layout, a General Introduction to the thesis theme has been presented, 
including the most important regulators and mechanisms of fetal lung growth, general concepts 
regarding the novel lung regulators here investigated (gp130 family of cytokines and RAS), and 
abnormal pulmonary development and pathophysiology that characterizes CDH. The following 
five chapters present the most important experimental work of this dissertation, addressing the 
questions raised in the aims, which resulted in published or submitted papers to international 
peer-reviewed scientific journals. Chapter II presents the first manuscript published from the 
scope of this work entitled ‘IL-6 is constitutively expressed during lung morphogenesis and enhan-
ces fetal lung explant branching’. In Chapter III is presented the article ‘Leukemia inhibitory 
factor in rat fetal lung development: expression and functional studies’. The research manuscript 
‘The role of gp130 family of cytokines on fetal lung development’, which has been submitted to 
a peer-reviewed journal, is attached in Chapter IV. Chapter V presents the article ‘Intrinsic 
catch-up growth of hypoplastic fetal lungs is mediated by IL-6’. Finally, the manuscript ‘Local fetal 
lung renin-angiotensin system as a target to treat congenital diaphragmatic hernia’ is presented in 
Chapter VI. Chapter VII is a general discussion of the most relevant results of this PhD work. 
A compendium of the major conclusions drawn from this work is presented along with the future 
perspectives in Chapter VIII. In the end of the thesis, in Chapter IX, all the references from 
the entire write up are presented in alphabetical order. 
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IL-6 Is Constitutively Expressed During Lung Morphogenesis
and Enhances Fetal Lung Explant Branching
CRISTINA NOGUEIRA-SILVA, MARTA SANTOS, MARIA J. BAPTISTA, RUTE S. MOURA, AND JORGE CORREIA-PINTO
Fetal and Neonatal Physiology [C.N.-S., M.S., M.J.B., R.S.M., J.C.-P.], Life and Health Sciences Research Institute (ICVS),
University of Minho, 4709-057 Braga, Portugal; Divisions of Pediatric Cardiology [M.J.B.] and Surgery [J.C.-P.], Hospital S Joa˜o,
4202-451 Porto, Portugal
ABSTRACT: Previous studies have shown that chorioamnionitis,
with increased IL-6, promotes fetal lung maturation and decreases the
incidence of respiratory distress syndrome in premature neonates.
However, the expression pattern and the effects of IL-6 on fetal lung
growth mechanisms remain unknown. IL-6 expression was assessed
by in situ hybridization and by real-time PCR between 14.5 and
21.5 d postconception. Normal and nitrofen-induced hypoplastic lung
explants were cultured with increasing IL-6 doses or IL-6 neutraliz-
ing antibodies. Branching, cellular proliferation (Ki-67) and MAPK
phosphorylation in fetal lung explants were analyzed. Pulmonary
primitive epithelium expressed IL-6 constitutively throughout all
gestational ages, displaying highest levels during earliest stages. In
normal and hypoplastic lung explants, IL-6 neutralizing antibodies
significantly reduced, whereas IL-6 supplementation induced a bi-
phasic effect (lower doses increased, while the highest dose did not
accomplish additional effect) on branching and cellular proliferation.
IL-6 enhanced p38-MAPK phosphorylation without changing
MEK1/2 and JNK pathways. The present study suggests a physio-
logical role for IL-6 on pulmonary branching mechanisms most
likely involving p38-MAPK intracellular signalling pathway. (Pe-
diatr Res 60: 530–536, 2006)
During the last decades, the regulating mechanisms of lungbranching have been unraveled. This morphogenic pro-
cess occurs through fundamental cross-talk interactions be-
tween epithelial and mesenchymal tissues via extremely com-
plex processes, involving a multitude of effectors including
growth factors, extracellular matrix interactions, and hormones
(1). The understanding of these mechanisms has clinical rele-
vance since it can open new perspectives in the treatment of fetal
lung hypoplasia as well as modulation of lung repair.
IL-6 is a pleiotropic cytokine with important roles on acute
inflammatory response, infection, hematopoiesis, regulation of
bone absorption, cell growth, differentiation, survival, apopto-
sis, and proliferation (2–4). Several studies have emphasized
the importance of IL-6 signaling in several processes of
branching organs such as embryonic submandibular gland
development (5,6), mammary gland remodeling (7), benign
and malign prostate growth (8,9), and lung maturation (10).
In fact, several clinical and animal-based studies suggest
that antenatal exposure to inflammatory mediators may im-
prove lung volume and compliance as well as accelerate fetal
lung maturation (10). In humans, it was demonstrated that
IL-6 elevation in fetuses with chorioamnionitis promoted fetal
lung maturation by enhancing surfactant protein A (SP-A)
synthesis. In fact, fetal IL-6 is a regulatory cytokine of pul-
monary surfactant proteins and plays an important role in lung
maturity decreasing the incidence of respiratory distress syn-
drome in preterm neonates (11). In different animal models
such as the rat (12), the rabbit (10), and the sheep (13), it was
shown that intra-amniotic injection of endotoxin or continuous
administration of IL-6 improved lung function by increasing
expression of surfactant apoprotein mRNA (12,14,15).
Recently, it was demonstrated that IL-6 plays an important
modulatory role in lung angiogenesis (16), a fundamental
process in fetal lung morphogenesis (17). Moreover, Dame
and Juul (4) demonstrated that IL-6 receptor was widely
distributed in developing human fetuses, including in bron-
chial epithelial cells. Such findings suggest an IL-6 nonhema-
topoietic role in the developing fetus.
IL-6 exerts its action via the signal transducer gp130 lead-
ing to the activation of the JAK/STAT (Janus kinase/signal
transducer and activator of transcription) and MAPK cascades
(2). Many of the effectors that modulate fetal lung branching
morphogenesis seem to activate signaling pathways that con-
verge into the mitogen-activated protein MAPK (18). There
are three major families of MAPK: the extracellular signal-
regulated kinases-1 and -2 (ERK1/2), c-Jun NH2-terminal
kinases (JNK), and p38 kinase.
Although several reports demonstrated that IL-6 can mod-
ulate lung development, the IL-6 expression pattern as well as
its effects during early lung development are largely unknown.
Therefore, in the current study, IL-6 expression during ante-
natal lung development was characterized. Furthermore, the
effects of IL-6 supplementation or IL-6 neutralizing antibodies
in normal and hypoplastic fetal lung explants were evaluated.
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Additionally, the potential activation of MAPK pathway by
IL-6 was investigated.
MATERIALS AND METHODS
Animal experiments were performed according to the Portuguese law for
animal welfare. Animals were housed in an accredited mouse house and
treated as specified by the recommendations of the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes of Health
(National Institutes of Health Publication No.85-23, revised 1996).
Animal model and experimental design. Sprague-Dawley female rats
(225g; Charles-River, Barcelona, Spain) were maintained in appropriate cages
under controlled conditions and fed with commercial solid food. The rats were
mated and checked daily for vaginal plug. The day of plugging was defined
as gestational d 0.5 for time dating purposes. Nine and a half dpc pregnant rats
were exposed to 100 mg of nitrofen (2,4-dichlorophenyl-p-nitrophenylether)
dissolved in 1 mL of olive oil administered by gavage (nitrofen-induced
hypoplastic lungs: nitrofen group) or with an equal volume of vehicle (normal
lungs: normal group) (19). For in situ hybridization and PCR studies, normal
lungs were used, whereas for fetal lung explant cultures normal and nitrofen-
induced hypoplastic lungs were used.
From the normal group, fetuses were removed by cesarean section at 14.5,
15.5, 17.5, 19.5, and 21.5 dpc. Fetuses at 14.5 dpc were processed in toto for
whole mount hybridization studies. Fetuses older than 14.5 dpc were killed by
decapitation and lungs were excised, processed, and embedded in paraffin for
in situ hybridization. Random left lung samples were collected for the
quantification of IL-6 expression by real-time PCR. These samples were
immersed in RNAlater (QIAGEN GmbH, Hilden, Germany) and stored at
80°C.
Fetuses harvested at 13.5 dpc from normal and nitrofen groups were
dissected and lungs collected for explant culture. After 4 d culture, explants
from each group were collected either for immunohistochemistry or Western
blot analysis.
ISH studies. Digoxigenin-labeled IL-6 probe was synthesized from a 901
bp fragment of the coding sequence of IL-6, inserted on a pBluescript KS-
vector (kindly supplied by Dr. Georg H. Fey, University of Erlangen, Nurn-
berg, Germany). The plasmid was linearized with BamHI and T3 RNA
polymerase was used to synthesize the antisense riboprobe. The in vitro
transcription reaction was performed using DIG RNA Labeling Mix (Roche
Molecular Biochemicals, Mannheim, Germany), according to the manufac-
turer’s instructions.
Whole mount. Embryos were fixed overnight at 4°C in 4% paraformal-
dehyde (PFA), rinsed in 1 PBS, dehydrated through a methanol series, and
stored in 100% methanol at –20°C. Whole mount ISH was performed as
previously described (20). Embryos were visualized as whole mounts in PBT
(PBS, 0.1% Tween20) under binocular microscopy (Leica MZFLIII; Leica
Geosystems AG, Heerbrugg, Switzerland), and photographed using Sony
3CCD Color Video Camera.
Paraffin sections. Tissue sections (10 m thick) were processed for ISH as
previously described by Strahle et al. (21). ISH slides were observed and
photographed on light microscope with an Axiocam color video camera (Carl
Zeiss GmbH, Jena, Germany).
RNA extraction and reverse transcription. Total mRNA from left lung
samples of 30 fetuses (15.5 dpc, n 9; 17.5 dpc, n 7; 19.5 dpc, n 7; 21.5
dpc, n  7) was extracted using the RNeasy Mini Kit Protect (QIAGEN
GmbH). Total mRNA quantification was done by spectrophotometry (Bio-
Photometer, Eppendorf AG, Hamburg, Germany).
Reverse transcription was performed as previously described by Santos et
al. (22).
Quantitative real-time PCR. Quantitative real-timePCR was performed as
previously described by Santos et al. (22).
Primer design was based on available sequences in GenBank (NCBI-
NLM-PubMed-Gene). All the primers are intron-spanning (Table 1). For IL-6
and -actin primer sets, standard amplification curves (ST curves) were made
with randomly selected cDNA samples setting r  0.99. In all the samples
IL-6 expression was normalized for -actin.
Fetal lung explant cultures. Harvesting and dissection of 13.5 dpc lungs
was made in DPBS (Cambrex, East Rutherford, NJ) under a dissection
microscope (Leica MZFLIII). The lungs were transferred to Nucleopore
membranes with an 8 m pore size (Whatman, Clifton, NJ) and incubated in
a 12-well culture plates from Costar (Corning, NY). The membranes were
presoaked in DMEM (Cambrex) for 1 h before the explants were placed on
them. Floating cultures of the explants were incubated in 200 L of 50%
DMEM, 50% nutrient mixture F-12 (Invitrogen, Carlsbad, CA) supplemented
with 100 g/mL streptomycin, 100 units/mL penicillin (Invitrogen), 0.25
mg/mL ascorbic acid (Sigma Chemical, Poole, Dorset, UK) and 10% FCS
(Invitrogen). The fetal lung explants were incubated in a 5% CO2 incubator at
37°C for 96 h, and the medium was replaced every 48 h. The branching
morphogenesis was monitored daily by photographing the explants. At d 0
(D0: 0 h) and d 4 (D4: 96 h) of culture, the total number of peripheral airway
buds (branching) in all lung explants was determined, whereas the epithelial
perimeter was measured using AxionVision Rel. 4.3 (Carl Zeiss GmbH). The
results of branching and epithelial perimeter were expressed as D4/D0 ratio.
IL-6 supplementation studies. Twelve normal and 12 nitrofen-hypoplastic
lung explants were used as control (0 pg/mL). Additionally, recombinant rat
IL-6 (R & D Systems, Minneapolis, MN) was added daily to normal and
nitrofen-induced hypoplastic lung explants to achieve a final concentration of
0.01, 0.1, 1, 10, 100 pg/mL (normal lungs: 0.01, n  8; 0.1, n  8; 1, n  8;
10, n  10; 100, n  8. Hypoplastic lungs: 0.01, n  10; 0.1, n  9; 1, n 
9; 10, n  12; 100, n  8).
IL-6 neutralizing studies. Normal explants were treated daily with IgG
anti-rat IL-6 neutralizing antibody (n 12) at concentration of 1.0 g/mL (30
times the concentration previously shown to suppress IL-6 effect) (R & D
Systems). Nonspecific effects were evaluated by adding identical concentra-
tion of normal goat IgG control antibody (n  10) (R & D Systems).
Proliferation assay by immunohistochemistry. Nontreated (0 pg/mL) and
IL-6 treated (10 and 100 pg/mL) normal and nitrofen explants as well as
normal explants treated with normal goat IgG and IgG anti-rat IL-6 neutral-
izing antibodies (interruption studies) were processed for proliferation assay
(5 per each group). Ki-67 immunostainings were performed on formalin-fixed
and paraffin-embedded lung explants. Sections (5 m) were placed on
SuperFrost Plus slides (Menzel-Glaser, Braunschweig, Germany). The pri-
mary antibody, a monoclonal rabbit serum anti-Ki-67 (NeoMarkers, Fremont,
CA), was used in a 1:200 dilution. After dewaxing in xylene and rehydration
in ethanol, the samples were incubated in 3% hydrogen peroxide in methanol
to quench endogenous peroxidase. Antigen retrieval was achieved by boiling
in 10 mM citrate buffer followed by cool down at room temperature. Samples
were blocked with 5% BSA (Roche Molecular Biochemicals). Incubation of
the primary antibody occurred at 4°C overnight. Negative control reactions
included omission of the primary antibody. Incubation with the UltraVision
detection system anti-polyvalent horseradish peroxidase (Lab Vision Corpo-
ration, Fremont, CA) was carried accordingly to manufacturer’s instructions.
To visualize the peroxidase activities in sections, diaminobenzidine tetrahy-
drochloride was used. Sections were counterstained with hematoxylin.
For cell proliferation quantification, epithelial and mesenchymal Ki-67
positive and negative cells were counted at 20 magnification (Olympus DP
70, Cell P; Olympus, Hamburg, Germany) in four independent peripheral
areas per explant. Results are presented as percentage of the ratio of positive-
to-total cells normalized for lung section area.
Western blot analysis. Nontreated (0 pg/mL) and 10 pg/mL IL-6 treated
normal explants were processed for Western blot analysis. Proteins from lung
explants were obtained according to Kling et al. (18). Five micrograms of
protein were loaded onto 12.5% acrylamide minigels, electrophoresed at 100
V at room temperature, and then transferred to Hybond-C Extra (Amersham
Pharmacia Biotech, Inc., Piscataway, NJ). Blots were probed with p38,
p44/42 (ERK1/2), JNK, phospho-p38 (dp-p38), phospho-p44/42 (dp-ERK1/
2), phospho-JNK (dp-JNK) MAb (New England Biolabs, US) according to
manufacturer’s instructions. For loading control, blots were probed with
-tubulin MAb (Santa Cruz Biotechnology Inc., US). Afterward blots were
incubated with a secondary horseradish peroxidase conjugate (New England
Table 1. Primers used for quantitative PCR
Gene Accession number Primer set Product size (bp)
IL-6 NM_012589 5=-CAA GAG ACT TCC AGC CAG-3=
5=-CTC CGA CTT GTG AAG TGG T-3=
141
-actin NM_031144 5=-GAT TTG GCA CCA CAC TTT CTA CA-3=
5=-ATC TGG GTC ATC TTT TCA CGG TTG G-3=
114
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Biolabs, Beverly, MA), developed with Super Signal West Femto Substrate
(Pierce Biotechnology, Inc., Rockford, IL) and exposed to Hyperfilm ECL
(Amersham Pharmacia Biotech, Inc.).
Statistical analysis. All quantitative data are presented as mean  SEM.
Statistical analysis was performed by one-way ANOVA (real-time PCR and
morphometric explants studies) or three-way ANOVA (proliferation studies)
on ranks and the Student-Newman-Keuls test was used for post-test analysis.
For IL-6 neutralizing studies (morphometric and proliferation studies), t test
analysis was used. Statistical significance was set at p  0.05.
RESULTS
IL-6 expression pattern during normal pulmonary devel-
opment. ISH studies revealed that IL-6 was expressed
throughout all studied gestational ages in fetal lung (Fig. 1).
Figure 1 illustrates IL-6 mRNA predominantly expressed in
primitive lung epithelium presenting significant expression
since the earliest studied stage of rat lung development (14.5
dpc). IL-6 mRNA levels appeared highest during pseudoglan-
dular stage (14.5 and 15.5 dpc) decreasing during subsequent
stages of lung development.
Real-time PCR analysis. The ISH results of IL-6 expres-
sion prompted us to perform real-time PCR to quantify rela-
tive expression of IL-6 levels during normal lung development
(Fig. 2). The mRNA levels of -actin were not significantly
altered during gestation and were subsequently used to nor-
malize the expression data for IL-6. In Figure 2, mRNA levels
of IL-6 normalized to -actin are presented. In normal fetal
lung development, IL-6 was expressed in all studied gesta-
tional ages. IL-6 mRNA levels were significantly higher in the
earliest assessed gestational age (15.5 dpc), which corre-
sponds to the pseudoglandular stage of lung development. In
the subsequent stages of lung development, as suggested by
ISH results, IL-6 mRNA levels decreased.
IL-6 supplementation studies. To evaluate IL-6 role during
lung morphogenesis, normal and hypoplastic fetal lung ex-
plants were treated with different doses of recombinant rat
IL-6. In Figure 3, representative examples of normal (Fig. 3A)
and hypoplastic (Fig. 3B) fetal lung explants treated with
increasing IL-6 doses are illustrated. IL-6 appears to have an
enhancing effect on lung explants growth, except with the
highest dose.
The results of morphometric analysis on fetal lung explants
are summarized in Figure 4. In normal and nitrofen explants,
increasing IL-6 doses induced a biphasic effect on total num-
ber of peripheral airway buds as well as on epithelial perim-
eter. Lower IL-6 doses enhanced explant growth, whereas the
highest dose did not induce significant effect. In normal
explants (Fig. 4, A and C), IL-6 treatment induced maximal
growth rates at 10 pg/mL, whereas in nitrofen explants, the
total number of peripheral airway buds (Fig. 4B) was maximal
at 10 pg/mL and epithelial perimeter (Fig. 4D) at 1 pg/mL.
The number of peripheral airway buds and the epithelial
Figure 1. IL-6 expression pattern during normal rat lung development. ISH studies showed that in normal fetal lung, IL-6 expression was localized to the
primitive airway epithelium. The positive IL-6 signal was detected during all the studied developmental ages, predominantly during the pseudoglandular phase
(14.5 and 15.5 dpc). Scale bar: 14.5 dpc  4960 m; 15.5, 17.5, 19.5, and 21.5 dpc  100 m.
Figure 2. IL-6 mRNA levels during normal fetal rat lung development,
expressed in arbitrary units normalized for -actin (15.5 dpc: n 9; 17.5 dpc:
n  7; 19.5 dpc: n  7; 15.5 dpc: n  7). *p  0.05 vs 15.5 dpc, § p  0.05
vs 17.5 dpc, ¶ p  0.05 vs 19.5 dpc.
Figure 3. Branching morphogenesis in rat lung explant system. (A) Normal
lung explants. (B) Nitrofen-hypoplastic lung explants. Upper panel is repre-
sentative of lungs at 13.5 dpc at culture d 0 (D0). Bottom panel represents
lungs, treated with different IL-6 doses, at d 4 (D4). Scale bar  6349 m (all
images at same magnification).
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perimeter were significantly reduced in nitrofen when com-
pared with normal explants at D0 (Table 2). However, in the
absence of IL-6 treatment and after 4 d in culture no signifi-
cant differences between normal and nitrofen groups were
observed. After IL-6 treatment, D4/D0 ratio of the number of
peripheral airway buds (Fig. 4B) and epithelial perimeter
(Fig. 4D) was always higher in the nitrofen group than in the
normal group, independently of IL-6 dose.
Figure 5 shows cellular proliferation assay in normal and
nitrofen explants nontreated and treated with either 10 pg/mL
(dose of maximal effect) or 100 pg/mL (dose with lesser
effect). Treatment with 10 pg/mL of IL-6 induced a significant
increase on proliferation rate in normal and nitrofen explants,
whereas in explants treated with 100 pg/mL of IL-6 a signif-
icant decrease is evident in such proliferation when compared
with 10 pg/mL. No significant differences between normal and
nitrofen groups were observed, although there is a statistically
significant interaction between variables: groups IL-6 doses
Figure 5. Cellular proliferation assay in normal and nitrofen explants by
Ki-67 immunohistochemistry. (A) Nontreated normal explants. (B) 10 pg/mL
IL-6 treated normal explants. (C) 100 pg/mL IL-6 treated normal explants. (D)
Nontreated hypoplastic explants. (E) 10 pg/mL IL-6 treated hypoplastic
explants. (F) 100 pg/mL IL-6 treated hypoplastic explants (five lungs ana-
lyzed per each group). The bottom graphics presents epithelial and mesen-
chymal cellular proliferation quantification. Results are expressed as percent-
age of positive-to-total cells ratio normalized for mm2. Scale bar  100 m
(all images at same magnification). *p  0.05 vs normal or nitrofen explants
nontreated, ¶ p  0.05 vs IL-6 at 10 pg/mL. ns, not statistically significant.
Figure 6. IL-6 neutralizing studies in normal lung explants treated with
normal goat IgG (control n  10) and IgG anti-rat IL-6 antibodies (n  12).
A: Branching morphogenesis (upper panel) and morphometric analysis of
lung growth (middle and bottom panels). B: Cellular proliferation assay (5
lungs analyzed per each group). Scale bar A  6349 m, B  100 m. p 
0.01: * vs. goat IgG.
Figure 4. Morphometric analysis of lung explant cultures treated with dif-
ferent IL-6 doses. (A) Number of total airway buds in normal explants. (B)
Number of total airway buds in hypoplastic explants. (C) Epithelial perimeter
in normal explants. (D) Epithelial perimeter in hypoplastic explants. Results
are expressed as D4/D0 ratio (Normal lungs: 0, n  12; 0.01, n  8; 0.1, n 
8; 1, n  8; 10, n  10; 100, n  8. Hypoplastic lungs: 0, n  12; 0.01, n
 10; 0.1, n  9; 1, n  9; 10, n  12; 100, n  8). *p  0.05 vs IL-6 at
0 pg/mL, § p  0.05 vs IL-6 at 0.01 pg/mL, † p  0.05 vs IL-6 at 1 pg/mL,
¶ p  0.05 vs IL-6 at 10 pg/mL.
Table 2. Number of peripheral airway buds and epithelial
perimeter in normal and nitrofen groups, at d 0 and 4 of culture
Group
Number of
peripheral airway buds Epithelial perimeter
D0 D4 D0 D4
Normal 6  0 54.8  4.9 7054  255 31 512  3887
Nitrofen 4.33  0.42 51.8  4.76 5046  294 29 222  3522
p Value 0.01 NS 0.01 NS
NS, not statistically significant.
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(p  0.001). Finally, no significant differences in proliferation
rate between epithelium and mesenchyme were observed.
IL-6 neutralizing studies. In Figure 6, results of morpho-
metric analysis (Fig. 6A, left panels) and proliferation studies
(Fig. 6B, right panels) in normal lung explants treated with
normal goat IgG (control) and IgG anti-rat IL-6 antibodies are
shown. IL-6 blocking antibodies significantly reduced the
number of peripheral airway buds, epithelial perimeter and
epithelial and mesenchymal cellular proliferation rate.
MAPK signaling pathway. Normal lung explants treated
with IL-6 at 10 pg/mL (dose with maximal effect), presented
(semi-quantitative analysis) an enhanced p-38 kinase phos-
phorylation when compared with nontreated explants. No
differences were observed in MEK1/2 and SAPK/JNK phos-
phorylation (Fig. 7).
DISCUSSION
This study demonstrated that IL-6 was constitutively ex-
pressed in pulmonary primitive epithelium, during all studied
gestational ages of lung development, presenting highest lev-
els of expression during pseudoglandular stage. Blocking IL-6
significantly reduced branching and cellular proliferation rate
in normal explants, whereas IL-6 supplementation, either in
normal or hypoplastic fetal lung explants, induced a biphasic
effect on branching and cellular proliferation rate, with in-
creased effect at lower doses, while no additional effect was
obtained with the highest dose. These effects of IL-6 are most
likely mediated through MAPK signaling pathway via p38.
IL-6 is a multifunctional inflammatory cytokine with im-
portant roles in cell proliferation, differentiation, growth, and
apoptosis (2–4). Several clinical and experimental studies
have investigated IL-6 role in pathophysiology of different
lung diseases. In the adult, IL-6 has a critical role on inflam-
matory pathogenesis of acute respiratory distress syndrome
(23), asthma (24), chronic obstructive pulmonary disease (25),
and non-small-cell lung cancer (26). IL-6 role during prenatal
and neonatal period has been studied since decreased risk of
respiratory distress syndrome in preterm neonates was dem-
onstrated (10,11). In fact, it has been proved that inflammatory
mediators, namely IL-6, promote fetal lung maturation by
inducing SP-A expression and protein synthesis consequently
improving lung mechanics and gas exchange (10,11). Studies
carried on different animal models of intra-amniotic inflam-
mation corroborated these observations in neonates exposed to
chorioamnionitis (12–15,27,28).
Pulmonary development is a complex process involving
two different cellular phenomena, growth and maturation (1).
All previous studies concerning the effect of IL-6 on prenatal
lung development had focused mainly in maturation processes
in a pathologic inflammatory context (11–15,27,28). In this
study, however, it was demonstrated that IL-6 was constitu-
tively expressed in normal primitive lung epithelium through-
out the studied ages. Interestingly, the epithelial IL-6 expres-
sion is in agreement with the findings previously documented
in adult lung (29). In adults, epithelial expression was also
observed in other branching organs such as salivary glands
(30), prostate (8,9), and mammary gland (7). However, IL-6
expression in fetuses was only described during submandib-
ular gland morphogenesis (5,6). In fact, Melnick et al. (5)
showed a significant increase in IL-6 mRNA with progressive
salivary gland development. Conversely, the current study
demonstrated that in fetal lung the highest IL-6 mRNA levels
occurred during early pseudoglandular stage decreasing pro-
gressively in subsequent stages of lung development.
Hypothesizing that IL-6 has a role during lung branching
morphogenesis, normal fetal lung explants were cultured with
increasing doses of IL-6 or with IL-6 neutralizing antibodies.
Furthermore, IL-6 effect in nitrofen-induced hypoplastic lungs
was also studied since it is well established that these lungs
have restricted branching (31,32). This work clearly demon-
strated that IL-6 supplementation induced a biphasic pattern
on branching either in normal or hypoplastic explants. In fact,
lower doses of IL-6 induced an increase in growth rate (total
number of peripheral airways buds and epithelial perimeter) of
normal and hypoplastic lung explants, whereas highest dose
did not accomplish additional effect. These observations were
corroborated by proliferation studies, which demonstrated that
10 pg/mL of IL-6 (maximal effect on branching) significantly
increased Ki-67 epithelial and mesenchymal positive cells. On
the other hand, 100 pg/mL of IL-6 induced no significant
changes in proliferation rate when compared with nontreated
explants. Interestingly, it seems that IL-6’s effects were exac-
erbated in nitrofen explants. Although nitrofen explants are
smaller at D0, after 4 d in culture, no significant differences
between normal and nitrofen explants could be detected (Ta-
ble 2). The ability of hypoplastic explants to grow in culture
with higher rates than normal explants had already been
previously observed (33), however, the explanation for this
phenomenon remains to be elucidated. A possible explanation
consists in hypoplastic lungs eliciting up-regulation of some
effectors as documented for neuroendocrine cellular products
(33). Interestingly, it was also reported that end-gestation
Figure 7. MAPK activities in nontreated (1) and treated with IL-6 at 10
pg/mL (2) lung explants. Western blot analysis of MAPK with MAbs to p38,
ERK1/2 and JNK1/2 (A) and to diphosphorylated forms of p38 (dp-p38), ERK1/2
(dp-ERK1/2) and SAPK/JNK (dp-JNK1/2) (B). Control loading was performed
using -tubulin (55 KDa). ERK1 and 2 correspond to 44 and 42 KDa, respec-
tively. JNK1 and 2 correspond to 46 and 54 KDa, respectively.
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human hypoplastic lungs present higher production of tumor
necrosis factor- than normal lungs (34).
Regarding the biphasic pattern of IL-6 effects on branching
rate, it is interesting to stress that previous studies relating
inflammation, lung maturation, and incidence of respiratory
distress syndrome (RDS) report a similar pattern. In fact,
although intrauterine infection seems to protect very prema-
ture infants against RDS, high quantities of pro-inflammatory
cytokines cause serious disease (35). On the other hand, our
findings suggest that IL-6 is constitutively produced during
the earliest gestational stages, which may contribute for the
explanation of enhanced fetal lung tolerance to inflammation
during early gestation when compared with later gestation (26).
Although IL-6 knockout mice do not seem to have signif-
icant lung development abnormalities (36–38), this study
clearly suggests a physiologic role of IL-6 in lung branching
morphogenesis. Although previous studies on IL-6 and lung
development emphasized maturational process, the highest
expression of IL-6 on the early fetal lung development stages
suggests that the physiologic role for IL-6 is most likely linked
to branching.
Previous reports demonstrated epithelial expression of
functional IL-6 receptor during fetal lung development (4,39).
The mechanism responsible for IL-6 enhancing effects during
lung branching morphogenesis is most likely dependent on
gp130 signaling pathway through Stat3 and/or MAPK (2–4).
In fact, it seems that IL-6 signaling through Stat3 is important
to normal submandibular gland morphogenesis in the mouse
(5) as well as in human prostate cancer cell growth (40).
Additionally, adult rat mammary gland remodeling depends
on gp130 signaling through Stat3 and MAPK (7). None of the
previous studies implied JAK/STAT signaling pathway in
fetal lung growth mechanisms. In contrast, MAPK signaling
was recently suggested as a crucial pathway for fetal lung
development (18). Thus, MAPK pathway activation by IL-6 in
fetal lung development was investigated. Explants treated with
10 pg/mL IL-6 were selected due to its maximal effect on
growth. These experiments clearly show activation of p38-
MAPK by IL-6 treatment, whereas no significant activation of
MEK1/2 and JNK pathways was observed.
In conclusion, IL-6 epithelial expression throughout fetal
lung development as well as the present in vitro studies
suggest a physiologic role for endogenous IL-6 on pulmonary
branching mechanisms most likely involving p38-MAPK in-
tracellular pathway.
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Abstract
Background: Leukemia inhibitory factor (LIF) and interleukin-6 (IL-6) are members of the family of the glycoprotein 130
(gp130)-type cytokines. These cytokines share gp130 as a common signal transducer, which explains why they show some
functional redundancy. Recently, it was demonstrated that IL-6 promotes fetal lung branching. Additionally, LIF has been
implicated in developmental processes of some branching organs. Thus, in this study LIF expression pattern and its effects
on fetal rat lung morphogenesis were assessed.
Methodology/Principal Findings: LIF and its subunit receptor LIFRa expression levels were evaluated by immunohisto-
chemistry and western blot in fetal rat lungs of different gestational ages, ranging from 13.5 to 21.5 days post-conception.
Throughout all gestational ages studied, LIF was constitutively expressed in pulmonary epithelium, whereas LIFRa was first
mainly expressed in the mesenchyme, but after pseudoglandular stage it was also observed in epithelial cells. These results
point to a LIF epithelium-mesenchyme cross-talk, which is known to be important for lung branching process. Regarding
functional studies, fetal lung explants were cultured with increasing doses of LIF or LIF neutralizing antibodies during 4
days. MAPK, AKT, and STAT3 phosphorylation in the treated lung explants was analyzed. LIF supplementation significantly
inhibited lung growth in spite of an increase in p44/42 phosphorylation. On the other hand, LIF inhibition significantly
stimulated lung growth via p38 and Akt pathways.
Conclusions/Significance: The present study describes that LIF and its subunit receptor LIFRa are constitu-
tively expressed during fetal lung development and that they have an inhibitory physiological role on fetal lung
branching.
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Introduction
Fetal lung development is a complex process, involving several
effectors such as growth factors, extracellular matrix interactions,
hormones and as, recently described inflammatory mediators [1–
3]. In fact, it was already demonstrated that interleukin-6 (IL-6)
promotes fetal lung maturation [4–6] and also that IL-6 is
constitutively expressed in pulmonary primitive epithelium and
enhances fetal lung branching [3].
IL-6 is one of the members of the family of the glycoprotein 130
(gp130)-type cytokines. This family comprises IL-6, leukemia
inhibitory factor (LIF), IL-11, oncostatin M, ciliary neurotrophic
factor (CNTF), cardiotropin-1 (CT-1) and cardiotrophin-like
cytokine. These cytokines share the membrane glycoprotein
gp130 as a common signal transducer which explains the fact
that these show some functional redundancy even though they also
exhibit specific biological activities [7,8].
LIF is a pleiotropic cytokine, that exists in both soluble and
matrix-bound forms, and that binds to a heterodimer LIF receptor
alpha subunit (LIFRa)/gp130. Signal transduction involves the
activation of Janus kinase (JAK) and the subsequent recruitment of
signal transducers and activators of transcription (STAT) proteins,
mainly STAT3. Alternatively, LIF can also initiate cell signaling
via the mitogen-activated protein kinase (MAPK) cascade [7–10].
Moreover, LIF displays several biological activities ranging from
the classic differentiation of myeloid leukemic cells into macro-
phage lineage to effects on proliferation of primordial germ cells,
maintenance of embryonic stem cell pluripotentiality, endometrial
decidualization, blastocyst implantation, neural development,
bone cell metabolism, adipocyte lipid and energy homeostasis,
muscle satellite cell proliferation, heart hypertrophy, inhibition of
retinal vascularization and inflammation [9–13]. Furthermore,
several studies have emphasized the importance of LIF signaling in
several processes of branching organs. For instance, this cytokine
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inhibits fetal nephrons formation [14–16], induces mammary
gland involution [17], decreases thyroid tumors growth [18,19]
and increases pancreatic regeneration [20]. It was already
described that LIF, together with insulin-like growth factor I
(IGF-I), regulates lung maturation. In fact, absence of LIF in
addition to IGF-I null mutant mice aggravates pulmonary
immaturity. Indeed, LIF/IGF-I double deficient embryos present
lung hypoplasia and defective differentiation of the alveolar
epithelium and vasculogenesis [21].
Regardless of several evidences in literature that point towards a
possible involvement of LIF during fetal lung development, LIF
expression pattern as well as its effects during lung morphogenesis
are largely unknown. Despite LIF/IGF-I double deficient mice
lung phenotype, LIF knockout mice have no significant abnormal
lung features [21,22]. However, in the current study, it was
demonstrated that LIF and LIFRa were constitutively expressed
during fetal lung development and that in vitro LIF supplemen-
tation significantly inhibited lung growth, likely through p44/42
pathway.
Results
LIF and LIFRa expression pattern during fetal lung
development
The immunohistochemistry (IHC) and western blot studies
revealed that LIF and LIFRa protein were expressed throughout
all studied gestational ages in fetal lung (Figure 1 and 2). LIF was
mainly expressed in bronchiolar and also in alveolar epithelium
from 13.5 days post-conception (dpc) until term. At 19.5 and 21.5
dpc, mesenchymal tissue also displayed scattered LIF positive cells
(Figure 1A and 1B). These LIF expression results prompted us to
perform a western blot analysis in order to quantify the relative
expression of LIF levels during normal lung development. LIF
expression levels were minimal at 13.5 dpc, increased slightly
throughout gestation and reached its maximum at the end of
gestation (21.5 dpc) (Figure 1C and 1D).
Regarding LIFRa, early in gestation, protein expression was
restricted to the mesenchyme (Figure 2A and 2B). Throughout
fetal lung development, namely from 17.5 dpc onwards, LIFRa
mesenchymal expression decreased and epithelial expression was
observed until term (Figure 2A and 2B). LIFRa expression levels
remained constant during fetal lung development (Figure 2C and
2D).
Role of LIF in fetal lung development
In order to evaluate the role of LIF on lung morphogenesis, fetal
lung explants were treated daily with increasing concentrations of
recombinant LIF. In Figure 3A, representative examples of fetal
lung explants treated with increasing LIF concentrations, after 4
days in culture, are illustrated. LIF appears to have a dose-effect
inhibitory action on lung explants growth. In fact, a decrease in
the total number of peripheral airway buds (Figure 3B), epithelial
perimeter (Figure 3C), area (Figure 3D) and external perimeter
(Figure 3E) of lung explants was observed in all concentrations
Figure 1. LIF expression pattern during fetal lung development (from 13.5 until 21.5 dpc). (A) IHC studies revealed that LIF expression
was localized to airway epithelium. Original magnification: Upper panel –6100; Bottom panel –6200. (B) IHC negative controls: Left – omission of
the primary antibody; Center – non-immune goat IgG isotype control; Right – simultaneous omission of the primary and secondary antibodies. In all
negative controls immunoreactive LIF staining was not observed. (C) Western blot analysis of LIF throughout gestation (45 kDa). Control loading was
performed using b-tubulin (55 kDa). (D) Relative LIF protein levels expressed in arbitrary units normalized for b-tubulin. p,0.05: *vs. 13.5 dpc, 1 vs.
15.5 dpc, { vs. 17.5 dpc, ¥ vs. 19.5 dpc.
doi:10.1371/journal.pone.0030517.g001
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tested, this effect is most significant in the highest LIF
concentrations studied, 20 and 40 ng/mL.
In Figure 4 it is shown the morphometric analysis of lung
explants treated with control IgG, anti-LIF IgG antibodies or
FGF-10. LIF inhibition significantly stimulated lung branching
(Figure 4B) and epithelial perimeter (Figure 4C) in a similar way as
FGF-10. No differences were observed on lung explant area
(Figure 4D) or external perimeter (Figure 4E).
Pooled samples of lung explants (n = 15) treated with LIF at
40 ng/mL (selected due to its maximal effect on inhibition of
explants growth) were evaluated for modulation of MAPK, Akt
and STAT3 pathways (Figure 5). Lung growth inhibition induced
by LIF significantly stimulated p44/42 phosphorylation (Figure 5).
On the other hand, the increase on lung branching induced by
blocking LIF action significantly stimulated p38 and Akt
phosphorylation (Figure 6).
Discussion
This study demonstrated that LIF was constitutively expressed
in pulmonary epithelium, whereas its subunit receptor, LIFRa,
was expressed in the mesenchyme until the pseudoglandular stage
and in epithelial cells, at later stages. Moreover, LIF supplemen-
tation significantly inhibited lung growth most likely through p44/
42 pathway. On the other hand, LIF inhibition significantly
increased lung branching and stimulated p38 and Akt phosphor-
ylation.
LIF is a multifunctional glycoprotein cytokine that regulates
many cellular responses such as proliferation, differentiation and
survival in different cellular types [8–13]. Regarding the lung,
several studies have investigated LIF’s role in the pathophysiology
of different lung diseases, such as acute respiratory distress
syndrome [23], asthma [24], chronic airway inflammation [25]
and inflammation induced by tobacco [23]. In fact, LIF is well
known to induce the synthesis and activation of phospholipase A2
in bronchial epithelial cells [12] and it has protective effects in the
setting of hyperoxic lung injury [26]. Concerning LIF’s putative
role during prenatal lung period, all previous studies had focused
mainly in maturation processes.
In the current study, it was demonstrated that LIF was
expressed in primitive lung epithelium, since early stages of lung
development (13.5 dpc), a moment in which predominantly occurs
growth phenomena. LIF expression in bronchiolar and also in
alveolar epithelium is in agreement with previous findings
documented in adult human lung [25,27,28]. In adults, epithelial
expression was also observed in other branching organs such as
mammary gland [29] and pancreas [20]. During murine fetal
development, LIF expression was already described in the ureteric
bud [15], skin, skeletal muscle, heart, brain, liver and gut [30,31]
supporting a role for this cytokine in the normal development of
Figure 2. LIFRa expression pattern during fetal lung development (from 13.5 until 21.5 dpc). (A) IHC studies revealed that LIFRa was first
mainly expressed in the mesenchyme, but after pseudoglandular stage it was also observed in epithelial cells throughout gestation. Original
magnification: Upper panel –6100; Bottom panel –6200. (B) IHC negative controls: Left – omission of the primary antibody; Center – non-immune
goat IgG isotype control; Right – simultaneous omission of the primary and secondary antibodies. In all negative controls immunoreactive LIFRa
staining was not observed. (C) Western blot analysis of LIFRa throughout the gestation (190 kDa). Control loading was performed using b-tubulin
(55 kDa). (D) Relative LIFRa protein levels expressed in arbitrary units normalized for b-tubulin. No significant difference was observed between
gestational ages.
doi:10.1371/journal.pone.0030517.g002
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several organ systems. Moreover, LIF expression was observed in
all studied gestational ages and its expression levels increased by
the end of the gestation, which is in accordance with the literature
[31].
Regarding LIFRa, it was expressed in constant levels through-
out gestation: first mainly in lung mesenchyme, and after
pseudoglandular stage it was predominantly observed in the
epithelium until term. LIFRa is known to be expressed in
numerous human lung structural cell types, namely fibroblasts,
bronchial smooth muscle cells and airway epithelial cells
[25,27,28]. Interestingly, during fetal kidney morphogenesis,
LIFRa was first detected in metanephric mesenchyme and later
in newly formed tubules [15]. It is necessary to stress that the
occurrence of epithelial LIF and mesenchymal LIFRa expression,
since early stages of lung development and until the end of
pseudoglandular stage, points to a LIF epithelium-mesenchyme
interaction during this stage of lung development, which is mainly
characterized by successive branching phenomena. It is well
described that lung development occurs through specific cross-talk
interactions between epithelium and mesenchyme [1]. Therefore,
LIF and LIFRa interaction might possibly be a new player on lung
branching mechanisms. Nonetheless, the highest LIF expression
was observed at the end of the gestation which also suggests a
physiological role for LIF in lung maturation, as already
demonstrated in literature [21,22].
In order to evaluate LIF’s role in lung branching morphogen-
esis, fetal lung explants were cultured with increasing doses of LIF
or LIF neutralizing antibodies. LIF supplementation inhibited
lung growth, whereas LIF blockage stimulated lung branching.
Interestingly, the blockage of LIF activity increased the number of
peripheral airways buds and epithelial perimeter in a similar way
as FGF-10, a classical and very important lung growth factor that
Figure 3. LIF supplementation studies in a fetal lung explant culture system. (A) Representative examples of fetal lung explants treated
daily with increasing concentrations of recombinant LIF, after 4 days in culture. Original magnification625. (B) Number of total airway buds; (C)
Epithelial perimeter; (D) Area; (E) External perimeter of lung explants treated with LIF. LIF significantly inhibited lung growth. Results are expressed as
ratio of day 4 (D4) and day 0 (D0) of culture (D4/D0 ratio). p,0.05:
* vs. LIF at 0 ng/mL (control), 1 vs. LIF at 0.4 ng/mL, ¥ vs. LIF at 4 ng/mL.
doi:10.1371/journal.pone.0030517.g003
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is known to increase lung branching [32,33]. LIF inhibitory effect
had already been described in fetal kidney development [16] and
in the proliferation of human normal and malign breast epithelial
cells [34] which, like the lung, develop by branching events.
Moreover, LIF inhibitory effect was also described on other cell
types such as embryonic stem cells [35], bone [36], endothelial
[11] and neuronal cells lines [37]. However, LIF stimulates duct
cell proliferation in adult pancreas [18]. Interestingly, this LIF
inhibitory effect on fetal lung branching opposes the stimulatory
effect described for IL-6 [3], also a member of family of the gp130-
type cytokines.
Although this in vitro study clearly suggests a physiological role
for LIF on lung branching, LIF knockout mice do not seem to
have abnormal lung features when compared to normal littermates
[21,22]. Indeed, LIF knockout mice are born normal and they
only exhibit defective blastocyst implantation, postnatal growth
retardation and hematopoiesis defects [22,38,39]. The absence of
significant lung development abnormalities in LIF knockout mice
does not mean a minor role for LIF during lung morphogenesis in
vivo. In fact, as demonstrated for several phenomena, mice lacking
individual members of gp130-type cytokines displayed milder
phenotype than expected, which is most likely due to the similarity
and redundancy of downstream events induced by gp130-
dependent cytokines [38]. On the other hand, LIFRa deletion
causes perinatal death with multiple defects [22,38,40–42].
However, it is necessary to stress that this receptor subunit is a
part of the receptor complexes for LIF, CNTF and CT-1 [8].
Moreover, it is necessary to stress that it is recognized that the
knockout approach also bears intrinsic problems, since the ensuing
phenotype may consist of compensatory events during develop-
ment and later life [43]. In opposition to LIF-deficient lungs, the
additional absence of LIF in the IGF-I-null background of mutant
mice aggravates the prenatal pulmonary immature phenotype and
these mice die due to respiratory failure [21,22]. These results
point to a possible LIF role on lung maturation, but only involving
also IGF-I. Furthermore, lung development is a complex process
involving two different cellular phenomena, maturation and
growth [1], and in the context of present work LIF’s involvement
was studied with regard to the growth phenomena.
In different cells and tissues, LIF signaling is mediated mainly by
JAK/STAT3, p44/42 kinase and PI3K/Akt pathways [7–10,17].
Interestingly, many of the effectors that modulate fetal lung
Figure 4. LIF neutralizing studies in a fetal lung explant culture system. (A) Representative examples of lung explants treated daily with
normal IgG (control; 1 mg/mL), anti-LIF IgG (1 mg/mL) or FGF-10 (500 ng/mL), after 4 days in culture. Original magnification625. (B) Number of total
airway buds; (C) Epithelial perimeter; (D) Area; (E) External perimeter of treated lung explants. Inhibition of LIF action significantly stimulated lung
branching in a similar way than FGF-10. Results are expressed as D4/D0 ratio. p,0.05:
* vs. control IgG.
doi:10.1371/journal.pone.0030517.g004
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branching morphogenesis seem to activate signaling pathways that
converge into the MAPK and PI3K/Akt cascades [44]. Thus,
MAPK, PI3K/Akt and STAT3 pathway modulation by LIF and
anti-LIF in fetal lung development was investigated. The
inhibition of lung growth induced by LIF significantly stimulated
p44/42 phosphorylation and did not significantly change p38,
JNK, Akt or STAT3 pathways. In contrast to these results, in lung
development, the p44/42 pathway has been involved in
stimulation of branching morphogenesis. Indeed, Kling et al
demonstrated that p44/42 inhibition reduces branching morpho-
genesis and causes mesenchymal cell apoptosis in fetal rat lungs
[44]. According to the literature, it is not the first association
between LIF, p44/42 pathway and growth inhibition/arrest. In
fact, in human medullary thyroid cancer cells, it was demonstrated
that p44/42 pathway induces autocrine-paracrine growth inhibi-
tion via LIF [19]. Moreover, the absence of LIF in the IGF-1 null
mice, which induces changes on pulmonary maturation and
vasculogenesis, also induces activation of p44/42 [21]. Further-
more, the LIF action mediated by p44/42 was already
demonstrated in earlier mammary gland development [17] and
myoblasts [45]. Thus, considering that lung explants were
incubated during 4 days, p44/42 stimulation might not be the
Figure 5. Analysis of intracellular signaling pathways that mediates LIF actions on lung growth. (A) Western blot analysis of p38, p44/42,
JNK1/2, Akt and STAT3, and to diphosphorylated forms of p38 (dp-p38), p44/42 (dp-p44/42), SAPK/JNK (dp-JNK1/2), Akt (dp-Akt) and STAT3 (dp-
STAT3) in control lung explants (C) and treated with LIF at 40 ng/mL (LIF). Control loading was performed using b-tubulin (55 kDa). p38 corresponds
to 38 kDa. p44/42 correspond to 44 and 42 kDa, respectively. JNK1 and 2 correspond to 46 and 54 kDa, respectively. Akt corresponds to 60 kDa.
STAT3 corresponds to two bands, 79 and 86 kDa. (B) Semi-quantitative analysis of expression of phosphorylated forms of these intracellular signaling
pathways. Results are presented as arbitrary units normalized for b-tubulin. p,0.05: * vs. control.
doi:10.1371/journal.pone.0030517.g005
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direct pathway that mediates LIF action, but the result of
crosstalks of other non-canonical intracellular pathway. Regarding
anti-LIF treatment, the increase on lung branching observed was
mediated by stimulation of p38 and Akt phosphorylation. PI3K/
Akt pathway is a classical stimulator of lung branching [44,46].
Moreover, p38 was already demonstrated as mediator of lung
branching [3,47]. Interestingly, it was demonstrated that IL-6,
another a gp130-type cytokines, also enhances lung branching via
p38 phosphorylation [3].
In this study, it was demonstrated that LIF inhibits lung
branching, in opposition to IL-6 (another cytokine of the gp130
family). Although cytokines of the gp130 family share a common
signal transducer, these findings suggest specific biological
activities for each cytokine on lung development. In fact, specific
characteristics are emerging for each member of this family,
brought about mainly through restricted temporal and spatial
release, differential expression of cell surface receptors, and
different signaling patterns between gp130 homodimers and
heterodimers [25]. Interestingly, LIF receptor is a gp130
heterodimer, whereas IL-6 receptor is a gp130 homodimer. Thus,
this raises the hypothesis that the effect, on lung development, of
cytokine signaling through gp130 heterodimers might be different
and even opposite to gp130 homodimers. Although this hypothesis
needs to be verified, this specificity can possibly represent a
Figure 6. Analysis of intracellular signaling pathways that mediates anti-LIF actions on lung branching. (A) Western blot analysis of p38,
p44/42, JNK1/2, Akt and STAT3, and to diphosphorylated forms of p38 (dp-p38), p44/42 (dp-p44/42), SAPK/JNK (dp-JNK1/2), Akt (dp-Akt) and STAT3
(dp-STAT3) in control IgG lung explants (IgG) and treated with anti-LIF IgG (Anti-LIF). Control loading was performed using b-tubulin (55 kDa). (B)
Semi-quantitative analysis of expression of phosphorylated forms of these intracellular signaling pathways. Results are presented as arbitrary units
normalized for b-tubulin. p,0.05: * vs. IgG.
doi:10.1371/journal.pone.0030517.g006
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regulatory mechanism of lung morphogenesis, intrinsic to this
family of cytokines, in order to achieve the correct lung growth.
In conclusion, LIF and LIFRa expression during fetal lung
development as well as the in vitro studies presented in this work
suggest an inhibitory physiological role for endogenous LIF,
mediated by epithelial-mesenchymal interactions, on pulmonary
branching mechanisms.
Materials and Methods
This study was carried out in strict accordance with the
recommendations in the ‘Guide for the Care and Use of
Laboratory Animals’, published by the US National Institutes of
Health (NIH Publication No.85-23, revised 1996). Animal
experiments were also performed according to the Portuguese
law for animal welfare and the protocol was approved by the
Committee on the Ethics of Animal Experiments of the Life and
Health Sciences Research Institute of the University of Minho
(DGV 022162 - 520/000/000/2006). Moreover, all efforts were
made to minimize animal suffering.
Animal model and experimental design
Sprague-Dawley female rats (225 g; Charles-River, Spain) were
maintained in appropriate cages under temperature-controlled
room (22–23uC) on a 12 hours light: 12 hours dark cycle, and fed
with commercial solid food. The rats were mated and checked
daily for vaginal plug. The day of plugging was defined as
gestational day 0.5 for time dating purposes. Fetuses were removed
by caesarean section at 13.5, 15.5, 17.5, 19.5 and 21.5 dpc (days
post-conception) and sacrificed by decapitation. Lungs were
dissected and processed for IHC and western blot analysis. To
perform fetal lung explant cultures fetuses were harvested at 13.5
dpc and their lungs dissected.
IHC
LIF and LIFRa immunostainings were performed on formalin-
fixed and paraffin-embedded lungs of different gestational ages
(13.5–21.5dpc). Sections (5 mm) were placed on SuperFrostHPlus
slides (Menzel-Glaser, Germany). LIF antibody (sc-1336; Santa
Cruz Biotechnology Inc., USA) was used in a 1:50 dilution and
LIFRa antibody (sc-659; Santa Cruz Biotechnology Inc.) in a 1:50
dilution. After dewaxing in xylene and rehydration in ethanol, the
samples were incubated in 3% hydrogen peroxide in methanol to
quench endogenous peroxidase. Antigen retrieval was achieved by
boiling in 10 mM citrate buffer followed by cool down at room
temperature. Samples were blocked with 5% BSA (Roche,
Germany). Incubation of the primary antibody occurred at 4uC
overnight. Negative control reactions included omission of the
primary antibody, the simultaneous omission of the primary and
secondary antibodies, and a non-immune goat IgG isotype control
diluted to a matching concentration as the primary antibody,
instead of the primary antibody. Incubation with the goat
ImmunoCruzTM Staining System (sc-2053; Santa Cruz Biotech-
nology Inc.) or with the UltraVision detection system anti-
polyvalent horseradish peroxidase (Lab Vision Corporation,
USA) was carried according to manufacturer’s instructions (for
LIF and LIFR immunostainings, respectively). To visualize the
peroxidase activities in sections, diaminobenzidine tetrahy-
drochloride (Dako, Denmark) was used. Sections were counter-
stained with hematoxyline. The slides were observed and
photographed with Olympus BX61 microscope (Olympus, Japan).
The pictures presented are representative of 6 animals (n = 6) and
12 samples for each gestational age, and three independent
experiments were performed.
Western blot analysis
Different pooled lung samples for each gestational age (13.5–
21.5 dpc) and cultured lung explants were processed for western
blot analysis. Proteins were obtained according to Kling et al [44].
Ten or twenty five mg of protein were loaded onto 10% or 7.5%
acrylamide minigels (respectively), electrophoresed at 100 V at
room temperature and then transferred to nitrocellulose mem-
branes (HybondTM -C Extra, GE Healthcare Life Sciences, UK).
Blots were probed with LIF and LIFRa polyclonal antibodies
(Santa Cruz Biotechnology Inc.) according to manufacturer’s
instructions (1:250 and 1:500, respectively). For loading control,
blots were probed with b-tubulin MAb (1:200000, Abcam, UK).
Afterwards blots were incubated with a secondary horseradish
peroxidase conjugate (Santa Cruz Biotechnology Inc.), developed
with Super SignalHWest Femto Substrate (Pierce Biotechnology,
USA) and the chemiluminescent signal was captured using the
Chemidoc XRS (Bio-Rad, USA). Quantitative analysis was
performed with Quantity One 4.6.5 1-D Analysis Software
(Bio-Rad). Three independent experiments were performed
(n = 3).
Fetal lung explant cultures
Harvesting and dissection of 13.5 dpc lungs was made in DPBS
(Lonza, Switzerland) under a dissection microscope (Leica
MZFLIII, Switzerland). The lungs were transferred to Nucleopore
membranes with an 8 mm pore size (Whatman, USA) and
incubated in a 24-well culture plates (Nunc, Denmark). The
membranes were pre-soaked in DMEM (Invitrogen, UK) for
1 hour before the explants were placed on them. Floating cultures
of the explants were incubated in 200 ml of 50% DMEM, 50%
nutrient mixture F-12 (Gibco, USA) supplemented with 100 mg/
ml streptomycin, 100 units/ml penicillin (Gibco), 0.25 mg/mL
ascorbic acid (Sigma-Aldrich, USA) and 10% FCS (Gibco). The
fetal lung explants were incubated in a 5% CO2 incubator at 37uC
for 96 hours, and the medium was replaced every 48 hours. The
branching morphogenesis was monitored daily by photographing
the explants. At day 0 (D0: 0 hours) and day 4 (D4: 96 hours) of
culture, the total number of peripheral airway buds (branching) in
all lung explants was determined, whereas the explants area,
epithelial perimeter and external perimeter were measured using
AxionVision Rel. 4.3 (Carl Zeiss, Germany). These results were
expressed as D4/D0 ratio.
LIF supplementation studies
Twelve lung explants were used as control (0 ng/mL).
Additionally, recombinant LIF (Sigma-Aldrich) was daily added
to lung explants in order to achieve a final concentration of 0.4, 4,
20 and 40 ng/mL (0.4 n= 15; 4 n= 12; 20 n= 12; 40 n= 15).
After 4 days in culture, control and LIF treated lung explants (at
40 ng/mL) were processed for western blot analysis of non-
phosphorylated and phosphorylated forms of p38, p44/42, JNK,
Akt and STAT3 (Cell Signaling Technology Inc., USA) according
to the method described above. Four independent experiments
were performed (n= 4).
LIF neutralizing studies
Lung explants were treated daily with IgG anti-LIF neutralizing
antibody (n= 12) at concentration of 1.0 mg/mL (R&D Systems,
USA). Non-specific effects were evaluated by daily addition of
identical concentration of normal IgG control antibody (n= 9;
R&D Systems). Moreover, lung explants were also treated with
FGF-10 that was added daily to the culture medium at a
concentration of 500 ng/mL (n= 9; R&D Systems).
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After 4 days in culture, normal IgG and anti-LIF IgG treated
lung explants were processed for western blot analysis of the
intracellular signaling pathways, as described above (n = 4).
Statistical Analysis
All quantitative data are presented as mean 6 SEM. Statistical
analysis was performed using the statistical software SigmaStat
(version 3.5; Systat Software Inc., USA). For LIF and LIFRa
expression levels evaluation and supplementation studies one-way
ANOVA was used. For LIF neutralizing studies and intracellular
signaling pathways analysis t-test analysis was used. The Student-
Newman-Keuls test was used for post-test analysis. Statistical
significance was set at p,0.05.
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Abstract
The glycoprotein 130 (gp130) dependent family of cytokines comprises interleukin-6 (IL-6), IL-
11, leukemia inhibitory factor (LIF), cardiotrophin-like cytokine (CLC), ciliary neurotrophic factor 
(CNTF), cardiotrophin-1 (CT-1), and oncostatin M (OSM). These cytokines share the membrane 
gp130 as a common signal transducer. Recently, it was demonstrated that IL-6 promotes, where-
as LIF inhibits fetal lung branching. Thus, in this study, the effects on fetal lung morphogenesis 
of the other classical members of the gp130-type cytokines (IL-11, CLC, CNTF, CT-1 and OSM) 
were investigated. Fetal rat lung explants were cultured in vitro with increasing concentrations 
of IL-11, CLC, CNTF, CT-1 and OSM. Treated lung explants were morphometrically analyzed 
and assessed for MAPK, PI3K/AKT and STAT3 signaling modifications. IL-11, which similarly 
to IL-6 acts through a gp130 homodimer receptor, significantly stimulated lung growth via p38 
phosphorylation. On the other hand, CLC, CNTF, CT-1 and OSM, whose receptors are gp130 
heterodimers, inhibited lung growth acting in different signal-transducing pathways. Thus, the 
present study demonstrated that although cytokines of the gp130 family share a common signal 
transducer, there are specific biological activities for each cytokine on lung development. Indeed, 
cytokine signaling through gp130 homodimers stimulate, whereas cytokine signaling through 
gp130 heterodimers inhibit lung branching.
Keywords: cardiotrophin-1; cardiotrophin-like cytokine; ciliary neurotrophic factor; fetal lung 
development; glycoprotein 130; interleukin-11; oncostatin M.
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Introduction
Normal lung development is particularly dependent on tightly regulated signaling networks, 
triggered by both its classically known effectors, such as growth factors, extracellular matrix 
molecules and hormones, and by its recently implicated regulatory factors like inflammatory 
cytokines (1-4).
The glycoprotein 130 (gp130) dependent family of cytokines or interleukin 6 (IL-6) family of 
cytokines is quite a large group of structurally related cytokines that includes IL-6, IL-11, leukemia 
inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), cardiotrophin-
like cytokine (CLC), and oncostatin M (OSM) (5, 6). Other family members have recently emer-
ged (IL-27 and neuropoietin), thus it is likely that the currently defined gp130 cytokine family is 
not complete (5, 7, 8). These small proteins are grouped in same family, since all signal through 
a common signal transducing receptor chain, the gp130. However, each cytokine interacts with 
a specific receptor that is a complex of receptor subunits. Thus, the multimeric receptor complex 
for gp130 family of cytokines consists of (i) gp130 homodimers with a ligand-specific α chain for 
IL-6 and IL-11; (ii) gp130 heterodimers (gp130/LIFR and gp130/OSMR) without specific α chain 
for LIF and OSM; (iii) or gp130 heterodimers with a ligand-specific α chain (CNTFRα) for CNTF 
and CLC or α chain-like for CT-1 (5-7). Until the moment, the α chain recruited by CT-1 has not 
been characterized (5).
The gp130 cytokine receptors signal directly through the Janus kinase-signal transducer and 
activator of transcription (JAK-STAT) pathway, particularly STAT3 and STAT1 (6, 9). Alternatively, 
gp130 cytokine family can also initiate cell signaling via other signaling pathways, including the 
mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K/Akt) cascades 
(6, 10, 11). Through these pathways, gp130 cytokine signaling activates target genes involved in 
several cellular responses namely, cell differentiation, survival, apoptosis and proliferation.
Adding to their reputation as classical regulators of immune response and inflammation, 
these cytokines are also well known for their regulatory role in diverse biological processes 
including, hematopoiesis, mammalian fertility, liver and neuronal regeneration, myocardial de-
velopment, pituitary proliferation, bone homeostasis, adipocyte differentiation and function, and 
embryonic development (5, 6, 10-12). Concerning lung development, IL-6 was demonstrated 
to have an enhancing effect on lung explant growth and proved to be an important regulator of 
normal lung growth, whereas in opposition to IL-6, LIF was found to inhibit lung branching (3, 4, 
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13). Such evidences lead us to speculate that other members of gp130 family of cytokines might 
be involved on normal lung development. Moreover, these cytokines present some functional 
redundancy, even though they also exhibit specific biological activities (6, 11). Therefore, we 
proposed to investigate the role of other gp130 family of cytokines on fetal lung growth.
Materials and methods
This study was carried out in strict accordance with the recommendations in the ‘Guide for 
the Care and Use of Laboratory Animals’, published by the US National Institutes of Health (NIH 
Publication No.85-23, revised 1996). Animal experiments were also performed according to the 
Portuguese law for animal welfare and the protocol was approved by the Committee on the Ethics 
of Animal Experiments of the Life and Health Sciences Research Institute of the University of Minho 
(DGV 022162 - 520/000/000/2006). Moreover, all efforts were made to minimize animal suffering.
Animal model and experimental design
Sprague-Dawley female rats (225 g; Charles-River, Spain) were maintained in appropriate 
cages under temperature-controlled room (22–23ºC) on 12 hours light: 12 hours dark cycle, and 
fed with commercial solid food. The rats were mated and checked daily for vaginal plug. The day 
of plugging was defined as gestational day 0.5 for time dating purposes. Fetuses were removed by 
caesarean section at 13.5 dpc (days post-conception), sacrificed by decapitation and their lungs 
dissected for fetal lung explant cultures.
Fetal lung explant cultures
Harvesting and dissection of 13.5 dpc lungs was made in DPBS (Lonza, Switzerland) under a 
dissection microscope (Leica MZFLIII, Switzerland). The lungs were transferred to Nucleopore mem-
branes with an 8 m pore size (Whatman, USA), previously presoaked in DMEM (Invitrogen, UK) for 1 
hour, and incubated in a 24-well culture plates (Nunc, Denmark). Floating cultures of the explants were 
incubated in 200 L of 50% DMEM, 50% nutrient mixture F-12 (Gibco, USA) supplemented with 100g/
mL streptomycin, 100 units/mL penicillin (Gibco), 0.25 mg/mL ascorbic acid (Sigma-Aldrich, USA) 
and 10% FCS (Gibco). The fetal lung explants were incubated in a 5% CO2 incubator at 37ºC for 96 
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hours, and the medium was replaced every 48 hours. The branching morphogenesis was monitored 
daily by photographing the explants. At day 0 (D0: 0 hours) and day 4 (D4: 96 hours) of culture, the 
total number of peripheral airway buds (branching) in all lung explants was determined, whereas the 
explants area, epithelial perimeter and external perimeter were measured using AxionVision Rel. 4.3 
(Carl Zeiss, Germany). These results were expressed as D4/D0 ratio.
IL-11, CLC, CNTF, CT-1 and OSM supplementation studies
In vitro cultures were daily supplemented with several doses of recombinant IL-11 (0.1; 1; 
10; 100 pg/mL), CLC (0.003; 0.03; 0.3; 3; 30 nM), CNTF (0.1; 1; 10; 100; 1000 ng/mL), CT-1 
(0.1; 1; 10; 100; 200 ng/mL), and OSM (0.1; 1; 10; 100 ng/mL). All recombinant proteins were 
purchased from R&D Systems, USA. Per each tested dose at least nine, often more, fetal lung 
explants were used, likewise twelve lung explants were used as control. For CLC and CT-1 supple-
mentation studies the control explants were supplemented with 4 mM of sterile HCL (according to 
manufacturer’s instructions of recombinant proteins reconstitution).
After 4 days in culture, control and cytokine treated lung explants at selected concentra-
tions (IL-11 at 0.1 pg/mL; CLC at 30 nM; CNTF at 1000 ng/mL; CT-1 at 200 ng/mL; OSM at 
100 ng/mL) were processed for western blot analysis of nonphosphorylated and phosphorylated 
forms of p38, p44/42, JNK, Akt and STAT3 (Cell Signaling Technology Inc., USA) according to 
the method described below.
Western blot analysis
Pooled samples of the cultured lung explants were processed for western blot analysis. 
Proteins were obtained according to Kling et al (14). Ten g of protein were loaded onto 10% 
acrylamide minigels, electrophoresed at 100 V at room temperature and then transferred to nitro-
cellulose membranes (HybondTM -C Extra, GE Healthcare Life Sciences, UK). Blots were probed 
with antibodies to non-phosporylated and phosporylated forms of p38, p44/42 (ERK1/2), JNK, 
Akt and STAT3 (1:1000; Cell Signaling Technology Inc., USA) according to the manufacturer’s 
instructions. For loading control, blots were probed with β-tubulin (1:150000, Abcam, UK). 
Afterwards blots were incubated with a secondary horseradish peroxidase conjugate (Santa Cruz 
Biotechnology Inc.), developed with Super SignalHWest Femto Substrate (Pierce Biotechnology, 
USA) and the chemiluminescent signal was captured using the Chemidoc XRS (Bio-Rad, USA). 
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Quantitative analysis was performed with Quantity One 4.6.5 1-D Analysis Software (Bio-Rad). 
Three independent experiments were performed (n = 3).
Statistical analysis
All quantitative data are presented as mean ± SEM. Statistical analysis was performed using 
the statistical software SigmaStat (version 3.5; Systat Software Inc., USA). For supplementation stu-
dies one-way ANOVA was used and for intracellular signaling pathways analysis t-test was used. The 
Student-Newman-Keuls test was used for post-test analysis. Statistical significance was set at p 0.05.
Results
Role of gp130 cytokines on fetal lung development
This study aimed to clarify the role of gp130 dependent family of cytokines on lung mor-
phogenesis. Thus, fetal lung explants cultured in vitro were treated daily with increasing concen-
trations of recombinant IL-11, CLC, CNTF, CT-1 and OSM. In Figure 1A representative examples 
of fetal lung explants treated with increasing IL-11 concentrations, after 4 days in culture, are 
illustrated. IL-11 appears to have an enhancing effect on lung explants growth which is maximal 
at the lowest concentration tested, 0.1 pg/mL. In fact, an increase in the total number of peri-
pheral airway buds (Figure 1B), epithelial perimeter (Figure 1C), area (Figure 1D) and external 
perimeter (Figure 1E) of lung explants was observed in all concentrations tested, except the hi-
ghest, 100 pg/mL. In all the above mentioned morphometric parameters, explants treated with 
the highest dose presented the most similar effect to the control explants. In detail, in fetal lung 
explants increasing doses of IL-11, induced a biphasic effect in all the morphometric parameters 
assessed, generally the lowest dose of IL-11 enhanced explant growth, whereas increasingly high 
doses gradually reduced explant growth when compared to the maximal effect observed.
Regarding the role of CLC in fetal lung growth, in Figure 2A representative examples of lung 
explants treated with increasing CLC concentrations, after 4 days in culture, are illustrated. CLC 
appears to have a dose-effect inhibitory action on lung explants growth. In fact, a decrease in the 
total number of peripheral airway buds (Figure 2B), epithelial perimeter (Figure 2C), area (Figure 
2D) and external perimeter (Figure 2E) of lung explants was observed in all concentrations tes-
ted, and this effect is most significant in the highest CLC concentration studied, 30nM.
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In Figure 3A, representative examples of fetal lung explants treated with increasing CNTF 
concentrations, after 4 days in culture, are illustrated. CNTF have an inhibitory action on lung 
explants growth, with the maximal effect induced by the highest CNTF concentration studied, 
1000 ng/mL.
Concerning CT-1, CT-1 appears to have a dose-effect inhibitory action on lung explants gro-
wth, as illustrated in figure 4A. In fact, a decrease in the total number of peripheral airway buds 
(Figure 4B), epithelial perimeter (Figure 4C), area (Figure 4D) and external perimeter (Figure 4E) 
of lung explants was observed in all concentrations tested, this effect is most significant in the 
highest CT-1 concentration studied, 200 ng/mL.
As illustrated in figure 5A, OSM appears to have an inhibitory effect on lung branching. 
In fact, OSM at 100 ng/mL induces a significant decrease in the total number of peripheral ai-
rway buds (Figure 5B), epithelial perimeter (Figure 5C), area (Figure 5D) and external perimeter 
(Figure 5E) of lung explants.
Gp130 cytokines supplementation effects on intracellular signaling pathways
The receptors of gp130 cytokines directly control the activities of STAT, MAPK, and PI3K/
AKT signaling pathways. In order to further investigate gp130 cytokines effects on fetal lung 
growth, treated lung explants were evaluated for signaling modulation of these pathways. Pooled 
samples of lung explants individually treated with recombinant cytokines (selected due to its 
maximal effect either on stimulation or inhibition of explants growth) were used to assess protein 
expression levels of non-phosporylated and phosphorylated forms of p38, p44/42 (ERK1/2), 
JNK, Akt and STAT3 by western blot (Figure 6). On one hand, lung growth stimulation induced 
by IL-11 significantly increased p38 phosphorylation. On the other hand,
inhibition of lung growth induced by CLC, significantly reduced JNK and AKT phosphoryla-
tion levels. Both CNTF and CT-1-induced inhibition of lung growth significantly stimulated STAT3 
phosphorylation and decreased JNK phosphorylation. Additionally, CNTF treatment also induced 
a significant increase of AKT phosphorylation, whereas CT-1 treatment significantly increased 
p38 phosphorylation. OSM inhibitory effects on lung growth appear to be mediated by significan-
tly increase of p38 and p44/42 phosphorylation, and also of AKT and STAT3 phosphorylation.
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Discussion
The gp130 cytokine family collectively exhibits a broad range of physiological functions, 
including important roles in embryonic development. Recently, some of these cytokines, namely 
IL-6 and LIF, have been proposed to be mediators in fetal lung development (3-4), but otherwise 
little is known about the role of additional classical members of this family in the developing lung.
In order to further clarify the role of the gp130 family of cytokines in lung branching morpho-
genesis, in vitro supplementation studies were performed individually. Thus, fetal lung explants 
were cultured with increasing concentrations of IL-11, CLC, CNTF, CT-1 or OSM, selected according 
to literature (15-24). Supplementation studies showed that cytokines within the gp130 family can 
elicit opposite effects in lung explant growth. Such observation suggests that despite their shared 
use of the common receptor subunit gp130, these cytokines can generate contradictory signals 
in branching morphogenesis. Additionally, intracellular signaling contribution to the effects of each 
cytokine on fetal lung growth were investigated by assessing non-phosphorylated and phosphoryla-
ted protein expression levels of several intracellular mediators, namely p38, p44/42, JNK, Akt and 
STAT3. It is well-established that numerous players account for the molecular basis of cytokine 
action, thus unsurprisingly in fetal lung development each cytokine proved to elicit the activation of 
either simple or combinatory signals from different signal-transducing pathways.
In this study, it was demonstrated that IL-11 supplementation stimulates lung branching evi-
denced by increased number of peripheral airways buds, epithelial perimeter, area and external 
perimeter of fetal lung explants, whereas CLC, CNTF, CT-1 and OSM inhibit lung growth. Together 
with previously obtained results which demonstrated that IL-6 and LIF have opposite effects in 
branching morphogenesis, the first stimulated lung explant growth while the latter inhibited, the 
current study extensively contributes for a thorough comprehension of the role of these cytokines 
in the complex process of lung development.
Similarly to what was previously describe for IL-6, IL-11 supplementation stimulated fetal lung 
branching. Interestingly, IL-11 has been demonstrated to stimulate proliferation and differentiation of 
intestinal cells and prevent apoptosis of epithelial cells (25, 26). Regarding the lung, IL-11 is produced 
by a variety of structural cells (fibroblasts, epithelial cells, human airway smooth muscle cells) and 
eosinophils in response to a variety of stimuli (27, 28). Indeed, IL-11 acts as a healing cytokine in 
the asthmatic airway and in other tissues. Interestingly, IL-11 also provides protective effects against 
oxidant-mediated injury in fetal and adult lung (29, 30).
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On the contrary, it was demonstrated that CLC, CNTF, CT-1 and OSM inhibit lung growth. 
Several evidences point towards a role of these inflammatory cytokines in varied aspects of lung 
physiology. Regarding CLC, during development this cytokine is expressed in lung, kidney, brain, 
tooth, epithelia and skeletal muscles. In the lung, CLC is expressed faintly in distal airway epithe-
lium (31), which suggests important biological roles of CLC in cellular functions. In opposition to 
lung growth inhibition here demonstrated, during kidney development (an organ that just like the 
lung develop by branching mechanisms), CLC promotes mesenchymal to epithelial conversion 
and nephrogenesis (17). Concerning CNTF, it was already described that it is widely expressed in 
the adult brain, lung, heart, liver, kidney and testis (32). During embryonic development, CNTF is 
specifically expressed in rat pineal gland and eyes (33). This cytokine has been described to act 
as a lesion factor, preventing neuronal cell death and facilitating axonal regeneration after nerve 
injury (21). About CT-1, it was already demonstrated that this cytokine is expressed in adult lung, 
heart, liver, kidney, skeletal muscle, dorsal root ganglia, ovary, colon, prostate and testis, as well 
as in fetal lung, heart and kidney (5, 34-36). In opposition to inhibitory effect on fetal lung growth 
described in this study, CT-1 has been related with hypertrophic and cytoprotective actions (34). 
In fact, CT-1 has been related with chronic asthma, contributing to airway wall thickening through 
reduction of apoptosis rates and induction of hypertrophy of airway smooth muscle cells (36). 
Finally, during fetal life, OSM has been described to be expressed only in hematopoietic tissues, 
choroid plexus and limb (37). After birth, it is detectable in other organs, such as lymph node, 
bone, heart, kidney, small intestine, skin, nasal cavity, and lung (38, 39). In the lung, OSM is 
detected in alveolar and bronchiolar epithelium (38). Interestingly, OSM overexpression is delete-
rious during mouse development (9). Moreover, OSM is a potent mediator of lung inflammation 
and extracellular matrix accumulation, and is up-regulated in patients with idiopathic pulmonary 
fibrosis and scleroderma (40).
Our findings on this dual contribution of gp130 family of cytokines, with inductive and 
suppressive actions in lung growth, clearly suggest a regulatory role in fetal lung development. 
Previously stressing a role for gp130 signaling during embryo development are many studies of 
transgenic and knockout mice for different components of this cytokine family or their receptors, 
which report defects in bone and neurologic development, disrupted placental architecture, hy-
poplastic development and a decrease in fetal liver hematopoiesis. The most severe phenotypes 
are displayed by mice lacking receptor components used by several members of the gp130 fa-
mily. In fact, gp130 or LIFR knockout mice die during development or shortly after birth (11, 41, 
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42). Investigation of the lungs, in conditional gp130-mutant mice, revealed pulmonary defects 
and development of emphysema with increasing age (42). Moreover,
mice with a lung epithelial cell-specific deletion in gp130 or STAT3 were unable to restore 
cell shape and cell density after pulmonary injury, which highlights an important role for gp130 
signaling in normal repair of the bronchiolar epithelium following injury (41, 44).
In the present study, it was revealed that individual gp130-type cytokines can both enhance 
or inhibit fetal lung growth. Besides, providing specificity for individual cytokines in fetal lung 
development, these data underlines that cytokines operating through gp130 homodimers may 
induce different and even opposite biological responses than those operating through gp130 
heterodimers. Both IL-6 and IL-11 receptors are gp130 homodimers and stimulate lung growth, 
whereas all the other receptors for this family of cytokines are gp130 heterodimers and inhibit 
lung growth. Thus, the main findings of this study stress the composition of these signaling 
receptor complexes as an important mechanism to acquire signaling specificity from pleiotropic-
acting cytokines in lung development. This is in agreement with the well-documented fact that 
such cytokines with pleiotropic activities can also retain tissue-specific activities. In fact, seve-
ral mechanisms can be accountable for generating and limiting those responses, specifically: 
cytokine restricted temporal and spatial release, differential expression of cell surface receptors 
and different signaling pattern between gp130 homodimers and heterodimers (45). In lung 
branching morphogenesis, our observations clearly support a specific and contrasting physio-
logical response obtained from cytokines acting on gp130 homomeric receptors versus gp130 
heteromeric receptors.
Cytokine signaling on a developing lung cell-specific context triggers diverging and non-
overlapping intracellular signaling cascades. For instance, IL-11 stimulating effect on lung growth 
was associated with an increase in p38 phosphorylation.
Interestingly, the stimulation of lung growth induced by IL-6 was also previously reported 
to be associated with increased p38 activation (4). In the case of gp130 cytokines that exert 
an inhibitory effect in lung explant growth, diverse and combinatory intracellular signals are 
more frequent. Clearly this study emphasizes that also in lung branching morphogenesis, gp130 
cytokine receptor activation is a rather complex means of initiation of signal transduction that 
leads to numerous possible signaling patterns able to elicit a similar biological outcome. CLC 
induced lung growth inhibition and concomitantly a decrease in the activation of JNK and AKT. 
Both CNTF and CT-1-induced lung growth inhibition is associated with activation of STAT3 and 
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decreased JNK phosphorylation. CNTF additionally activates PI3K/AKT cascade whereas CT-1 
activates p38. OSM inhibition of lung growth demonstrated to activate PI3K/AKT, different MAPK 
signaling pathways (p38 and p44/42) and also STAT3. Collectively, these results suggest that 
integration of the activities transduced by multiple pathways might ultimately provide a balanced 
biological outcome intended to respond to a particular physiological situation.
In conclusion, in a similar way to IL-6, IL-11 acts in a gp130 homodimer receptor and it was 
demonstrated that stimulates lung branching. On the other hand, CLC, CNTF, CT-1 and OSM re-
ceptors are gp130 heterodimers and it was described that they inhibit lung growth. All these results 
demonstrated that cytokine signaling through gp130 homodimers stimulate, whereas cytokine sig-
naling through gp130 heterodimers inhibit lung branching. This specificity of gp130-type cytokines 
might represent a regulatory mechanism of lung morphogenesis, intrinsic to this family of cytoki-
nes, in order to achieve the correct lung growth.
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Figure 1 
 
Figure 1. IL-11 supplementation studies in a fetal lung explant culture system. (A) Representative examples of fetal lung explants treated daily 
with increasing concentrations of recombinant IL-11, after 4 days in culture. Original magnification: x25. (B) Number of total airway buds; (C) 
Epithelial perimeter; (D) Area; (E) External perimeter of lung explants treated with IL-11. Results are expressed as ratio of day 4 (D4) and day 0 
(D0) of culture (D4/D0 ratio). p<0.05: * vs. IL-11 at 0 pg/mL (control), § vs. IL-11 at 0.1 pg/mL, ¥ vs. IL-11 at 1 pg/mL.
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Figure 2 
 
Figure 2. CLC supplementation studies in a fetal lung explant culture system. (A) Representative examples of fetal lung explants treated daily 
with increasing concentrations of recombinant CLC, after 4 days in culture. Original magnification: x25. (B) Number of total airway buds; (C) 
Epithelial perimeter; (D) Area; (E) External perimeter of lung explants treated with CLC. Results are expressed as ratio of day 4 (D4) and day 0 
(D0) of culture (D4/D0 ratio). p<0.05: * vs. CLC at 0 nM (control plus 4 mM HCL), § vs. CLC at 0.003 nM, ¥ vs. CLC 
at 0.03 nM, † vs. CLC at 0.3 nM, ‡ vs. CLC at 3 nM.
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Figure 3 
 
 
Figure 3. CNTF supplementation studies in a fetal lung explant culture system. (A) Representative examples of fetal lung explants treated daily 
with increasing concentrations of recombinant CNTF, after 4 days in culture. Original magnification: x25. (B) Number of total airway buds; (C) 
Epithelial perimeter; (D) Area; (E) External perimeter of lung explants treated with CNTF. Results are expressed as ratio of day 4
(D4) and day 0 (D0) of culture (D4/D0 ratio). p<0.05: * vs. CNTF at 0 nM (control), § vs. CNTF at 0.1 ng/mL, ¥ vs. CNTF at 1 ng/mL, † vs. 
CNTF at 10 ng/mL.
Chapter IV GP130 FAMILY OF CYTOKINES AND FETAL LUNG GROWTH 107
Figure 4 
 
Figure 4. CT-1 supplementation studies in a fetal lung explant culture system. (A) Representative examples of fetal lung explants treated daily 
with increasing concentrations of recombinant CT-1, after 4 days in culture. Original magnification: x25. (B) Number of total airway buds; (C) 
Epithelial perimeter; (D) Area; (E) External perimeter of lung explants treated with CT-1. Results are expressed as ratio of day 4 (D4) and day 0 
(D0) of culture (D4/D0 ratio). p<0.05: * vs. CT-1 at 0 ng/mL (control plus 4 mM HCL), § vs. CT-1 at 0.1 ng/mL, ¥ 
vs. CT-1 at 1 ng/mL, † vs. CT-1 at 10 ng/mL, ‡ vs. CT-1 at 100 ng/mL.
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Figure 5. OSM supplementation studies in a fetal lung explant culture system. (A) Representative examples of fetal lung explants treated daily 
with increasing concentrations of recombinant OSM, after 4 days in culture. Original magnification: x25. (B) Number of total airway buds; (C) 
Epithelial perimeter; (D) Area; (E) External perimeter of lung explants treated with OSM. Results are expressed as ratio of day 4 (D4) and day 0 
(D0) of culture (D4/D0 ratio). p<0.05: * vs. OSM at 0 ng/mL (control), † vs. OSM at 0.1 ng/mL, § vs. OSM at 1 ng/mL, ¥ vs. OSM at 10 ng/mL.
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Figure 6 
Figure 6. Analysis of intracellular signaling pathways that mediates IL-11, CLC, CNTF, CT-1 and OSM actions on lung growth. (A) Western blot 
analysis of p38, p44/42, JNK1/2, Akt and STAT3, and to diphosphorylated forms of p38 (dp-p38), p44/42 (dp-p44/42), SAPK/JNK (dp-JNK1/2), 
Akt (dp-Akt) and STAT3 (dp-STAT3) in control (1), control plus 4 mM HCL for CLC and CT-1 lung explants (2) and treated with IL-11 at 0.1 pg/mL 
(3), CLC at 30 nM (4), CNTF at 1000 ng/mL (5), CT-1 at 200 ng/mL (6), and OSM at 100 ng/mL (7). Control loading was performed using -tubulin 
(55 kDa). p38 corresponds to 38 kDa. p44/42 correspond to 44 and 42 kDa, respectively. JNK1 and 2 correspond to 46 and 54 kDa, respectively. 
Akt corresponds to 60 kDa. STAT3 corresponds to two bands, 79 and 86 kDa. Semi-quantitative analysis for dp-p38 (B), dp-p44/42 (C), dp-JNK1/2 
(D), dp-Akt (E), and dp-STAT3 (F). Results are presented as arbitrary units normalized for -tubulin and the respective control. p<0.05: * vs. control.
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Intrinsic Catch-Up Growth of Hypoplastic
Fetal Lungs Is Mediated by Interleukin-6
Cristina Nogueira-Silva, MD,1 Rute S. Moura, PhD,1 Nuno Esteves,1
Sı´lvia Gonzaga,1 and Jorge Correia-Pinto, MD, PhD1,2*
Summary. Fetal lung hypoplasia is a common finding in several fetal conditions such as
congenital diaphragmatic hernia (CDH). Interestingly, previous studies have demonstrated that
hypoplastic lungs have the ability to recover to normal size, when relieved frommechanical factors.
However, the underlying mechanisms remain largely unknown. Recently, interleukin-6 (IL-6) has
been involved in catch-up growth phenomenon in children. Thus, we hypothesized that IL-6 could
mediate fetal growth recover fromhypoplastic lungs.Control and nitrofen-induced hypoplastic lung
explants were cultured either in normal conditions or with IL-6 neutralizing antibodies. The total
number of peripheral airway buds, epithelial perimeter, and total explant area were analyzed and
daily branching rates were calculated. Additionally, IL-6 mRNA and protein expression was
assessedboth in qualitative (by in situ hybridization and immunohistochemistry) and in quantitative
(by real-time PCR and Western blot) approaches, in control and hypoplastic lungs (nitrofen and
CDHgroups). Nitrofen-inducedhypoplastic lungs showed in vitro, out of systemic environment, the
ability to recover from hypoplasia and presented daily branching rates significantly higher than
controls. Blocking IL-6 activity significantly diminished the intrinsic capacity of hypoplastic fetal
lungs to recover from hypoplasia and attenuated their daily branching rates. Although more
exacerbated in CDH, both nitrofen-exposed lungs presented significant IL-6 mRNA and protein
over-expression throughout all studied gestational ages. The present study suggests, for the
first time, that fetal lung is able to recover fromgrowth retardation through away that resembles the
catch-up growth phenomenon, and it seems to be, at least partially, orchestrated by intrinsic
mechanisms implicating IL-6. Pediatr Pulmonol. 2008; 43:680–689.  2008 Wiley-Liss, Inc.
Key words: fetal lung hypoplasia; lung development; congenital diaphragmatic hernia.
INTRODUCTION
Congenital diaphragmatic hernia (CDH) is a severe
developmental anomaly with a mean incidence of ap-
proximately 1/2,500 live-born infants.1 It is characterized
by a congenital diaphragmatic defect that allows passage
of the developing viscera into the thoracic cavity.2
Consequently, lung development is impaired, and at birth
CDH infants suffer from severe respiratory distress due
mainly to lung hypoplasia, what limits their chance to
survive.1
The nitrofen-induced CDH rat model is considered one
of the best experimental models to study the pathophysio-
logy of pulmonary hypoplasia.1 In this model, it was
previously demonstrated that fetal lung hypoplasia
results from a complex dynamic process associating early
and late gestational determinants.3 Early determinants
appear to be secondary to molecular disturbances, in a
background of genetic and environmental factors, affect-
ing predominantly the pseudoglandular stage of lung
development (branching stage). Recently, using pro-
teomics analysis, it was demonstrated that a deficiency
in contractile proteins myosin light chain 1a and 2 might
have a role amongst the early molecular determinants of
lung hypoplasia in nitrofen-induced CDH rat model.4 On
the other hand, late determinants seem to be primarily
related to mechanical compression secondary to visceral
thoracic herniation and affect essentially canalicular,
saccular and alveolar stages of lung development
(maturation stages).3,5,6
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The catch-up growth is a classic infantile phenomenon
defined as growth acceleration beyond the normal rate.7–9
An interesting point about CDH is the ability of
hypoplastic lung to recover to normal size, when relieved
from mechanical factors. In fact, in rat fetuses exposed to
nitrofen that did not develop diaphragmatic defect, fetal
lung recovered from lung growth retardation throughout
gestation.5,6 Similarly, clinical observations demonstrated
that hypoplastic lungs from surviving CDH infants
undergo a tremendous growth after post-natal diaphrag-
matic repair. Recently, it was also demonstrated that
in vitro nitrofen-exposed fetal lungs were able to recover
from hypoplasia, suggesting that a phenomenon of catch-
up growthmight be occurring.10 Although the underlying
mechanisms of this phenomenon remain largely un-
known, it is possible that their knowledge might be
particularly useful envisioning prenatal therapy of lung
hypoplasia.
Interleukin-6 (IL-6) is a pleiotropic cytokine with
important roles on processes of branching organs, such
as fetal lung. Several studies have emphasized the
importance of IL-6 signaling in fetal lung maturation by
enhancing pulmonary surfactant proteins.11–14 Recently,
it was demonstrated that IL-6 is constitutively expressed in
pulmonary primitive epithelium during normal lung
morphogenesis, and enhances fetal lung branching.10
As IL-6 is commonly involved in repairing mecha-
nisms, we hypothesized that IL-6 could mediate the fetal
catch-up growth phenomenon of hypoplastic lungs.
MATERIALS AND METHODS
Animal experiments were performed according to the
Portuguese law for animal welfare. Animals were housed
in an accredited mouse house and treated as specified by
the recommendations of the ‘‘Guide for the Care and Use
of Laboratory Animals’’ published by the US National
Institutes of Health (NIH Publication No.85-23, revised
1996).
Animal Model and Experimental Design
Sprague–Dawley female rats (225 g; Charles-River;
Barcelona, Spain) were maintained in appropriate cages
under controlled conditions and fedwith commercial solid
food. The rats were mated and checked daily for vaginal
plug. The day of plugging was defined as gestational day
0.5 for time dating purposes. Pregnant rats were exposed
on 9.5 dpc (days post-conception) to 100 mg of nitrofen
(2,4-dichlorophenyl-p-nitrophenylether) dissolved in 1ml
of olive oil administered by gavage or with an equal
volume of vehicle.15 At different time-points (13.5, 15.5,
17.5, 19.5, and 21.5 dpc), fetuses were harvested by
caesarean section. Under binocular surgical microscopy
(Leica, Wild M651.MS-D, Heerbrugg, Switzerland) and
after fetal decapitation, a laparotomy was performed to
inspect the diaphragm. Through a median sternotomy, the
lungs were excised. Fetuses were assigned to three
experimental groups: (i) Control group, fetuses exposed
to olive oil alone; (ii) Nitrofen group, fetuses exposed to
nitrofen without CDH; (iii) CDH group, fetuses exposed
to nitrofen with CDH. Because at 13.5 and 15.5 dpc
accurate identification of the diaphragmatic defectwas not
feasible, only two groups were defined at these gestational
ages: Control and Nitrofen (exposed to nitrofen with or
without CDH).
For lung explant cultures, fetuses were harvested at
13.5 dpc from control and nitrofen groups and their lungs
were dissected.
For in situ hybridization (ISH), real-time PCR,
immunohistochemistry (IHC) and Western blot studies,
fetuses were harvested by caesarean section at 15.5, 17.5,
19.5, and 21.5 dpc. Random left lung samples of each
experimental group from all time-points were processed
and embedded in paraffin for ISH and IHC, whereas other
sampleswere collected forWestern blot analysis. Samples
from 15.5 dpc were also collected for the quantification of
IL-6 expression by real-time PCR. These samples were
immersed in RNAlater (Qiagen, Hieden, Germany) and
stored at �808C.
Fetal Lung Explant Cultures
Harvesting and dissection of 13.5 dpc lungs was made
in DPBS (Cambrex, NJ) under a dissection microscope
(Leica MZFLIII, Herbrugg, Switzerland). The lungs
were transferred to Nucleopore membranes with an
8 mm pore size (Whatman, NY) and incubated in a 12-well
culture plates fromCostar (Corning,NY). Themembranes
were pre-soaked in DMEM (Cambrex) for 1 hr before the
explants were placed on them. Floating cultures of the
explants were incubated in 200 ml of 50% DMEM, 50%
nutrient mixture F-12 (Invitrogen, Carlsbad, CA) supple-
mented with 100 mg/ml streptomycin, 100 units/ml
penicillin (Invitrogen), 0.25 mg/ml ascorbic acid (Sigma
Chemical, Gillingham, UK) and 10% FCS (Invitrogen).
Twelve control and 12 nitrofen explants were incubated
without any treatment. Thirteen control and 12 nitrofen
explants were treated daily with IgG anti-rat IL-6 neutral-
izing antibody at concentration of 1.0 mg/ml (30 times the
concentration previously shown to suppress IL-6 effect;
R&D Systems, Minneapolis, MN). Non-specific effects
were evaluated by adding identical concentration of
normal goat IgG control antibody (control n¼ 10, nitrofen
n¼ 9) (R&D Systems).
The fetal lung explants were incubated in a 5% CO2
incubator at 378C for 96 hr, and the medium was replaced
every 48 hr. The branchingmorphogenesis was monitored
daily by photographing the explants. At day 0 (D0: 0 hr),
1 (D1: 24 hr); 2 (D2: 48 hr); 3 (D3: 72 hr), and 4 (D4: 96 hr)
of culture, the total number of peripheral airway buds
Pediatric Pulmonology
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(branching) in all lung explants was determined, whereas
the epithelial perimeter and total explant area were mea-
sured using AxionVision Rel. 4.3 (Carl Zeiss, Go¨ttingen,
Germany). For all experimental conditions, the results of
branching, epithelial perimeter and explant area were
expressed as D4/D0 ratio, whereas daily branching rate
was calculated through the formula Dn/Dn�1.
In Situ Hybridization (ISH) Studies
Digoxigenin-labeled IL-6 probewas synthesized froma
901 bp fragment of IL-6 coding sequence, inserted on a
pBluescript KS-vector (kindly supplied by Dr. Georg H.
Fey, University of Erlangen-Nurnberg, Germany). The
plasmid was linearized with BamHI and T3 RNA
polymerase was used to synthesize the antisense ribop-
robe. The in vitro transcription reaction was performed
using DIG RNA Labeling Mix (Roche Molecular
Biochemicals, Mannheim, Germany), according to the
manufacturer’s instructions.
Tissue sections (10mm thick)were processed for ISH as
previously described by Strahle et al.16 ISH slides were
observed and photographed on light microscope with an
Axiocam color video camera (Carl Zeiss, Germany).
Real-Time PCR Studies
RNA Extraction
TotalRNAfrom left lung samples of 18 fetuses (15.5 dpc:
control n¼ 9, nitrofen n¼ 9) was extracted using the
RNeasy Mini Kit Protect (Qiagen). After extraction, total
RNA was digested with RNase-free DNase (Promega,
Madrid, Spain) to avoid DNA contamination. Total RNA
quantification was done by spectrophotometry (Bio-
Photometer, Eppendorf, Cologne, Germany). The ratio
A260/A280 was used to test protein contamination of the
extracted RNA.
Reverse Transcription
For the cDNA synthesis, 100 ng of extracted RNAwas
used. The reverse transcription was carried out on a
T-gradient thermoclycer (Biometra, Goettingen, Germany)
using the Superscript II kit (Invitrogen). Briefly, 125 ng
random primers (Invitrogen), 4 ml of 5� buffer, 2 ml of
1 mM DTT, 1 ml of 10 mM dNTP mix (MBI Fermentas,
St. Leon-Rot, Germany), 1 ml of recombinant Rnasin
(Promega) and 1ml of Superscript IIReverseTranscriptase
were added in a total volume of 20 ml. The following
program was used to carry out the reverse transcriptase
reaction: 428C for 60 min and 708C for 15 min. In all re-
actions a negative control, omission of mRNA, was used.
Quantitative Real-Time PCR
According to a 2-Step model, cDNA was used for
relative quantification of IL-6 and of reference gene b-actin
expression by real-time PCR (LightCycler, RocheMolec-
ular Biochemicals). Each run consisted of 15min hot-start
and 55 cycles (958C, 15 sec; 588C, 20 sec; 728C, 15 sec).
The following protocol was used: 10 ml of QuantiTech
SYBRgreen PCR mix (Qiagen), 2 ml of cDNA and
10 pmol of each primer were added in a total volume of
20 ml. A negative control was included in all the runs,
which consisted in omitting the cDNA and performing
a melting curve analysis, thus allowing the detection of
putative contamination.
Primer design was based on available sequences in
GenBank (NCBI-NLM-PubMed-Gene). All the primers
are intron-spanning (Table 1). For IL-6 and b-actin primer
sets standard amplification curves (ST curves) were made
with randomly selected cDNA samples setting r¼ 0.99. In
all samples IL-6 expression was normalized for b-actin.
Immunohistochemistry (IHC) Studies
IL-6 immunostainings were performed on formalin-
fixed and paraffin-embedded lung. Sections (5 mm) were
placed on SuperFrost1Plus slides (Menzel-Glaser,
Braunschweig, Germany). The primary antibody, a poly-
clonal goat anti-IL-6 (Santa Cruz Biotechnology, Inc.,
Heidelberg, Germany), was used in a 1:50 dilution. After
dewaxing in xylene and rehydration in ethanol, antigen
retrieval was achieved by boiling in 10 mM citrate buffer
followed by cool down at room temperature. Incubation
with the goat Immuno CruzTM Staining System (Santa
Cruz Biotechnology, Inc.) was carried according to
manufacturer’s instructions. Incubation of the primary
antibody occurred at 48C overnight. Negative control
reactions included omission of the primary antibody. To
visualize the peroxidase activities in sections, diamino-
benzidine tetrahydrochloride was used. Sections were
counterstained with hematoxylin. The slides were
observed and photographed with Olympus BX61 micro-
scope (Olympus, Hamburg, Germany). The percentage
of IL-6 stained cells per microscopic field was scored
TABLE 1—Primers Used for Quantitative PCR
Gene
Accession
number Primer set
Product
size (bp)
IL-6 NM_012589 50-CAA GAG ACT TCC AGC CAG-30, 50-CTC CGA CTT GTG AAG TGG T-30 141
b-actin NM_031144 50-GAT TTGGCACCACAC TTT CTACA-30, 50-ATC TGGGTCATC TTT TCACGG TTGG-30 114
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in a single-blinded fashion (magnification 400�) in four
independent peripheral areas per section (four sections per
each experimental group). Scoring was as follows: 1, 0–
25% cells/field; 2, 25–50% cells/field; 3, 50–75% cells/
field; 4, 75–100% cells/field.
Western Blot Analysis
Proteins were obtained according to Kling et al.17 Fifty
micrograms of protein were loaded onto 12.5%
acrylamide minigels, electrophoresed at 100 V at room
temperature and then transferred to HybondTM-C Extra
(GE Healthcare Life Sciences, Orsay, France). Blots were
probed with polyclonal rabbit anti-IL-6 (Abcam, Inc.,
Cambridge, UK) (1:500) according to the manufacturer’s
instructions. For loading control, blots were probed with
b-tubulin rabbit polyclonal antibody (1:80,000) (Abcam,
Inc.). Afterwards blots were incubated with a secondary
horseradish peroxidase conjugate (Cell Signaling Tech-
nology, Inc., Danvers, MA), developed with Super
Signal1West Femto Substrate (Pierce Biotechnology,
Rockford, IL) and exposed to HyperfilmTM ECLTM (GE
Healthcare Life Sciences).
Statistical Analysis
All quantitative data are presented as mean� SEM. For
morphometric analysis of lung explant cultures, statistical
analysis was performed, using SigmaStat 3.5, by two-way
ANOVA (factor A: groups (control vs. nitrofen); factor
B: treatment (no treatment vs. treatment with IgG or
anti-IL-6)). The Holm–Sidak test was used for post-test
analysis. For real-time PCR studies, Mann–Whitney rank
sum test was used. For score of IL-6 stained cells, one-way
ANOVA analysis on ranks was used and the Dunn test was
performed for post-test analysis. Statistical significance
was set at P< 0.05.
RESULTS
Fetal Lung Explant Culture
Figure 1 shows representative fetal lung explants of
control (Fig. 1A,B) and nitrofen groups (Fig. 1E,F) at D0
and D4, respectively. Although nitrofen-induced hypo-
plastic explants are significantly smaller at D0 (Fig. 1E),
after 4 days in culture, normal and nitrofen hypoplastic
lung explants are apparently similar. In fact, morpho-
metric analysis revealed that the number of peripheral
airway buds, the epithelial perimeter and the explant area
were significantly reduced in nitrofen when compared to
normal explants at D0. However, after 4 days in culture
no significant differences between control and nitrofen
groups were observed relating to these parameters
(Table 2). Figure 1 also illustrates control and nitrofen
lung explants treated with normal goat IgG (Fig. 1C—
controlþ IgG; Fig. 1G—nitrofenþ IgG) and IgG anti-rat
IL-6 antibodies (Fig. 1D—controlþ anti-IL-6; Fig. 1H—
nitrofenþ anti-IL-6) at D4. IL-6 blocking antibodies
significantly reduced the number of peripheral airway
buds and epithelial perimeter of control explants (Table 2).
Inhibition of IL-6 activity also reduced the ability of
growth recover of nitrofen lung explants. The number
of peripheral airway buds, the epithelial perimeter
and the explant area were significantly reduced in
Fig. 1. Branchingmorphogenesis in rat lung explant system.Representative examplesof control
lung explants at day 0 (A) and day 4 (B) of culture; control lung explants treated with IgG (C) and
IgG anti-IL-6 antibody (D) at day 4 of culture; nitrofen-induced hypoplastic lung explants at day 0
(E) and day 4 (F) of culture; nitrofen-induced hypoplastic lung explants treated with IgG (G) and
IgG anti-IL-6 antibody (H) at day 4 of culture. Scale bar¼6349 mm (all images at same
magnification).
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nitrofenþ anti-IL-6 group when compared to nitrofen,
nitrofenþ IgG and controlþ anti-IL-6 groups, at D4
(Table 2). The significant decrease of morphometric
parameters in nitrofenþ anti-IL-6 group when compared
with controlþ anti-IL-6 at D4 demonstrates that anti-IL-6
treatment affected more the nitrofen treated explants than
the controls (Table 2).
Figure 2 shows the evolution of total number of
peripheral airway buds in control, nitrofen, controlþ
anti-IL-6 and nitrofenþ anti-IL-6 groups, throughout
all days of culture. At D0, nitrofen and nitrofenþ anti-
IL-6 groups present a significant decrease of number
of peripheral airway buds when compared to control
and controlþ anti-IL-6 groups. However, the nitrofen
group shows the ability to recover from hypoplasia and the
number of peripheral airway buds of nitrofen group
exceeds the branching of control group, between D2 and
D3. Interestingly, at D4 no significant differences between
control and nitrofen explants could be detected. Treatment
with IL-6 blocking antibodies reduced normal growth
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. Fig. 2. Analysis of the total number of peripheral airway buds in
control, nitrofen, controlþ anti-IL-6 and nitrofenþ anti-IL-6
groups, throughout 4daysof culture. Thegraphwasconstructed
using a logit scale on Y-axis in order to clearly show the
differences at D0. P<0.05:
a versus factor A, * versus control,
§ versus nitrofen, ¥ versus controlþanti-IL-6, { interaction (factor
A� factor B).
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of control explants and the ability of nitrofen group to
recover from hypoplasia. In fact, inhibition of IL-6 action
significantly reduced branching of control explants, at
D4. Furthermore, nitrofenþ anti-IL-6 explants’ growth
started to decrease at D2 and was progressively reduced.
At D4, blocking IL-6 significantly reduced branching of
nitrofenþ anti-IL-6 lung explants when compared with
nitrofen and controlþ anti-IL-6 explants. At D3 and D4
there is a statistically significant interaction between
variables: groups� treatment.
In Figure 3 daily growth rates of control, nitrofen,
controlþ anti-IL-6 and nitrofenþ anti-IL-6 explants are
shown. D1/D0 ratio of the number of peripheral airway
buds was similar in all groups. However, D3/D2 ratio
of nitrofen explants was significantly higher than
control explants. This ability of nitrofen-induced hypo-
plastic explants to grow in culture with higher rates than
control explants explains the absence of differences
between control and nitrofen explants on the number of
peripheral airway buds, the epithelial perimeter and the
explant area, at D4 (Table 2). The representative curves of
daily growth rates of nitrofen and nitrofenþ anti-IL-6
explants have a similar shape. However, IL-6 inhibition in
nitrofen lung explants induced a decrease in later growth
rates, mainly at D4/D3 ratio. In fact, the D4/D3 ratio of
the number of peripheral airway buds was significant
lower in nitrofenþ anti-IL-6 group than in nitrofen and
controlþ anti-IL-6 groups. Moreover, in D4/D3 ratio
there was a statistically significant interaction between
variables: groups� treatment (P< 0.001).
Relatively to control groups, the representative curves
of daily growth rates of control and controlþ anti-IL-6
explants have also a similar shape. However, in contrast to
the results observed in nitrofen groups, IL-6 blocking
antibodies induced a decrease in earlier growth rates,
mainly D2/D1. Indeed, the D2/D1 ratio was significant
lower in controlþ anti-IL-6 explants than in control
explants.
IL-6 Expression Pattern During Hypoplastic
Pulmonary Development
The IL-6 mRNA and protein expression was assessed
both in qualitative (ISH and IHC) and in quantitative
(real-time PCR andWestern blot) approaches. ISH studies
revealed that primitive pulmonary epithelium expresses
IL-6 mRNA throughout all studied gestational ages in
control, nitrofen andCDH groups (Fig. 4A)mainly during
pseudoglandular stage. As depicted in Figure 4A,
CDH lungs (Fig. 4A,b00–d00) seem to express higher IL-6
mRNA levels than control lungs at any gestational age
(Fig. 4A,a–d). At 17.5 dpc, nitrofen lungs seem express
similar IL-6 mRNA to CDH lungs. However, at 19.5 and
21.5 dpc, nitrofen lungs seem express lower IL-6 mRNA
than CDH lungs and similar to control lungs. These data
were corroborated by real-time PCR studies (Fig. 4B),
which demonstrated a significant increase of IL-6 mRNA
expression in nitrofen group when compared with control
group at pseudoglandular stage (15.5 dpc), the stage for
maximal pulmonary IL-6 expression which corresponds
to fetal lung cultures timing.
IL-6 protein expression pattern during normal and
hypoplastic lung development is presented in Figure 5.
Likewise IL-6 mRNA expression, IL-6 protein is
expressed in pulmonary epithelium throughout all studied
gestational ages in control, nitrofen and CDH groups.
However, whereas in normal lung IL-6 expression
appeared to be restricted to the epithelium, in nitrofen
(at 17.5 dpc) and CDH lungs (at all gestational ages)
mesenchymal tissue also displayed scattered IL-6 positive
cells. Additionally, CDH lungs (Fig. 5A,b00–d00) seem to
express higher IL-6 protein levels than control lungs
(Fig. 5A,a–d). At 17.5 dpc, nitrofen lungs seem express
similar IL-6 protein as CDH lungs. However, at 19.5 and
21.5 dpc, nitrofen lungs seem express lower IL-6 protein
than CDH lungs and similar to control lungs. At 15.5,
nitrofen lungs presented a statistically significant increase
of score of IL-6 stained cells when compared to control
lungs. At 17.5 dpc, both nitrofen-exposed groups (nitrofen
and CDH) presented a significant increase of score of IL-6
stained cells when compared to control group (Fig. 5B).
However, as gestation progressed (19.5 and 21.5 dpc),
in the nitrofen group the score of IL-6 stained cells
decreased, whereas in the CDH group score was
maintained high. In fact, at 21.5 dpc, CDH group
presented a statistically significant increase of score of
IL-6 stained cells when compared to control and nitrofen
lungs (Fig. 5B). Moreover, this IL-6 protein over-
expression in CDH group was confirmed by Western blot
analysis (Fig. 5C).
Fig. 3. Daily growth rates of the number of peripheral airway
buds in control, nitrofen, controlþanti-IL-6 and nitrofenþ
anti-IL-6 groups. P<0.05: a versus factor A, * versus control,
§ versus nitrofen, ¥ versus controlþanti-IL-6, { interaction
(factor A� factor B).
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DISCUSSION
The current study clearly demonstrated that nitrofen-
induced hypoplastic explants have the ability to grow
in vitro at higher rates than control explants and
consequently recover from early hypoplasia. Moreover,
this work suggests that IL-6 might be involved in
the mechanisms underlying this phenomenon, since IL-6
mRNA and protein were over-expressed in fetal hypo-
plastic lungs and blocking of IL-6 activity significantly
reduced the ability of nitrofen lung explants to recover
from growth retardation.
The catch-up growth phenomenon was defined in
infants as growth acceleration beyond the normal rate
for age after a transient period of growth inhibition.7–9 In
humans, this phenomenon has been described following a
wide variety of growth-retarding illnesses, such as growth
hormone deficiency, intrauterine growth retardation,7
celiac disease,18 hypothyroidism19 and malnutrition.7
In clinical and experimental studies about CDH patho-
physiology, it was already recognized that hypoplastic
lungs have the ability to recover to normal size when
relieved from mechanical factors. In fact, hypoplastic
lungs from surviving CDH infants undergo a tremendous
Fig. 4. IL-6mRNA expression during rat lung development. A: ISH studies in control (a, 15.5 dpc;
b, 17.5 dpc; c, 19.5 dpc; d, 21.5 dpc), nitrofen (a0, 15.5 dpc; b0, 17.5 dpc; c0, 19.5 dpc; d0, 21.5 dpc)
and CDH (b00, 17.5 dpc; c00, 19.5 dpc; d00, 21.5 dpc) lungs. B: IL-6 mRNA levels in control and
nitrofen-induced hypoplastic rat lungs at 15.5 dpc, expressed in arbitrary units normalized for
b-actin.Scalebar: 15.5, 17.5, and19.5dpc¼ 250mm,21.5dpc¼100mm.P<0.001: * versuscontrol
group. [Color figure can be viewed in the online issue, which is available at www.interscience.
wiley.com.]
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growth after post-natal diaphragmatic repair. Further-
more, in nitrofen-induced CDH rat model was also
demonstrated that lung hypoplasia observed in fetuses
exposed to nitrofen (that did not develop diaphragmatic
hernia) decreased as gestational age progresses. Such
studies suggested that when mechanical factors are
removed, fetal lung shows an ability to recover from
lung growth retardation throughout gestation.5,6 This
study demonstrated that nitrofen-induced hypoplastic
explants have ability to growth recover by increasing
significantly their daily branching rates. In fact, although
nitrofen explants are significantly smaller at D0, no
significant differences between control and nitrofen
groups were observed in the number of peripheral airway
buds, the epithelial perimeter and the explant area, after
4 days in culture. Moreover, in this study daily branching
rates were calculated and it was demonstrated that D3/D2
ratio of nitrofen explants was significantly higher than
control ones. This phenomenon of lung growth recover
with acceleration beyond the normal rate, after a transient
period of growth inhibition (molecular disturbances due to
nitrofen), clearly resembles the phenomenon of height
catch-up growth well-known in infants.
An interesting point about lung ability to recover to
normal growth relates to the fact that it occurs either in
vivo or in vitro scenarios. This lung ability to growth
recover in vitro, out of systemic environment, such as
stimulation/inhibition of neuroendocrine axis, supports a
novel idea that hypoplastic lungs have local and intrinsic
mechanisms orchestrating catch-up growth phenomenon.
Interestingly, similar intrinsic mechanisms have also
been attributed to growth plate to explain the body size
catch-up growth phenomenon.20,21 In fact, the catch-up
growth was primarily attributed to a central nervous
system mechanism that compared the individual’s actual
body size with an age-appropriated set-point and then
adjusted the growth rate accordingly.22 However, this
systemic hypothesis has not been subject to a definitive
experimental test.21 More recently, it was demonstrated
that transient growth inhibition within a single growth
Fig. 5. IL-6 protein expression during lung development. A: IHC studies in control (a, 15.5 dpc; b,
17.5 dpc; c, 19.5 dpc; d, 21.5 dpc), nitrofen (a0, 15.5 dpc; b0, 17.5 dpc; c0, 19.5 dpc; d0, 21.5 dpc) and
CDH (b00, 17.5 dpc; c00, 19.5 dpc; d00, 21.5 dpc) lungs. B: Graph showing results of the scores of IL-6
stainedcells, incontrol, nitrofenandCDH lungs.C: IL-6 (21kDa)Westernblot analysis incontrol (C),
nitrofen (N)andCDH(H)groups.b-tubulin (55kDa)wasemployedas loadingcontrol.Scalebar: 15.5
and 17.5 dpc¼50 mm, 19.5 and 21.5 dpc¼100 mm. P< 0.05: * versus control, § versus nitrofen.
[Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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plate is followed by local catch-up growth, a finding not
readily explained by the systemic model.20,21 Additional
research is needed to determine whether the mechanisms
governing catch-up growth are local, systemic, or both.
Although these mechanisms remain largely unknown,
IL-6 has been involved. Recently, it was demonstrated
that small for gestational age children who showed rapid
post-natal weight gain and catch-up growth had an
associated proinflammatory state with increased IL-6
serum levels.23 Additionally, growth hormone therapy
was found to induce a proinflammatory shift, as judged
by a rise of neutrophil count and circulating IL-6.23,24
Such observations clearly suggest involvement of inflam-
matory mediators, namely IL-6, in the catch-up growth
phenomenon.
Also in liver regeneration process, in which liver is able
to undergo a compensatory hyperplasia in order to
reestablish the optimal mass set in relationship to its body
size, it was shown that IL-6 is involved. In fact, in liver
regeneration serum levels of IL-6 rise within the first few
hours after partial hepatectomy, whereas in IL-6 knockout
mice liver regeneration is significantly impaired. These
studies clearly indicate that IL-6 is of fundamental
importance for liver regeneration.25–27
Recently, it was demonstrated that IL-6 is constitutively
expressed in pulmonary primitive epithelium during lung
morphogenesis, and regulates fetal lung branching most
likely implicating p38 phosphorylation.10 Considering all
evidences that involve IL-6 in growth plate catch-up
growth, in liver regeneration and lung morphogenesis, we
hypothesized that IL-6 might also have a role on intrinsic
fetal lung catch-up growth. To test this hypothesis control
and nitrofen-induced hypoplastic lung explants were
cultured with IL-6 neutralizing antibodies. According to
previously described,10 IL-6 blocking antibodies signifi-
cantly reduced the number of peripheral airway buds and
epithelial perimeter of control explants (Table 2). This
study also demonstrated that the inhibition of IL-6 activity
induced a decrease in growth rates. Furthermore, IL-6
neutralizing antibodies clearly arrested the intrinsic
capability of hypoplastic fetal lungs to recover from
hypoplasia (Figs. 1 and 2, Table 2) and significantly
attenuated daily branching rates (Fig. 3) exhibited by
nitrofen fetal lungs. Interestingly, IL-6 blocking anti-
bodies decreased earlier growth rates of control explants,
whereas it reduced later growth rates of nitrofen-induced
hypoplastic explants. Whereas the reduction of earlier
growth rates of control lungs support the physiological
role for IL-6 on pulmonary branching mechanisms (as
previously suggested), the decrease of later growth rates
corroborate the role of IL-6 on catch-up growth. It is
also relevant that anti-IL-6 treatment influenced more
the nitrofen treated explants than the controls, and this
fact supports the role of IL-6 in the catch-up growth
phenomenon.
Since these results clearly suggest that intrinsic
catch-up growth of hypoplastic fetal lungs is mediated
by IL-6, the IL-6 mRNA and protein expression during
hypoplastic lung development was studied. In hypoplastic
lungs (nitrofen and CDH groups), IL-6 mRNA expression
was localized in the primitive lung epithelium, as it was
previously documented for normal lungmorphogenesis.10
However, whereas in normal lungs IL-6 protein expres-
sion appeared to be restricted to the epithelium, in nitrofen
(at 17.5 dpc) and CDH lungs (at all gestational ages)
mesenchymal tissue also displayed scattered IL-6 positive
cells. Moreover, nitrofen-induced hypoplastic lungs
presented higher IL-6 mRNA levels than control lungs
as confirmed by real-time PCR studies at pseudoglandular
stage, which corresponds to fetal lung cultures timing. IL-
6 protein levels were also over-expressed in fetal hypo-
plastic lungs (nitrofen group at 15.5 and 17.5 dpc; and
CDH groups during all studied gestational ages) when
compared to control lungs, as corroborated by score of
IL-6 stained cells andWestern blot analysis. Interestingly,
nitrofen and CDH groups presented IL-6 mRNA and
protein over-expression at the gestational ages, where the
lungs were hypoplastic. In fact, it was already described
that at 17.5 dpc both nitrofen-exposed groups present
similar and significant lung hypoplasia. With gestation
progression (19.5 and 21.5 dpc), lung hypoplasia decrease
in the nitrofen group, whereas in the CDH group lung
hypoplasia is exacerbated relative to control lungs.5,6
Thus, the present results demonstrate that IL-6 over-
expression accompanies the severity of lung hypoplasia.
This fact supports the role of IL-6 in the catch-up growth
phenomenon.
Although all these observations clearly suggest an
intrinsic mechanism, one cannot rule out an involvement
of systemic or local neuroendocrine loops. In fact, some
genes such as EGF28 and neuroendocrine products
(bombesin, ghrelin)29,30 are also over-expressed in CDH
lungs and might be involved in this growth recover
phenomenon. However, it remains unknown if their over-
expression is induced by local or systemic factors.
Moreover, although IL-6 is certainly an important factor
on catch-up growth mechanisms, several growth factors
might be involved and more studies are necessary to
identify those factors.
In conclusion, this study suggests for the first time
that fetal lung is able to recover from growth retardation
through a way that resembles the catch-up growth
phenomenon, which seems to be, at least partially,
orchestrated by intrinsic mechanisms implicating IL-6.
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INTRODUCTION
Congenital diaphragmatic hernia
(CDH) is a severe developmental anom-
aly, with a mean incidence of 1:2,500
live births, in which etiology remains
poorly understood (1,2). This congenital
anomaly is characterized by a diaphrag-
matic defect that allows intrathoracic
herniation of abdominal organs, and
consequently, maldevelopment of the
alveoli and pulmonary vessels. For
many years, this malformation was
thought to be a surgical emergence,
solely related to a diaphragmatic defect,
and potentially curable by surgical clo-
sure of this defect after birth, which al-
lowed lung expansion. However, during
90 years, CDH pathophysiology pro-
gressed for a physiological emergence
(3,4). It is now clear that lung hypopla-
sia and consecutive persistent pul-
monary hypertension (PH) associated
with this disorder are the key determi-
nants of mortality (1–4). Despite the im-
provements in understanding CDH
pathophysiology and advances in neo-
natal care, such as the use of extra cor-
poreal membrane oxygenation and in-
haled nitric oxide, the mortality (50%)
and morbidity rate in CDH newborns
remains exceedingly high (1–4). In hu-
mans, CDH can be accurately diagnosed
at second trimester during routine ultra-
sound examination. Therefore it is
amenable to antenatal therapies. Hence,
antenatal therapies that promote fetal
lung growth remain an appealing ap-
proach to improve survival of CDH fe-
tuses. However, fetal surgical interven-
tions, such as fetal tracheal occlusion,
are invasive, technically demanding,
limited by the maternal and fetal risks,
and their efficacy is still not determined,
with controversial results in survival
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Antenatal stimulation of lung growth is a reasonable approach to treat congenital diaphragmatic hernia (CDH), a disease
characterized by pulmonary hypoplasia and hypertension. Several evidences from the literature demonstrated a possible in-
volvement of renin-angiotensin system (RAS) during fetal lung development. Thus, the expression pattern of renin, angiotensin-con-
verting enzyme, angiotensinogen, type 1 (AT1) and type 2 (AT2) receptors of angiotensin II (ANGII) was assessed by immunohisto-
chemistry throughout gestation, whereas the function of RAS in the fetal lung was evaluated using fetal rat lung explants. These
were morphometrically analyzed and intracellular pathway alterations assessed by Western blot. In nitrofen-induced CDH model,
pregnant rats were treated with saline or PD-123319. In pups, lung growth, protein/DNA ratio, radial saccular count, epithelial dif-
ferentiation and lung maturation, vascular morphometry, right ventricular hypertrophy and overload molecular markers, gasom-
etry and survival time were evaluated. Results demonstrated that all RAS components were constitutively expressed in the lung
during gestation and that ANGII had a stimulatory effect on lung branching, mediated by AT1 receptor, through p44/42 and Akt
phosphorylation. This stimulatory effect on lung growth was mimicked by AT2-antagonist (PD-123319) treatment. In vivo antenatal
PD-123319 treatment increased lung growth, ameliorated indirect parameters of pulmonary hypertension, improved lung function
and survival time in nonventilated CDH pups, without maternal or fetal deleterious effects. Therefore, this study demonstrated a
local and physiologically active RAS during lung morphogenesis. Moreover, selective inhibition of AT2 receptor is presented as a
putative antenatal therapy for CDH.
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and morbidity rates (5,6). Therefore, less
invasive approaches such as antenatal
pharmacological treatment to stimulate
lung growth before birth and to treat
PH are also under investigation (3,7–10).
The renin–angiotensin system (RAS) is
a classical endocrine system regulating
blood pressure, electrolyte and fluid ho-
meostasis, involving several key compo-
nents, namely angiotensinogen (the
 hepatic-derived precursor), two critical
enzymes, renin (secreted from the juxta-
glomerular apparatus of the kidney) and
angiotensin-converting enzyme (ACE,
pulmonary-bound metalloproteinase),
whose sequential actions produce an-
giotensin I and the physiologically ac-
tive, angiotensin II (ANGII), respectively
(11). ANGII operates on two G protein-
coupled receptors, the ANGII type 1
(AT1) and type 2 (AT2) receptors (11).
During the last two decades, in addition
to this classic endocrine system, evidence
has demonstrated the presence of a local
RAS with autocrine/paracrine actions in
several developing organs, such as fetal
kidney, heart, vasculature and adrenal
development (12).
Regarding lung morphogenesis, there
is some evidence that lung expresses
ACE as well as AT1 and AT2 receptors
during fetal development (13–15). How-
ever, RAS components expression pat-
tern, as well as effects during lung mor-
phogenesis, is largely unknown.
In this study, we assessed the expres-
sion pattern and function of RAS during
fetal lung development. Moreover, we
assessed the role of RAS as a putative
target for treatment of fetal lung hy-
poplasia in CDH.
MATERIALS AND METHODS
Animal experiments were performed
according to the Portuguese law for ani-
mal welfare (16; Diário da República, Por-
taria 1005/92). Animals were housed in
an accredited mouse house and treated
as specified by the recommendations of
the Helsinki convention (17) and the
Guide for the Care and Use of Laboratory
Animals, published by the National
Academy Press (18).
Experimental Design and Animal
Model
In vitro studies were carried out to as-
sess expression and function of RAS in
fetal lung, whereas in vivo studies were
performed to explore RAS as a target to
treat fetal lung hypoplasia using the
 nitrofen-induced CDH rat model (19).
Sprague Dawley female rats (225 g;
Charles River; Barcelona, Spain) were
maintained in appropriate cages under
controlled conditions and fed with com-
mercial solid food. The rats were mated
and checked daily for vaginal plug. The
day of plugging was defined as gesta-
tional d 0.5 for time-dating purposes. 
According to the nitrofen-induced CDH
rat model (19), at 9.5 d postconception
(dpc), randomly selected pregnant rats
were exposed to 100 mg nitrofen (2,4-
dichlorophenyl-p-nitrophenylether). At
different time points, fetuses were har-
vested by cesarean section. After fetal de-
capitation, a toraco-laparotomy was per-
formed under a binocular surgical
microscope (Leica, Wild M651.MSD,
Heerbrugg, Switzerland) to inspect the
diaphragm and harvest the organs. Fe-
tuses were assigned to three experimen-
tal groups: (i) Control group (C), fetuses
not exposed to nitrofen; (ii) Nitrofen
group (N), fetuses exposed to nitrofen
without CDH; (iii) CDH group, fetuses
exposed to nitrofen with CDH.
In Vitro Studies
Normal fetuses removed by cesarean
section at 13.5, 15.5, 17.5, 19.5 and 21.5
dpc were killed by decapitation, and
lungs dissected and processed for im-
munohistochemistry (IHC). Lungs of fe-
tuses with 13.5 dpc were also dissected
to perform fetal lung explants cultures
and posterior western blot analysis.
IHC
IHC was performed on formalin-fixed
and paraffin-embedded lungs, as previ-
ously described by Nogueira-Silva et al.
(7). Renin antibody (sc-27320; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) was
used in a 1:25 dilution, ACE antibody (sc-
20791; Santa Cruz Biotechnology Inc.) in a
1:75 dilution, angiotensinogen antibody
(Abbiotec LLC, San Diego, CA, USA) in a
1:100 dilution, AT1 receptor antibody (sc-
1173; Santa Cruz Biotechnology Inc.) in a
1:50 dilution and AT2 receptor antibody
(sc-9040; Santa Cruz Biotechnology Inc.)
in a 1:25 dilution. Incubation with the
 UltraVision detection system anti-
 polyvalent horseradish peroxidase (Lab
Vision Corporation, Fremont, CA, USA)
or with the goat ImmunoCruz™ Staining
System (Santa Cruz Biotechnology Inc.)
was carried out according to the manufac-
turer’s instructions.
Fetal Lung Explant Cultures
Recombinant ANGII (Sigma, St Louis,
MO, USA), AT1-antagonist (ZD-7155;
Tocris Cookson, Bristol, UK) and AT2-
 antagonist (PD-123319; kindly supplied
by Pfizer, Groton, CT, USA) were added
daily to lung explants to achieve increas-
ing concentrations of ANGII (from 10–9 to
10–4 mol/L) or ZD-7155 or PD-123319 at
10–5 mol/L. These doses were selected ac-
cording to the literature (20,21). This set of
experiments created the following groups:
control (n = 30), ANGII 10–9 (n = 10),
ANGII 10–8 (n = 11), ANGII 10–7 (n = 11),
ANGII 10–6 (n = 12), ANGII 10–5 (n = 12),
ANGII 10-4 (n = 12), ZD-7155 (n = 12), and
PD-123319 (n = 15). Furthermore, explants
were treated with ANGII at 10–9 mol/L in
the presence of ZD-7155 or PD-123319 at
10–5 mol/L, creating the additional
groups: ANG 10–9 + ZD-7155 (n = 12) and
ANG 10–9 + PD-123319 (n = 15). Cultures
were photographed daily and branching
morphogenesis was assessed according to
Nogueira-Silva et al. (22).
Western Blot Analysis
After 4 d in culture, lung explants
treated with ANGII at 10–9 mol/L, ZD-
7155 or PD-123319 were processed for
western blot analysis of nonphospory-
lated and phosporylated forms of mitogen-
activated protein kinases (MAPKs)
[p44/42, p38, JNK (mAbs; Cell Signaling
Technology, Danvers, MA, USA)] and
phosphatidylinositol-3-kinase (PI3K/Akt)
(Cell Signaling Technology) according to
Nogueira-Silva et al. (22). For loading
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control, blots were probed with β-tubulin
mAb (Abcam plc, Cambridge, UK) (n = 3).
Quantitative analysis was performed
with Quantity One 4.6.5 1-D Analysis
Software (Bio-Rad Laboratories, Her-
cules, CA, USA).
In Vivo Studies
Pregnant rats, control or exposed to ni-
trofen, were anesthetized at 12.5 dpc
with a mix of ketamine (75 mg/kg) and
medetomidine (0.5 mg/kg) for subcuta-
neous implantation of an osmotic micro-
pump filled either with saline or PD-
123319 (randomly), on mid scapular
region (Alzet osmotic pump Model
2ML1; Durect Corporation, Cupertino,
CA, USA). Saline or PD-123319 solution
was infused with a rate of 10 μL/h
(20 mg/kg/d for PD-123319). For the re-
versal of the sedative effect, atipamezole
(0.25 mg/kg) was used and butorfanole
(1 mg/kg) was administered immedi-
ately after the surgery. Fetuses were as-
signed to six experimental groups: Con-
trol rats treated with saline (C + S);
Control rats treated with PD-123319 (C +
PD); Nitrofen rats treated with saline 
(N + S); Nitrofen rats treated with PD-
123319 (N + PD); CDH rats treated with
saline (CDH + S); and CDH rats treated
with PD-123319 (CDH + PD).
Pregnant rats were randomly assigned
for cesarean section at 21.5 dpc or for
spontaneous delivery at term.
The pregnant rats killed at 21.5 dpc
were laparotomized, and after longitudi-
nal hysterotomy, each fetus (C + S, n =
14; C + PD, n = 15; N + S, n = 15; N + PD,
n = 12; CDH + S, n = 15; CDH + PD, n =
24) was extracted, weighed and decapi-
tated for organ harvesting (lungs, heart
and kidneys). Organs were also weighed
independently, organs-to-body weight
ratios were assessed and lungs were ei-
ther snap frozen in liquid nitrogen for
biochemical analyses or fixed in 4%
paraformaldehyde (PAF) for histological
analyses. In this set of experiments, the
level of lung hypoplasia was calculated
according to Baptista et al. (9).
The pups that were delivered sponta-
neously at term were placed immediately
after birth in a light-heated box and ran-
domly killed 5 min after birth or allowed
to survive, without any care, support
strategies or ventilatory support. Those
killed by decapitation at min 5 (C + S, n =
15; C + PD, n = 9; N + S, n = 11; N + PD,
n = 6; CDH + S, n = 12; CDH + PD, n =
14) were used for blood collection (neck
bleeding) and gasometric evaluation (i-
Stat1 analyser; Abbott, Chicago, IL, USA).
These were then dissected for identifica-
tion of CDH. Moreover, hearts were dis-
sected for right ventricular hypertrophy
evaluation and myocardial samples of
right ventricular free wall were harvested
and processed for q-PCR studies. The re-
maining fetuses were allowed to survive
(C + S, n = 10; C + PD, n = 9; N + S, n =
14; N + PD, n = 21; CDH + S, n = 14;
CDH + PD, n = 28), evaluated by two in-
dependent–blind observers (MJ Baptista
and S Nunes) and scored at 1, 3, 5 and
subsequently at each 5 min, using an
APGAR-like score (Table 1, adapted from
Dauger et al. [23]). The moment of death
was registered and defined by the mo-
ment in which the two observers attrib-
uted an APGAR 0 (marked cyanosis,
apnea, no spontaneous movements, no
response to stimulus). All experiments
were recorded in video to clarify any
doubt. These pups were opened post-
mortem for diaphragm inspection.
Lungs, heart and kidneys from all
pregnant rats were weighed for maternal
organ-to-body weight ratio analysis.
Biochemical Studies for Protein/DNA
Ratio Assessment
Total lungs (left and right) were
processed to determine protein and DNA
contents. Protein content was assessed
by Bradford method (24). DNA was ex-
tracted using the DNeasy Blood & Tissue
Kit (Qiagen, Hilden, Germany).
Histological Studies
The trachea was cannulated and the
lungs were fixed with PAF under a con-
stant pressure of 20 cmH2O. Lungs were
embedded in paraffin and 4-μm sections
were used to determine radial saccular
count [RSC; using hematoxilin-eosin
stain (H&E)], epithelial differentiation
[IHC for clara cell secretory protein
(CCSP) and prosurfactant protein C 
(SP-C) and determination of glycogen-
content using periodic acid-Schiff stain
(PAS)] and medial arterial thickness
(using Weigert stain).
RSC was estimated according to
Emery and Mithal adapted method (25),
at 100× magnification (Olympus BX61
microscope; Olympus, Tokyo, Japan), in
5 animals per group, 6 slides per animal
(200 μm apart each other), and 10 seg-
ments per slide, by a blinded examiner
(E Carvalho-Dias).
Regarding epithelial differentiation,
IHC was performed as previously de-
scribed by Nogueira-Silva et al. (7),
briefly described above. CCSP antibody
[07-623; Upstate (Millipore), Billerica,
MA, USA] was used in a 1:800 dilution
and SP-C antibody (AB3428; Chemicon
International, Temecula, CA, USA) in a
1:400 dilution. These slides and PAS
stained slides were observed and pho-
tographed (Olympus BX61 microscope).
The percentage of CCSP, SP-C and PAS
stained cells per microscopic field was
scored in a single-blinded fashion (100×
and 400× magnification, respectively) in
6 independent peripheral and 4 central
Table 1. APGAR-like score.a
Sign Score 0 Score 1 Score 2
Skin color Marked cyanosis Mild cyanosis/ pale Pink
Breathing Apnea Irregular or weak breathing Regular breathing
Spontaneous motor No movements Weak movements Vigorous movements
activity
Reactivity to stimulus No response Gasping movements Active movements
aThis score is obtained by assigning a value (0, 1 or 2) to 4 characteristics: skin color, breathing,
spontaneous motor activity and reactivity to stimulus. The scores vary between 0 and 8.
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areas per section (6 slides per animal,
200 μm apart each other, and 5 animals
per each experimental group). Scoring
was as follows: 1, 0–20% cells/field; 2,
20–40% cells/field; 3, 40–60% cells/field;
4, 60–80% cells/field; 5, 80–100%.
Weigert resorcin fuchsin solution
stains elastic fibbers, and it was used for
morphometric assessment of pulmonary
arteries (26). Pulmonary arteries were
distinguished from pulmonary veins on
the basis of the structure and position.
Arteries that were approximately round
[that is, the longest external diameter
(ED, distance between the external elastic
laminae), did not exceed the minimal ED
by more than 50%] and had both clearly
visible external and internal elastic lami-
nae were analyzed. As the structural
changes and pharmacological effects on
pulmonary arteries might be vessel size
dependent, we selected for further analy-
sis arteries subcategorized into 3 sizes:
ED less than 30 μm, ED 30 μm to 50 μm,
and ED greater than 50 μm. Then, using
AxionVision Rel. 4.3 (Carl Zeiss, Göttin-
gen, Germany), internal area (IA, defined
by internal elastic lamina), external area
(EA, defined by external elastic lamina)
and total area (TA, defined by edge of
the vascular sheath) were measured. The
percentage of medial (MA) and adventi-
tial arterial area (AA) were calculated ac-
cording to the following formulas: MA
(%) = [(EA – IA)/EA] × 100; AA (%) =
[(TA – EA)/EA] × 100. At least 10 arteries
for each section were evaluated, 6 sec-
tions per animal (200 μm apart each
other), and 3 animals per each experi-
mental group (at 400× magnification).
Right Ventricular Hypertrophy
Evaluation
Hearts (C + S, n = 8; CDH + S, n = 6;
CDH + PD, n = 8) were used for right
ventricle (RV) and left ventricle (LV) dis-
section (LV contains septum). RV and LV
were weighed separately. The ratio
RV/LV was determined and used as an
index of right ventricular hypertrophy.
Other hearts (C + S, n = 7; CDH + S, 
n = 6; CDH + PD, n = 6) were dissected,
transversally cut and orientated accord-
ing to short-axis view of the heart, before
fixed in PAF and embedded in paraffin.
Four micrometer sections were stained
with H&E and photographed at 40×
magnification (Olympus BX61 micro-
scope). The right ventricular wall thick-
ness was determined in the short-axis
view of the heart, in the maximum dis-
tance between the right side of the inter-
ventricular septum to the right ventricu-
lar free wall, using AxionVision Rel. 4.3
(Carl Zeiss) (5 measurements per animal,
20 μm apart each other).
q-PCR Studies
Right ventricular mRNA expression of
angiotensinogen, B-type natriuretic pep-
tide (BNP) and endothelin-1 (ET-1),
genes previously defined as ventricular
overload markers, was evaluated accord-
ing to Baptista et al. (27).
Statistical Analysis
Data are presented as mean ± SEM.
Statistical analysis was performed using
the statistical software SigmaStat (ver-
sion 3.5; Systat Software Inc., Chicago,
IL, USA). Multiple group comparisons
were made by analysis of variance. For
morphometric explants studies, Western
blot analysis, biochemical studies, histo-
logical studies, right ventricular hyper-
trophy evaluation and q-PCR studies,
one-way ANOVA on ranks was used.
Two-way ANOVA on ranks was used for
organ-to-body weight ratio analysis and
gasometric studies. Student-Newman-
Keuls test was used for posttest analysis.
Statistical significance was confirmed at
P < 0.05.
All supplementary materials are available
online at www.molmed.org.
RESULTS
RAS Components Expression Pattern
during Fetal Lung Development
The IHC studies revealed that all RAS
components, renin, ACE, angiotensino-
gen, AT1 and AT2 receptors, were ex-
pressed throughout all studied gesta-
tional ages in the fetal lung (Figure 1).
Renin was expressed in bronchiolar and
also in alveolar epithelium throughout
gestation (Figure 1A) since 13.5 dpc 
and appears to be maximal in the most
immature buds (see Supplemental Fig-
ures 1A-D). Endothelial ACE expression
started in larger proximal vessels, early
in the gestation, and spreads distally to
involve progressively smaller vessels
(Figure 1B). Interestingly, ACE protein
was also detectable in epithelial cells since
13.5 dpc (see Supplemental Figure 1E).
Regarding angiotensinogen, protein ex-
pression was clearly observed in epithe-
lial cells since 15.5 dpc (Figure 1C). Mes-
enchymal tissue also displayed scattered
angiotensinogen positive cells, first in
endothelial cells and in the later gesta-
tional ages (19.5 and 21.5 dpc) clearly in
vascular smooth muscle cells (Figure 1C).
AT1 receptor protein was first mainly ex-
pressed by undifferentiated mes-
enchyme at 15.5 dpc and, throughout
the gestation, it was predominantly ex-
pressed by vascular smooth muscle cells
and scattered in the mesenchyme (Fig-
ure 1D). AT2 receptor was expressed in
bronchial epithelial cells and since 19.5
dpc muscle cells of large blood vessels
also expressed it (Figure 1E). Moreover,
the epithelial AT2 expression was also
demonstrated at 13.5 dpc (see Supple-
mental Figure 1F).
Role of ANGII in Fetal Lung
Development
The presence of renin, ACE, angio -
tensinogen and AT1 and AT2 protein 
on lung during fetal development
prompted us to evaluate the role of
ANGII, the physiologically active pep-
tide of RAS, on lung morphogenesis. For
this purpose, fetal lung explants were
treated with increasing concentrations of
recombinant ANGII (Figure 2A). ANGII
significantly increased the number of pe-
ripheral airway buds, mainly with con-
centration of 10–9 mol/L, the minimal
concentration studied (Figure 2). On the
other hand, treatment of lung explants
with an AT1- antagonist (ZD-7155) signif-
icantly inhibited, whereas AT2-antago-
nist (PD-123319) treatment significantly
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enhanced lung branching in a similar
way to the dose of ANGII-inducing
maximal effect (Figure 2C). Moreover,
the stimulatory effect on lung branching
induced by ANGII 10–9 mol/L was com-
pletely abolished by AT1-antagonist
treatment, and the simultaneous lung
treatment with ANG 10–9 mol/L and PD-
123319 did not accomplish additional
stimulatory effect on explants growth
when compared with ANG 10–9 mol/L
treatment (Figure 2C). Thus, these re-
sults demonstrated that ANGII had a
stimulatory effect on lung branching,
mediated by AT1 receptor. Interestingly,
this stimulatory effect was mimicked by
treatment with AT2-antagonist alone.
To clarify the intracellular signaling
pathways that mediate ANGII actions on
lung growth, lung explants treated with
ANGII at 10–9 mol/L (selected due to its
maximal effect in explant growth), 
ZD-7155 or PD-123319 were evaluated
for MAPK and Akt pathways activation
(Figure 3A). AT1 receptor blockage in-
duced a significant decrease of p-38 and
JNK phosphorylation when compared
with control explants (Figures 3B, D, re-
spectively). On the other hand, the in-
crease on lung branching, induced by
ANGII at 10–9 mol/L and AT2 receptor
antagonist, significantly stimulated
p44/42 and Akt phosphorylation (Fig-
ures 3C, E, respectively).
In Vivo Antenatal PD-123319
Treatment Improves Fetal Lung Growth
Left, right and total lung-to-body
weight ratio (LW/BW) were analyzed
for different experimental groups. Ac-
cording to the nitrofen-induced CDH
experimental model, pups of nitrofen-
treated dams presented left and right
lung hypoplasia, which was maximal in
CDH + S group. Maternal PD-123319
treatment induced significant growth of
both left and right lungs in control,
 nitrofen and CDH groups. In fact,
LW/BW was significantly higher in the
control, nitrofen and also CDH rats
treated with PD-123319 when compared
with the respective saline-treated
groups (Figure 4A). Indeed, PD-123319
treatment stimulated partial recovery of
lung hypoplasia in CDH neonates, in-
ducing an increase of 11.4% in total lung
weight (Figure 4B). Considering these
results and to assess the potential of PD-
123319 as a useful treatment for severe
lung hypoplasia associated with CDH,
we pursued our study focused in com-
paring C + S, CDH + S and CDH + PD
groups.
Biochemical analysis of lung protein
and DNA content demonstrated that
there was no significant difference in
the protein/DNA ratio between C + S,
CDH + S and CDH + PD groups (C + S
0.024 ± 0.005; CDH + S 0.030 ± 0.004;
CDH + PD 0.026 ± 0.002).
The histological analysis of lung archi-
tecture showed that CDH + S lungs ap-
peared to have a thickened septal and
saccular walls and an increased amount
of interstitial tissue when compared with
C + S. However, CDH + PD had a signif-
icantly greater development of saccules
Figure 1. Protein expression pattern of RAS components during fetal lung development
(from 15.5 until 21.5 dpc). (A) Renin was predominantly expressed in epithelium. (B) ACE
expression. (C) Angiotensinogen expression in epithelial, endothelial (arrow) and vascular
smooth muscle cells (arrowhead). (D) AT1 receptor immunostaining. (E) AT2 receptor im-
munostaining. Original magnification 200×.
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and airspaces when compared with
CDH + S lungs (Figure 5A). In fact, RSC
of CDH + S pups was significantly lower
when compared with C + S group (Fig-
ure 5B). However, PD-123319 treatment
induced a significant increase on RSC of
CDH pups, that is, promoted distal lung
development (Figure 5B).
Regarding epithelial differentiation
and lung maturity, CCSP (proximal ep-
ithelial cell differentiation marker), SP-C
(distal epithelial cell differentiation
marker) and PAS+ glycogen stores (an in-
direct signal of immaturity) were evalu-
ated (Figure 6). No significant differences
in score of CCSP (Figure 6A), SP-C (Fig-
ure 6B) and PAS-stained cells (Figure 6C)
between C + S and CDH groups were
observed.
Concerning other organs than lungs,
nitrofen treatment (nitrofen and CDH
groups) induced decrease of heart-to-
body weight (HW/BW) and kidney-to-
body weight (KW/BW) ratios. However,
antenatal PD-123319 treatment did not
significantly change either HW/BW or
KW/BW (see Supplemental Figure 2).
Antenatal PD-123319 Treatment
Partially Reversed Arterial Structural
Abnormality and Decreased
Molecular Markers of PH on CDH
Model
MA percentage was significantly in-
creased in all arteries (independently of
its size) in CDH + S group when com-
pared with C + S and CDH + PD groups
(Figure 7). CDH + PD neonates pre-
sented a significant decrease in MA per-
centage when compared with CDH + S
for all arterial sizes, with maximal effect
on smaller arteries. The effect was so evi-
dent that CDH + PD arteries had no sig-
nificant difference in MA percentage
when compared with C + S group (Fig-
ure 7B). Regarding adventitial layer,
saline or PD-treated CDH groups pre-
sented a significant increase in AA per-
centage when compared with C + S for
all arterial sizes (Figure 7C). Thus, PD-
123319 treatment induced decrease of
MA percentage and did not induce any
change on AA percentage.
Regarding right ventricular hypertro-
phy index and right ventricle thickness,
markers of right ventricular hypertrophy
secondary to chronic PH, CDH neonates
did not present differences when com-
pared with control group. Moreover, PD-
123319 treatment did not change these
parameters (Table 2).
Additionally, expression levels of right
ventricular molecular markers of PH (an-
giotensinogen, BNP and ET-1) were as-
sessed in pups allowed to be delivered at
5 min after birth. In Figure 7D, mRNA
levels of these markers normalized to
β-actin are shown. CDH + S group pre-
sented a significant increase of angio -
tensinogen and an increase (although not
statistical significant) of BNP and ET-1
compared with C + S group. On its turn,
PD-123319 treatment significantly de-
creased these overload markers on CDH
pups.
Antenatal PD-123319 Treatment
Improves Lung Function and Survival
The adaptation of fetuses to extrauter-
ine life was monitored within the first
5 min after delivery by determining an
APGAR-like score (0-8). CDH + S
neonates presented an APGAR score of
2.35 ± 0.17, 1.82 ± 0.12 and 2.28 ± 0.18, at
1, 3 and 5 min after birth, respectively.
On the other hand, antenatal PD-123319
treatment improved APGAR score to
3.23 ± 0.26, 2.97 ± 0.09 and 2.71 ± 0.13, 
at 1, 3 and 5 min after birth (P < 0.05), 
respectively.
Five minutes after birth, a moment in
which all neonates were alive, neonates
of C + S, N + S, CDH + S, N + PD and
CDH + PD groups were used for blood
collection (collected after decapitation)
and gasometric evaluation. When com-
pared with control pups, neonates of
 nitrofen-treated dams (N + S and 
CDH + S) presented significant acidosis,
decrease of PO2 and SatO2, and increase
of PCO2 and lactate, which was maximal
in CDH + S neonates (pups with maxi-
mal degree of lung hypoplasia) (Table 3).
On its turn, antenatal PD-123319 treat-
ment allowed a statistical significant in-
crease of pH, PO2 and SatO2, and de-
crease of PCO2 and lactate concentration.
Indeed, there was no difference in gaso-
Figure 2. Branching morphogenesis in a rat lung explant system. (A) Representative exam-
ples of control and fetal lung explants treated with ANGII at 10–9 mol/L, ZD-7155 (an AT1-
 antagonist) or PD-123319 (an AT2-antagonist). Original magnification 25×. (B) Number of
total airway buds of lung explants treated with increasing ANGII concentrations or (C) with
ZD-7155 (ZD), PD-123319 (PD), ANG 10–9 + ZD or ANG 10–9 + PD. Results are expressed as
ratio of d 4 (D4) and d 0 (D0) of culture (D4/D0 ratio). P < 0.05: *versus ANGII at 0 mol/L (con-
trol, C), §versus ANGII at 10–9 mol/L, †versus ZD-7155 at 10–5 mol/L, ‡versus ANG 10–9 + ZD.
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metric parameters between control, nitro-
fen, and CDH groups treated with PD-
123319 (Table 3).
Concerning neonatal survival, the aver-
age survival time was significantly longer
in PD-123319-treated pups than in CDH +
S pups (30.3 ± 3.2 min for CDH + S versus
42.4 ± 1.3 min for CDH + PD, P < 0.001).
As a result, all CDH + PD pups, but only
57% of the CDH + S pups, survived for
up to 30 min. At 45 min after birth, only
7% of CDH + S pups were alive, as op-
posed to over a third of CDH + PD pups.
In fact, PD-123319 treatment increased
survival rates of CDH neonates for all
time points evaluated (Figure 8).
Figure 3. MAPK and Akt kinase activities in control (C) lung explants and treated with
ANGII at 10–9 mol/L (Ang 10–9), ZD-7155 (ZD) or PD-123319 (PD). (A) Western blot analy-
sis of p38, p44/42, JNK1/2 and Akt and to diphosphorylated forms of p38 (dp-p38),
p44/42 (dp-p44/42), SAPK/JNK (dp-JNK1/2) and Akt (dp-Akt). Control loading was per-
formed using β-tubulin (55 kDa). p38 corresponds to 38 kDa. p44/42 correspond to 44
and 42 kDa, respectively. JNK1 and 2 correspond to 46 and 54 kDa, respectively. Akt
corresponds to 56 kDa. Semiquantitative analysis for dp-p38 (B), dp-p44/42 (C), 
dp-JNK1/2 (D), and dp-Akt (E). Results are presented as arbitrary units normalized for 
β-tubulin. P < 0.05: *versus ANGII at 0 mol/L (control, C), §versus ANGII at 10–9 mol/L,
†versus ZD-7155 at 10–5 mol/L.
Figure 4. In vivo antenatal PD-123319
treatment effects on lung growth. (A) Ratio
of left, right and total lung-to-body weight
in control (C), nitrofen (N) and CDH groups
treated with saline (C + S, N + S, CDH + S)
or PD-123319 (C + PD, N + PD, CDH + PD).
Antenatal administration of PD-123319 en-
hanced lung growth in all studied groups.
(B) Effect of PD-123319 treatment on left,
right and total lung hypoplasia. Prenatal
administration of PD-123319 ameliorated
both left and right lung hypoplasia. Results
are expressed as %. P < 0.001: *versus C + S,
†versus N + S, ‡versus CDH + S, llversus C +
PD, §versus N + PD. For left lung, there is a
statistically significant interaction between
variables: disease–treatment (P = 0.009).
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Regarding potential secondary effects
of PD-123319 on maternal organs, their
lungs, heart and kidneys were weighed.
PD-123319 treatment did not signifi-
cantly change maternal HW/BW,
KW/BW or LW/BW ratios (see Supple-
mental Figure 3).
DISCUSSION
This study demonstrated that all com-
ponents of RAS (renin, ACE, angio -
tensinogen, AT1 and AT2 receptors) were
constitutively expressed in the lung dur-
ing all studied gestational ages and that
ANGII had a stimulatory effect on lung
branching, mediated by AT1 receptor,
through p44/42 and Akt phosphoryla-
tion. This stimulatory effect on lung
growth was mimicked by treatment with
AT2-antagonist. Therefore, AT2 receptor
antagonist was evaluated as a putative
antenatal treatment for diseases charac-
terized by fetal lung hypoplasia such as
CDH. In an animal model of CDH, ante-
natal PD-123319 treatment increased neo-
natal lung growth, ameliorated indirect
parameters of PH, improved lung func-
tion and survival, without maternal or
fetal deleterious effects.
In past years, it has been demonstrated
that local ANGII formation and its
 tissue-specific effects on growth and dif-
ferentiation are thought to be extremely
important for embryonic and fetal devel-
opment (12). Regarding fetal lung, this
study corroborated previous evidences
concerning ACE, AT1 and AT2 expression
(13–15,28). For the first time, the present
study showed that renin and angio -
tensinogen are also expressed during
lung development. Interestingly, renin,
ACE and AT2 were expressed at very
early stages (since 13.5 dpc), suggesting
an important role for a local RAS since
early stages of lung development.
The results of RAS components expres-
sion prompted us to hypothesize that a
local RAS is active in the developing
lung. Therefore, the role of ANGII on
lung morphogenesis was evaluated.
ANGII supplementation induced an in-
crease in lung explants growth, and it is
necessary to stress that this enhancing ef-
fect of ANGII on number of peripheral
airways buds of lung reached about 37%,
whereas the stimulatory effect induced
by fibroblast growth factor-10 (FGF-10), a
classical and very important lung growth
factor, in a similar model of murine lung
explants, was around 20% (29). The pos-
sible mechanism by which RAS inter-
feres with the airway branching or pul-
monary vascular development is still
unclear, and further investigation is re-
quired. However, it was already substan-
tially demonstrated that reciprocal inter-
actions between airways and blood
vessels are critical for normal lung devel-
opment. For instance, it was demon-
strated that ablation of lung epithelium
impair lung vascular cells development
(30). Moreover, VEGF inhibition in neo-
natal rats leads to arrested alveolar de-
velopment, suggesting that inhibition of
vascular growth itself may directly im-
pair lung development (31–33). Thus,
given that, in the present study, it was
demonstrated that some components of
RAS are expressed on epithelium and
others on mesenchyme/vascular cells, it
is possible that RAS is involved in both
processes: airway and vasculature
branching.
Interestingly, AT1 receptor inhibitor de-
creased, whereas AT2-antagonist signifi-
cantly increased lung growth in explants.
This opposite effect of AT1 and AT2 re-
ceptors, namely a stimulatory effect of
AT1 and inhibitory effect of AT2, is also
described on other tissues (34–39).
Many of the effectors that modulate
fetal lung branching seem to activate
MAPK and/or PI3K/Akt cascades (40).
Thus, MAPK and PI3K/Akt pathway ac-
tivation by ANGII and AT1 and AT2 an-
tagonists in fetal lung development was
investigated. ANGII and AT2 receptor an-
tagonist treatment induced an increase in
lung branching by the stimulation of
p44/42 and Akt phosphorylation. These
intracellular mediators are also involved
in AT1 effects on proliferation and sur-
vival of cells in other tissues (34,36). Re-
garding lung growth inhibition induced
by AT1 antagonist, it was mediated by a
decrease of p-38 and JNK phosphoryla-
tion. These MAPK families were already
Figure 5. Antenatal PD-123319 treatment increased RSC. (A) Representative H&E stained
sections of C + S, CDH + S and CDH + PD lungs, used to RSC analyzes. Note greater sac-
cular development and increase of lung aeration in CDH + PD compared with CDH + S.
Original magnification 100×. (B) Mean radial saccular count in C + S, CDH + S and CDH +
PD groups. PD-123319 treatment induced increase of RSC in CDH pups. P < 0.001: *versus
C + S, ‡versus CDH + S.
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demonstrated to be involved on induc-
tion of lung branching (22).
The in vitro studies demonstrated that
a local RAS is functional at early stages
of lung morphogenesis. Moreover, the
significant stimulatory effect on lung
growth mediated by AT2 receptor antag-
onist led us to hypothesize that AT2
could be a new target for treatment of
diseases characterized by fetal lung hy-
poplasia, such as CDH. In fact, AT2 re-
ceptor is described to be expressed virtu-
ally only during fetal life (11,12,41),
which would annul potential maternal
adverse effects. Thus, treatment with AT2
antagonist (PD-123319) was selected for
the in vivo study, in which the nitrofen-
induced CDH rat model (19,42) was
used. The gestational age selected for
maternal PD-123319 administration was
based on the effect observed on lung ex-
plants that were harvested at 13.5 dpc.
The nitrofen-induced CDH model is an
experimental model of severe lung hy-
poplasia, which reasonably replicates the
major abnormalities and the pathophysi-
ology described in human CDH (42–44).
Although the mechanism by which nitro-
fen induces the diaphragmatic defect and
lung hypoplasia is not fully understood,
recent evidences suggest the involve-
ment of abnormalities linked with the
retinoid signaling pathway in this model
and also in human CDH etiology
(42–45). Indeed, one clinical study
demonstrated the presence of decreased
levels of retinol and retinol-binding pro-
tein in human CDH, suggesting a possi-
ble deterioration of retinol transport
across the placenta (46). Regarding the
nitrofen-induced CDH model, it was al-
ready demonstrated that nitrofen inhibits
retinal dehydrogenase 2 (RALDH2), a
key enzyme responsible for the conver-
sion of retinal to retinoic acid (47). More-
over, the co-administration of retinoids
(Vitamin A or retinoic acid) in nitrofen-
induced CDH induces lung growth and
reduces the incidence of CDH (9,10,48).
Interestingly, some studies have de-
scribed an inhibitory interaction between
retinoid acid pathway and RAS, namely
in adult cardiac remodeling (49,50).
Thus, a possible interaction between
retinoid acid pathway and RAS might 
be present during lung morphogenesis,
but the underlying mechanisms remain
unclear and further investigation is 
required.
Maternal PD-123319 subcutaneous ad-
ministration significantly increased lung
growth in control, nitrofen and CDH
groups. In fact, in CDH neonates, despite
the presence of mechanical forces that
compress lungs, PD-123319 induced par-
tial recovery of lung hypoplasia as as-
sessed by LW/BW (an increase of 11.4%).
In face of these results and to assess if
the treated-lung is structural and func-
tionally ameliorated, we focused further
studies in comparing C + S, CDH + S
and CDH + PD groups. In human and
experimental CDH there is a reduction in
peripheral lung development (1,10). PD-
123319 treatment stimulated lung growth
by promoting distal lung development as
measured by the enhanced RSC. The po-
tential clinical relevance of this effect
should be emphasized, since such an in-
crease in lung parenchyma can be deter-
minant in providing a better adaptation
of CDH fetus to extrauterine life.
Regarding epithelial differentiation
and lung maturity, CCSP (a Clara cells
marker, marker for proximal lung), SP-C
(a type II pneumocytes marker, marker
for distal lung) and PAS glycogen stores
(a signal of immaturity) were assessed.
No differences between groups were de-
tected in CCSP, SP-C and PAS-stained
cells score. Contradictory results about
lung maturity and surfactant status in
CDH animal models have been pub-
lished, with studies demonstrating that
the CDH lung is surfactant deficient
(51–53) and others indicating no change
in alveolar surfactant composition, un-
Figure 6. Antenatal PD-123319 treatment did not interfere with epithelial differentiation
and lung maturation. (A) Representative CCSP-stained sections of C + S, CDH + S and
CDH + PD lungs. Original magnification 100×. (B) Score of CCSP-stained cells in C + S,
CDH + S and CDH + PD groups. (C) Representative SP-C stained sections in different
groups. Original magnification 200×. (D) Score of SP-C-stained cells. (E) Representative PAS
stained sections of C + S, CDH + S and CDH + PD lungs. Original magnification 400×. Ar-
rows: PAS+ (glycogen-rich) cells. (F) Score of PAS-stained cells. No significant difference be-
tween experimental groups was observed in CCSP, SP-C and PAS.
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changed or even increased surfactant
protein expression (54–57). However,
one of the most recent studies per-
formed with human CDH fetuses
demonstrated that surfactant maturation
is not delayed (54). The present study
corroborates the idea that CDH does not
appear to interfere or delay epithelial
differentiation and surfactant accumula-
tion (54). Moreover, PD-123319 treat-
ment did not impair fetal lung matura-
tion in CDH neonates.
Persistent PH accounts for significant
mortality and morbidity in CDH
(1,2,58). In severe human CDH and also
in nitrofen-induced model of CDH, it
was already demonstrated that PH re-
sults from decreased number of arteries,
increased thickness of media and ad-
ventitia of pulmonary arterial walls and
distal muscular extension to the non-
muscular intraacinar arteries (58,59). In
this study, the effect of PD-123319 treat-
ment on PH was indirectly assessed by
morphometric pulmonary vascular anal-
ysis (59) and its cardiac repercussion by
determination of right ventricular hy-
pertrophy index and right ventricle
thickness, and quantification of right
ventricular overload molecular markers
(Angiotensinogen, BNP and ET-1) (27).
To better analyze the vessel morphol-
ogy, areas were measured instead of
thickness since this approach avoids the
bias introduced by irregular shape of
elastic laminae. Thus, PD-123319 treat-
ment induced decrease of MA percent-
age for all arterial sizes, with maximal
effect on smaller arteries. Moreover,
CDH + S neonates did not present dif-
ferences in right ventricular hypertro-
phy index and right ventricular wall
thickness (morphological markers)
when compared with C + S group, but
they presented an increase of molecular
markers of right ventricular overload.
Thus, 5 min after birth, CDH + S
neonates only presented molecular
changes secondary to PH, but not yet
morphological alterations (secondary to
chronic PH). PD-123319-treated CDH
pups presented a significantly decrease
of right ventricular overload molecular
Figure 7. Indirect pulmonary hypertension assessment. (A) In upper panel are presented
representative examples of pulmonary arteries > 50 μm stained with Weigert resorcin
fuchsin solution of C + S, CDH + S and CDH + PD groups; in lower panel, representative
examples of small pulmonary vessels (<30 μm) for each group are presented. Original
magnification 400×. (B) Percentage medial area of pulmonary arteries of different exter-
nal diameters. (C) Percentage adventitial area of pulmonary arteries of different exter-
nal diameters. (D) Right ventricular levels of angiotensinogen, BNP and ET-1 mRNA in 
C + S, CDH + S and CDH + PD neonates, expressed in arbitrary units normalized for 
β-actin. PD-123319 treatment significantly decreased arterial medial area and these
overload markers on CDH pups. P < 0.001: *versus C + S, ‡versus CDH + S. , C + S; 
, CDH + S; , CDH + PD.
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markers and did not influence morpho-
logical markers. Therefore, PD-123319
maternal administration partially re-
versed pulmonary arterial structural ab-
normality that characterizes CDH and
decreased molecular markers of PH,
which suggest that PD-123319 might re-
duce pulmonary vascular reactivity, and
the risk of postnatal persistent PH ob-
served in CDH neonates.
Regarding other antenatal pharmaco-
logical strategies to decrease PH in
CDH, Luong et al. demonstrated recently
that antenatal sildenafil treatment (from
11.5 to 20.5 dpc, daily subcutaneous in-
jection) attenuates PH in experimental
CDH (3). In fact, that study demon-
strated that antenatal sildenafil treat-
ment improved lung structure, increased
pulmonary vessel density and reduced
right ventricular hypertrophy in CDH
(3). However, in opposition to PD-
123319 treatment, sildenafil had not pro-
moted lung growth, as demonstrated by
LW/BW, and consequently it did not in-
duce a recover of lung hypoplasia (3).
Moreover, it is necessary to stress that
the idea that there is PH in CDH, since
fetal period, is underlying to Luong’s
study (3). Nonetheless, it was already
demonstrated that there is vascular hy-
poplasia in nitrofen-induced CDH and
neonatal PH, but it is not yet proven the
presence of PH in CDH fetus (27,58,59).
Indeed, immediately after the birth,
Luong et al. demonstrated the presence
of right ventricular hypertrophy (an in-
direct signal of PH) in CDH neonates
(3). In the present study, CDH neonates
at 5 min after the birth did not present
increase of right ventricular hypertrophy
index or right ventricle thickness. How-
ever, CDH + S neonates presented an in-
crease of right ventricular overload
markers which reveals a molecular car-
diac repercussion. According to the liter-
ature, it was already demonstrated that
CDH vascular pulmonary alterations
only affect neonatal and not fetal hemo-
dynamics. Baptista et al. demonstrated
that CDH is associated with significant
molecular alterations secondary to PH,
but only in the right ventricle and after
birth (27). Moreover, also in fetal lamb
CDH model, it was demonstrated that
newborn CDH lambs had no differences
in right ventricular weight or right ven-
tricular wall thicknesses compared with
control lambs (60). Thus, despite the oc-
currence of pulmonary vascular modifi-
cations from early stages of prenatal de-
velopment, the present study also shows
that PH is only present after birth, likely
occurring secondary to vascular hy-
poplasia that characterizes CDH, and
also consequently to pulmonary vaso-
constriction, which is secondary to alve-
olar hypoplasia, hypoxia and acidosis.
So, antenatal PD-123319 treatment in-
terfered and improved the key determi-
nants of mortality associated with CDH,
namely lung hypoplasia and PH. Fur-
thermore, maternal PD-123319 adminis-
tration improved lung function, namely
pulmonary gas exchange, as demon-
strated by APGAR score, gasometric
Figure 8. Survival analysis. (A) Representa-
tive examples of cyanotic color of CDH + S
versus pink coloration of CDH + PD
neonates at 5 min of life. (B) Survival rates
(expressed as percentage of pups surviving
at each 5 min) of CDH + S and CDH + PD
neonates. Antenatal PD-123319 treatment
improved survival time in CDH pups (mean
survival time: CDH + S 30.3 ± 3.2 min; CDH +
PD 42.4 ± 1.3 min, P < 0.001). , CDH + S; 
, CDH + PD.
Table 2. Right ventricular hypertrophy evaluation 5 min after birth.a
Ratio of right/left ventricular weight Right ventricular wall thickness (μm)
C + S 0.49 ± 0.08 214.02 ± 9.29
CDH + S 0.44 ± 0.05 200.59 ± 4.27
CDH + PD 0.52 ± 0.05 220.31 ± 12.26
C, control; CDH, congenital diaphragmatic hernia; PD, PD-123319; S, saline.
aValues represent the mean ± SEM of measurements. P < .05: No significant difference
between experimental groups was observed.
Table 3. Neonatal blood gasometric evaluation 5 min after birth.a
pH PCO2 (mmHg) PO2 (mmHg) SatO2 (%) Lactate (mmol/L)
C + S 7.30 ± 0.03 22.69 ± 2.33 102.80 ± 7.78 93.60 ± 2.50 6.83 ± 0.39
N + S 6.94 ± 0.03b 38.49 ± 3.21b 62.50 ± 5.36b 67.25 ± 5.58b 8.50 ± 0.51b
CDH + S 6.92 ± 0.02b 51.05 ± 1.71bc 52.00 ± 6.06b 58.50 ± 7.06b 9.56 ± 0.57b
N + PD 7.18 ± 0.08c 23.62 ± 3.39c 95.67 ± 6.49c 90.83 ± 2.44c 6.88 ± 0.82c
CDH + PD 7.03 ± 0.04de 24.63 ± 5.83d 95.00 ± 8.20d 87.80 ± 3.65d 6.73 ± 0.70d
C, control; CDH, congenital diaphragmatic hernia; N, nitrofen; PD, PD-123319; PCO2, CO2
partial pressure; PO2, O2 partial pressure; S, saline; SatO2, O2 saturation. 
aValues represent the mean ± SEM of measurements.
bP < 0.05 versus C + S; cversus N + S; dversus CDH + S; eversus N + PD. There is a statistically
significant interaction between variables: disease–treatment for pH, PCO2, PO2 and SatO2.
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and survival evaluation. Regarding gas-
ometry it is necessary to stress that due
to low fetal blood volume, all blood
possibly collected by decapitation was
used for gasometric evaluation. So, gas-
ometry evaluated a mix of arterial and
venous blood. Nonetheless, antenatal
PD-123319 treatment allowed a statisti-
cal significant improvement of acidosis,
hypercapnia, hypoxia and lactate con-
centration that characterizes CDH fe-
tuses. The results of these direct indica-
tors of ventilation/perfusion matching
quality suggest an obvious improve-
ment of pulmonary gas exchange and
peripheral O2 delivery. Furthermore,
this enhancement on lung function had
important consequences on neonatal
survival, namely PD-123319 treatment
induced significantly longer average
survival time. However, it is necessary
to stress that the survival evaluation
was performed without neonatal care or
ventilatory support. This fact might be
the explanation for the death of all
neonates, despite the increase on lung
function and survival time induced by
antenatal PD-123319 treatment.
Regarding potential fetal adverse ef-
fects, the nitrofen-exposed pups pre-
sented decrease of HW/BW and
KW/BW ratios as previously docu-
mented (10,61–63). On the other hand,
PD-123319 beneficial effect seemed lung-
specific, since HW/BW and KW/BW ra-
tios of the pups were not altered. Con-
cerning potential maternal secondary
effects induced by PD-123319, no differ-
ences on heart, kidneys and lungs were
observed. The absence of maternal dele-
terious effects could be due to the fact of
AT2 receptor expression is dramatically
decreased after birth, being restricted to
a few organs (11,12,41). Indeed, an in-
crease of AT2 receptor expression during
adult life has been only observed under
pathological conditions (41).
CONCLUSION
In conclusion, this study demonstrated
the existence of a functional local RAS in
fetal lung. Moreover, it establishes AT2
receptor antagonist (PD-123319) as a pu-
tative antenatal therapy for pathologies
characterized by fetal lung hypoplasia,
such as CDH.
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Supplemental Data
Supplemental Figure 1. Protein expression pattern of renin-angiotensin system compo-
nents during early stages of fetal lung development. (A-D) Renin expression at 13.5, 15.5,
17.5 and 19.5 d post-conception (dpc), respectively. Renin protein expression appears to
be maximal in the branching buds. (E) ACE and (F) AT2 receptor expression in epithelial
cells at 13.5 dpc. Original magnification: x100 (B-D), x200 (A), x400 (E, F).
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Supplemental Figure 3. Heart, kidney and lung-to-body weight ratios in control and ex-
posed to nitrofen pregnant rats, treated with ( , C+S; , N+S) or PD-123319 ( , C+PD;
,N+PD). PD-123319 treatment did not significantly change heart, kidney or lung-to-
body weight ratios. Results are expressed as %.
Supplemental Table 1. Morphometric assessment of pulmonary arteries stained with
Weigert’s resorcin fuchsin solution.
Arteries examined 
per animal (n) ED (μm) ID (μm) MA(%) AA (%)
C+S 71.33±11.62 49.86±1.65 44.43±1.63 23.71±0.62 16.04±0.41
CDH+S 62.2±12.99 35.01±1.51* 27.75±1.49* 43.67±1.27* 30.27±0.87*
CDH+PD 70.33±9.60 34.69±1.34* 29.96±1.33*‡ 30.07±0.84*‡ 29.14±0.79*
AA: adventitial area; C: control; CDH: congenital diaphragmatic hernia; ED: external
diameter; ID: internal diameter; MA: medial area; PD: PD-123319; S: saline. Values
represent the mean ±SEM of measurements. p<0.001: *vs. C+S; ‡vs. CDH+S.
Supplemental Figure 2. Antenatal PD-123319 treatment effects on fetal heart and kidney.
Heart-to-body weight and kidney-to-body weight ratios in control (C), nitrofen (N) and
CDH groups treated with saline ( , C+S; , N+S; , CDH+S) or PD-123319 ( , C+PD;
, N+PD; , CDH+PD).The nitrofen treatment (nitrofen and CDH groups) induced de-
crease of heart and kidney-to-body weight ratios. Antenatal PD-123319 administration did
not significantly change either heart or kidney growth. Results are expressed as %. p<0.05:
* vs. C+S, ll vs. C+PD.
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Discussion 
Pulmonary development involves two distinctively regulated complex processes consisting 
of different cellular phenomena: early branching morphogenesis and late maturation processes 
[Warburton et al., 2005; McMurtry, 2002]. The branching morphogenesis or lung growth process 
occurs through fundamental cross-talk interactions between epithelial and mesenchymal tissues, 
involving a multitude of effectors [Warburton et al., 2005]. The knowledge of all effectors and 
regulators of lung development might be particularly useful envisioning therapy of lung diseases 
characterized by fetal lung hypoplasia as well as in modulation of lung repair. It is in this scientific 
context that this project comes out.
In this thesis, two new physiological regulators of fetal lung growth are proposed: inflammatory 
mediators and RAS. 
Preterm birth is associated with both acute and chronic intrauterine infection and inflam-
mation. Indeed, local uterine inflammation has been demonstrated in association with preterm 
delivery, and both chorioamnionitis and high amniotic fluid concentrations of pro-inflammatory 
cytokines are found among infants born before 30 weeks’ gestation [Murthy & Kennea, 2007; 
Kallapur & Jobe, 2006; Demayo et al., 2002]. Lung hypoplasia and immaturity and, conse-
quently, RDS and BPD, are one of the most important complications associated to prematurity 
[Murthy & Kennea, 2007]. Since inflammation is common in the lungs of the preterm newborns, 
complex interactions between inflammation and lung development are been explored. 
The fetal lung inflammation has been associated with decreased alveolar septation and mi-
crovascular development [Kallapur et al., 2004]. At molecular level, it has been demonstrated that 
TNF-α, which is abundantly expressed in the lungs of preterm neonates, negatively regulates TTF-1 
gene expression [Demayo et al., 2002; Ohmori et al., 1999]. Since TTF-1 controls lung develop-
ment by regulating target genes, the latter interactions may inevitably inhibit lung development, 
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cellular differentiation, and production of pulmonary surfactant. Furthermore, members of the 
TGF-β family of growth factors play vital roles in early embryogenesis. A significant correlation exists 
between lung TGF-β levels immediately following premature birth and adverse pulmonary outcome 
[Demayo et al., 2002; Lecart et al., 2000]. TGF-β inhibits epithelial cell proliferation and diffe-
rentiation, and lung morphogenesis in general. Moreover, inflammation activates the ubiquitous 
transcription factor NF-κβ, which mediates many of its biological effects. Induced perturbations 
in NF-κβ gene expression disrupt epithelial-mesenchymal interactions, repress BMP-4 and FGF-
10 expression and, consequently, induce abnormal lung morphogenesis [Demayo et al., 2002; 
Muraoka et al., 2000]. Thus, a tight operational and functional linkage between inflammation and 
lung development exist [Demayo et al., 2002]. Interestingly, injection of lipopolysaccharide into the 
amniotic fluid of fetal mice (at 15 dpc) induces toll-like receptor 4 (TLR4)-mediated inflammatory 
responses that alter airway fibronectin expression, potentially inhibiting distal-airway branching and 
alveolarization [Prince et al., 2005; Levy, 2007]. In addition, activation of TLR2 or TLR4 in the de-
veloping mouse lung inhibits the production of FGF-10 [Benjamin et al., 2007; Levy, 2007]. Overall, 
these observations provide examples of potential interactions between inflammatory mediators and 
normal morphogenetic pathways.
Regarding lung maturation, in opposition to deleterious effects on lung growth, several clinical 
and animal-based studies have suggested that antenatal exposure to inflammatory mediators may 
improve lung volume and compliance as well as accelerate fetal lung maturation [Jobe & Ikegami, 
2001; Jobe et al., 2000]. In fact, using different animal models, such as the rat, the rabbit or the 
sheep, it was shown that intra-amniotic injection of endotoxin or continuous administration of IL-
1α, IL-6 or IL-8 improved lung function by increasing expression of SPs [Moss et al., 2002; Kramer 
et al., 2002; Willet et al., 2002; Jobe & Ikegami, 2001; Bachurski et al., 2001; Jobe et al., 2000; 
Ikegami et al., 2000; Willet et al., 2000]. In human premature newborns, it was already proved 
that an increase of cytokines, namely IL-6, promotes lung maturation and decreases the incidence 
of RDS [Kallapur & Ikegami 2006; Jobe & Ikegami, 2001; Shimoya et al., 2000]. Moreover, the 
presence of funisitis has been associated with a decreased risk for the development of neonatal 
RDS in preterm gestations. This observation also suggests that the fetal involvement of placental 
inflammation may be beneficial to the fetal lung maturation [Lee et al., 2011]. Thus, several clinical 
and experimental studies validated the concept that fetal exposure to inflammation can have pro-
found effects on the lung and fetal responses vary depending on the severity of the inflammation 
[Kallapur & Jobe, 2006]. Nonetheless, several controversies involve this issue.
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IL-6, a multifunctional inflammatory cytokine, presented contradictory roles according to 
adult or fetal perspectives. Several adult pulmonary diseases, namely asthma, chronic obstruc-
tive pulmonary disease and non-small-cell lung cancer, implicate IL-6 in their pathophysiology 
[Doganci et al., 2005; Bhatia & Moochhala, 2004; Chung, 2001]. Regarding fetal lung deve-
lopment, previous reports focused IL-6 in maturation processes and in a pathological context 
[Willet et al., 2002; Kramer et al., 2002; Moss et al., 2002; Bachurski et al., 2001; Shimoya et 
al., 2000; Ikegami et al., 2000; Willet et al., 2000]. However, several studies have demonstra-
ted that IL-6 can also modulate lung growth. Indeed, it was demonstrated that IL6Rα is widely 
distributed in developing human fetuses including in bronchial epithelial cells, which suggest an 
IL-6 nonhematopoietic role in the developing fetus [Dame & Juul, 2000]. Moreover, McClintock 
& Wagner described that IL-6 plays an important modulatory role in lung angiogenesis, a funda-
mental process in fetal lung morphogenesis [McClintock & Wagner, 2005]. Furthermore, several 
studies have emphasized the importance of IL-6 signaling in several processes of branching 
organs, such as embryonic submandibular gland development, mammary gland remodeling, 
and benign and malign prostate growth [Culig et al., 2005; Zhao et al., 2004; Jobe & Ikegami, 
2001; Melnick et al., 2001; Jaskoll & Melnick, 1999].  In this context, we evaluated the role of 
IL-6 during fetal lung development (Chapter II). 
Our study demonstrated that IL-6 was constitutively expressed in primitive lung epithelium 
throughout gestation, displaying highest mRNA levels of expression during pseudoglandular sta-
ge. While previous studies on IL-6 and lung development emphasized maturational process, the 
highest expression of IL-6 on the early fetal lung development stages suggests that the physio-
logical role for IL-6 is most likely linked to branching. Thus, hypothesizing a role for endogenous 
epithelial expression of IL-6 during lung growth, functional studies were performed. Blocking IL-6 
significantly reduced branching and cellular proliferation rate in normal fetal lung explants, whe-
reas IL-6 supplementation induced a biphasic effect on branching and cellular proliferation rate, 
with increased effect at lower doses, while no additional effect was obtained with the highest 
dose. These IL-6’s effects were most likely mediated through p38 signaling pathway. Regarding 
the biphasic pattern of IL-6 effects on branching rate, it is interesting to stress that these results 
mimic the effect of intrauterine infection, which seems to protect very premature infants against 
RDS, while high quantities of pro-inflammatory cytokines cause serious disease [Hallman et al., 
2001]. In conclusion, this study suggested a physiological role for endogenous IL-6 on pulmona-
ry branching mechanisms. Interestingly, chorioamnionitis induces the production of IL-6, possi-
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bly providing a mechanism by which the innate immune system can hasten the development of 
respiratory function in the context of infection-induced preterm birth [Levy, 2007].
IL-6 belongs to the family of the gp130-type cytokines. This family comprises IL-6, LIF, IL-
11, OSM, CNTF, CT-1 and CLC [Heinrich et al., 2003; White & Stephens, 2011]. Recently, IL-27 
and NP had been also added to this cytokines family [White & Stephens, 2011]. These cytokines 
share the membrane glycoprotein gp130 as a common signal transducer which explains the fact 
that these show some functional redundancy, even though they also exhibit specific biological 
activities [Carbia-Nagashima & Arzt, 2004; Heinrich et al., 2003]. According to our results de-
monstrating that IL-6 is an important regulator of normal lung growth, it is possible that other 
inflammatory mediators, namely the other members of gp130 family of cytokines, are involved 
on normal lung development. Thus, we decided to clarify if the other gp130-type cytokines are 
important physiological regulators of fetal lung growth (Chapters III and IV).
LIF is a pleiotropic cytokine, that exists in both soluble and matrix-bound forms, and that binds to 
a heterodimer LIFRα/gp130 [Carbia-Nagashima & Arzt, 2004; Heinrich et al., 2003; Metcalf, 2003; 
Auernhammer & Melmed, 2000]. LIF was already largely studied and it was demonstrated that it 
regulates many cellular processes and displays several biological activities [De Breuck et al., 2006; 
McColm et al., 2006; Park et al., 2005; Kurdi et al., 2005; Metcalf, 2003; Kritikou et al., 2003; Wang 
et al., 2003; Sariola, 2002; Plisov et al., 2001; Auernhammer & Melmed, 2000]. Regarding the lung, 
numerous lung structural cell types express LIF and the LIFRα, suggesting previously unrecognized 
roles for this cytokine in lung biology [Knight, 2001; Knight et al., 1997; Knight et al., 1999]. It was 
already described that LIF, with IGF-I, regulates lung maturation. In fact, LIF/IGF-I double deficient 
embryos present lung hypoplasia and defective differentiation of the alveolar epithelium and vascu-
logenesis [Moreno-Barriuso et al., 2006; Pichel et al., 2003]. Our study demonstrated that LIF and 
its subtype receptor is constitutively expressed during lung development and that, in opposition to 
IL-6, LIF inhibits lung branching (Chapter III). These findings suggest that although cytokines of 
the gp130 family share a common signal transducer, there are specific biological activities for each 
cytokine on lung development. In fact, specific characteristics are emerging for each member of this 
family, brought about mainly through restricted temporal and spatial release, differential expression of 
cell surface receptors and different signaling patterns between gp130 homodimers and heterodimers 
[Knight, 2001]. Interestingly, LIF receptor is a gp130 heterodimer, whereas IL-6 receptor is a gp130 ho-
modimer. Thus, this raises the hypothesis that the effect, on lung development, of cytokine signaling 
through gp130 heterodimers might be different and even opposite to gp130 homodimers. 
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In this sequence, the other members of the gp130-type cytokines (IL-11, OSM) were also 
assessed (Chapter IV). In a similar way to IL-6, IL-11 acts in a gp130 homodimer receptor and it 
was demonstrated that stimulates lung branching. On the other hand, OSM receptors are gp130 
heterodimers and it was described that inhibit lung growth. All these results demonstrated that 
cytokine signaling through gp130 homodimers stimulate, whereas cytokine signaling through 
gp130 heterodimers inhibit lung branching. This specificity of gp130-type cytokines might repre-
sent a regulatory mechanism of lung morphogenesis, intrinsic to this family of cytokines, in order 
to achieve the correct lung growth. Moreover, regarding previous studies relating inflammation, 
lung maturation and incidence of RDS, it is well known that although intrauterine infection see-
ms to protect very premature infants against RDS, high quantities of pro-inflammatory cytokines 
cause serious disease [Hallman et al., 2001]. Therefore, our results arouse a new explanation 
for inflammation effects on lung growth and maturation. In this way, the beneficial effect of a 
mild inflammatory context and the deleterious effect of a severe inflammatory context on these 
processes might not rely on the dose-effect of each cytokine, but instead on the balance between 
agonists of homodimers vs. heterodimers receptors. These results bring a new field for further 
studies not only in normal lung development, but also in lung diseases and regeneration. 
As well known, lung is composed by two branched tree-like systems, the airways and the 
vessels, which development occur in a reciprocal coordinated way [Morrisey & Hogan, 2010; 
Shi et al., 2009]. In fact, developing pulmonary vasculature may not be passively accompanying 
the development of airways, as was previously believed, but it has an important regulatory role 
in airway branching morphogenesis in mammals [Tuder et al., 2009; Chinoy, 2002]. It was 
demonstrated that an anti-angiogenic factor, endothelial monocyte activating peptide II, also 
inhibits lung airway morphogenesis [Schwarz et al., 2000]. In a heart–lung culture model, the 
enhancement of pulmonary vasculature development was associated with improved airway de-
velopment [Zgleszewski et al., 1997]. Moreover, VEGF inhibition in neonatal rats leads to arrested 
alveolar development, suggesting that inhibition of vascular growth itself may directly impair lung 
development [Thébaud et al., 2005; van Tuyl et al.,2005; Compernolle et al., 2002; Jakkula et 
al., 2000; Healy et al., 2000; Gerber HP et al., 1999]. On the other hand, lung explants supple-
mentation with VEGF stimulated epithelial and vascular morphogenesis [Del Moral et al., 2006; 
Compernolle et al., 2002; Corne et al., 2002]. It was also demonstrated that ablation of lung 
epithelium impairs lung vascular cells development [Sarah et al., 2000]. Therefore, reciprocal 
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Figure 5. Overview of the two new physiological regulators of fetal lung development identified in the present dissertation: gp130 family of 
cytokines and lung RAS. Regarding the role of gp130 family of cytokines during fetal lung development, cytokines signaling through gp130 
homodimers (IL-6 and IL-11) stimulate fetal lung growth, whereas cytokines acting in a gp130 heterodimer receptor (LIF, CT-1, CNTF, CLC 
and OSM) inhibit lung growth. Furthermore, a local and physiologically active RAS was described during fetal lung morphogenesis. Renin, 
angiotensinogen and AT2 receptor are predominantly expressed on lung epithelium, whereas ACE is expressed in endothelial cells and AT1 
receptor in vascular smooth muscle cells. ANG II induces a stimulatory effect on lung branching, mediated by AT1 receptor, through p44/42 
and Akt phosphorylation. In opposition, ANG II acting in AT2 receptor inhibit lung branching, through decrease of p38 and JNK phosphorylation. 
Chapter VII DISCUSSION 155
interactions between airways and blood vessels are critical for normal lung development [Hislop, 
2002; Warburton et al., 2000; Kasahara et al., 2000).
Having in the mind the major aim of this thesis, the discovery of new physiological regulators of 
lung development, and after the elucidation of the role of gp130-type cytokines, epithelial media-
tors, looking for new vascular mediators emerged as the logical approach.
The RAS has been largely studied and it has important physiological roles. Classically, it is a 
major regulator of blood pressure, electrolyte and fluid homeostasis [Lavoie & Sigmund, 2003]. 
During the last decades, evidences have demonstrated the presence of a functional local RAS 
with autocrine/paracrine actions in a lot of organs or systems and with functions on develop-
ment of fetal kidney, heart, vasculature and adrenal development. In fact, local ANGII formation 
and its tissue-specific effects on growth and differentiation are thought to be extremely important 
for embryonic and fetal development [Paul et al., 2006]. Regarding lung morphogenesis, there 
is some evidence that lung expresses ACE as well as AT1 and AT2 receptors during fetal develop-
ment [Morrell et al., 1996; Shanmugam et al., 1996; Shanmugam et al., 1994]. Moreover, it is 
known that the maternal administration of ACE-I or ARA against hypertension, during gestation, 
induces several congenital anomalies, such as lung hypoplasia [Walfisch et al., 2011; Quan, 
2006; Cooper et al., 2006]. Motivated by these evidences, a possible role of RAS during fetal 
lung development was studied (Chapter VI)
Our study demonstrated that all RAS components (renin, ACE, angiotensinogen, AT1 and 
AT2 receptors) are constitutively expressed in the lung during gestation and that ANG II has an 
important stimulatory effect on lung branching, mediated by AT1 receptor, through p44/42 and 
Akt phosphorylation. These results allowed the description of a local and physiologically active 
RAS during fetal lung morphogenesis. Interestingly, an opposite effect of AT1 and AT2 receptors 
on lung growth, namely a stimulatory effect of AT1 and inhibitory effect of AT2, were described. 
This functional antagonism between AT1 and AT2 receptors, with respect to tissue growth, could 
be physiological interpreted as a basis of a RAS homeostasis at the tissue level.
The possible mechanism by which RAS interferes with the airway branching or pulmonary 
vascular development is still unclear and further investigation is required. However, given that 
in our study it was demonstrated that some components of RAS are expressed on epithelium 
and others on mesenchyme/vascular cells, it is possible that RAS is involved in both processes: 
airway and vasculature branching. Indeed, renin and its substrate angiotensinogen are mainly 
expressed in epithelial cells, while ACE that will produce ANG II is expressed in endothelial cells. 
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AT1 receptor is predominantly expressed by vascular smooth muscle cells, while AT2 receptor is 
expressed in bronchial epithelial cells. Thus, ANG II, the physiologically active peptide, could act 
on the airway and vasculature. Interestingly, excluding renin, all the other RAS components are 
expressed in vascular cells in the later gestational ages. This fact might represent a functional 
change of RAS near of the term.
Regarding the literature there are reports describing lung hypoplasia as a deleterious effect 
of ACE-I or ARA in pregnant women. Until this moment, the mechanism by which pulmonary 
hypoplasia develops is unknown, but may be related to compression of the fetal chest wall in 
the oligohydramniotic milieu with a restriction of fetal breathing movements [Quan, 2006]. Our 
study provides a new possible molecular explanation for fetal lung hypoplasia induced by ACE-I 
or ARA drugs, independent of amniotic fluid volume. ACE-I induce complete inhibition of ANG 
II synthesis and, as demonstrated by our results, ANG II increases lung growth. Regarding ARA 
drugs, these are AT1 receptor specific, and AT1 receptor mediates stimulation of lung growth. So, 
in this way, the fetal lung hypoplasia induced by ACE-I and ARA could be explained.
In figure 5 is schematically depicted the two new physiological regulators of lung develop-
ment described in the present work. 
We are conscious of the apparent absence of pulmonary defects in KO mice for gp130-type 
cytokines [Fasnacht & Müller, 2008; Carbia-Nagashima & Arzt, 2004; Nakashima, 1999; Betz 
et al., 1998] and RAS components [Paul et al., 2006; Stoll & Unger, 2001; Akishita et al., 1999; 
Kakinuma Y et al., 1997; Hein et al., 1995]. Despite, the KO approach bears intrinsic problems, 
since the ensuing phenotype may consist of compensatory events during development and later life 
[Stoll & Unger, 2001], we believe that gp130 family of cytokines and RAS contributes to branching 
morphogenesis, but most likely as a modulator. Thus, we propose that in lung growth there are 
morphogens, factors that plays a critical role in patterning the early branching events in lung deve-
lopment, such as FGF-10, TTF-1, SHH and BMP-4. Null mutant mice for these morphogens present 
a dramatic inhibition of bronchial branching [DeFelice et al., 2003; Sekine et al., 1999; Motoyama 
et al., 1998; Pepicelli et al., 1998; Bellusci et al., 1996; Peters et al., 1994]. The new physiological 
regulators now described are more modulator systems of the lung growth, but they are not the only 
modulators and other systems could have the same modulator function on lung growth. 
In last decades, the knowledge in science and medicine has evolved exceedingly. In clini-
cal practice, health indicators significantly improved. Nonetheless, pediatric and adult diseases 
characterized by lung hypoplasia or dysplasia are yet an epidemiological relevant issue, involving 
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important morbidity and mortality rates. For someone that has a medical and physiological 
formation and everyday performs functions as resident in Obstetrics and Gynecology, the develo-
pment of basic studies in fetal lung development, looking for its new regulators, has obviously a 
clinical rationale and aim:  try to contribute for the development of new therapeutic strategies for 
lung diseases. In this sequence, since long, the lab where this thesis was developed has focused 
research on the pathophysiology and development of potential prenatal therapeutics for CDH.
CDH is still a mysterious disease and a clinical huge challenge. Despite the extensive experi-
mental and clinical investigation in this disease as well as advances in neonatal care, in the most 
severely affected subset of CDH newborns, the prognosis remains poor, with a morbidity and mor-
tality rates that remains exceedingly high [Luong et al., 2011; Keller el al., 2010; van den Hout et 
al., 2009; Colvin et al., 2005; Gallot et al., 2005; Greer et al., 2003]. Thus, the actual consensus 
for the high-risk fetuses is that something needs to be done before birth.
Lung hypoplasia and persistent PH associated with this disorder are the key determinants of 
mortality [Luong et al., 2011; Keller el al., 2010; van den Hout et al., 2009]. Since prenatal therapy 
directed to cope with late mechanical determinants of lung hypoplasia (surgical approach) is appa-
rently unsuccessful, antenatal therapies aiming to promote fetal lung growth and/or modulation 
of PH remain an appealing approach. In this context, antenatal pharmacological treatment to sti-
mulate lung parenchyma and to treat PH are under investigation [Luong et al., 2011; Santos et al., 
2006; Baptista  et al., 2005; Thébaud et al., 1999]. In fact, it should be emphasized that even a 
small gain in total lung parenchyma might be determinant in providing a better adaptation of CDH 
fetuses to extra-uterine life. However, until the moment, none of the above strategies had resulted 
in significant clinical impact. Therefore, new therapeutic strategies are required and we believe that 
it is necessary to go and fro from the bed to bench side and to investigate the disease and new 
regulators of normal lung growth. Furthermore, it is necessary to stress that fetal lung hypoplasia 
and PH are common findings in other several conditions (such as oligoamnios, congenital cystic 
adenomatoid malformation, congenital heart disease, idiopathic pulmonary arterial hypertension, 
pulmonary capillary hemangiomatosis), which increase the relevance to develop new strategies 
that promote lung growth and treat PH. 
In this context, we assessed the role of the new physiological regulators of lung development 
described by us, gp130 family of cytokines and local lung RAS, in CDH (Chapters V and VI).
For that we used the nitrofen-induced CDH model that is one of the best to investigate the etio-
logy, pathogenesis and therapeutic options in CDH. In fact, the nitrofen model reasonably replicates 
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Figure 6. Proposed model for regulation of lung growth. This dissertation demonstrated that hypoplastic fetal lung has the intrinsic ability to 
regulate its growth in order to achieve the expected size. These observations suggest an intrinsic mechanism of lung growth regulation. We 
proposed that afferent pathways detect the lung size and send this information to lung size sensor. This sensor is able to modulate lung growth, 
stimulating or inhibiting efferent effectors that induce or inhibit lung growth. PNEC products and inflammatory mediators, namely IL-6, are 
upregulated in fetal hypoplastic lungs and we proposed them as possible effectors, responsible for inducing fetal lung compensatory response 
to growth retardation. The knowledge of mediators (afferent arms, sensor and efferent arms) involved on this hypothetic feedback mechanism 
during lung development is relevant, since this would open the possibility to modulate lung growth. 
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the major abnormalities (diaphragmatic defect, lung hypoplasia, PH, and cardiovascular and skeletal 
defects) and the pathophysiology described in human CDH [van Loenhout et al., 2009; Kling & 
Schnitzer, 2007; Migliazza et al., 1999a; Migliazza et al., 1999b; Tenbrinck et al., 1990].
An interesting point about CDH is the ability of hypoplastic lung to recover to normal size, 
when relieved from mechanical factors. In fact, clinical observations demonstrated that hypo-
plastic lungs from surviving CDH infants undergo a tremendous growth after post-natal diaphrag-
matic repair. Similarly, in the nitrofen-induced CDH rat model, it was already described that in 
fetuses exposed to nitrofen that did not develop diaphragmatic defect, fetal lung recovered from 
lung growth retardation throughout gestation [Correia-Pinto et al., 2003; Baptista et al., 2005]. 
Moreover, we also demonstrated that in vitro nitrofen-exposed fetal lungs are able to recover 
from hypoplasia (Chapter II). On the other hand, the catch-up growth is a classic infantile phe-
nomenon defined as growth acceleration beyond the normal rate [Kay’s & Hindmarsh, 2006; 
Gafni & Baron, 2000]. Based on this classical concept, we analyzed the daily branching rates of 
nitrofen-induced hypoplastic explants and we demonstrated that hypoplastic explants have the 
ability to grow in vitro at higher rates than control explants and, consequently, recover from early 
hypoplasia. Thus, this phenomenon of lung growth recovery with acceleration beyond the normal 
rate, after a transient period of growth inhibition, clearly resembles the phenomenon of height 
catch-up growth well-known in infants. Therefore, we demonstrated, for the first time, that fetal 
lung is able to recover from growth retardation through a way that resembles the catch-up growth 
phenomenon (Chapter V).
Envisioning prenatal therapeutic strategies that promote lung growth in CDH, the knowled-
ge of underlying mechanisms of this phenomenon might be particularly useful. Then, since we 
described that IL-6 is involved in lung morphogenesis and that this inflammatory mediator had 
already been involved in growth plate catch-up growth and in liver regeneration, we hypothesized 
that IL-6 might also have a role on intrinsic fetal lung catch-up growth. In fact, we showed that IL-6 
might be involved in the mechanisms underlying this phenomenon, since blocking of IL-6 activity 
significantly reduced the ability of nitrofen lung explants to recover from growth retardation.
An interesting point about lung ability to recover to normal growth relates to the fact that it 
also takes place in the in vitro scenario, out of systemic environment. This clearly suggests that 
lung growth is regulated by a local and intrinsic feedback mechanism. Interestingly, similar intrinsic 
mechanisms have also been attributed to growth plate to explain the body size catch-up growth 
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phenomenon [Gafni et al., 2001]. The knowledge of mediators (afferent arms, sensors, efferent 
arms) involved on this hypothetic feedback mechanism during lung development is relevant, since 
this would open the possibility to modulate lung growth. In this context, another remarkable obser-
vation of our studies is the fact that IL-6 mRNA and protein were over-expressed in fetal hypoplastic 
lungs. Interestingly, IL-6 over-expression accompanies the severity of lung hypoplasia. Also PNEC 
and its products, calcitonin gene-related peptide (CGRP), GRP, and ghrelin, have been reported to 
be increased in CDH [Santos et al., 2006; Dakhama et al., 2004; Emanuel et al., 1999; Ijsselstijn 
et al., 1997; IJsselstijn et al., 1995]. These PNEC products as well as IL-6 have mitogenic properties 
and promote lung growth. Thus, we propose that these upregulated molecules in hypoplastic lungs 
are biologically responsible for inducing fetal lung compensatory response to growth retardation. 
Therefore, these IL-6 overexpression and PNEC hyperfunction might be interpreted as the efferent 
actions, aiming to increase the mitogenic potential of CDH hypoplastic fetal lungs. Other questions 
remain to be clarified namely the afferent mediators and the sensors of lung hypoplasia as well 
as other efferent growth factors. In addition to these observations that clearly suggest an intrinsic 
mechanism of lung growth regulation, one can not rule out also an involvement of systemic loops. 
In fact, it remains unknown if IL-6 and neuroendocrine products over-expression is induced by local 
and/or systemic factors.
In figure 6 is depicted our proposed model for regulation of correct lung size and growth. 
Future studies aiming to clarify this regulatory loop and its mediators have clinical relevance for 
pathologies characterized either by lung hypoplasia or dysplasia.
Concerning new therapeutic targets and strategies that promote lung growth is necessary to 
remind that, in CDH fetuses, lung growth recovery of the affected side is limited by mechanical 
compression. On the other hand, the contra-lateral lung develops almost normally, it is not being 
compressed and, therefore, theoretically it has potential to develop compensatory overgrowth if the-
rapeutically stimulated. In this context, regarding the existence of a functional local RAS in fetal lung 
morphogenesis, our results demonstrated a significant stimulatory effect on lung growth mediated 
by ANG II and mimicked by the treatment with an AT2-antagonist (PD-123319). These results led us 
to hypothesize that AT2 could be an excellent new target (in opposition to maternal treatment with 
ANG II) for treatment of diseases characterized by fetal lung hypoplasia, such as CDH (Chapter 
VI). In fact, AT2 receptor is described to be expressed virtually only during fetal life [Paul et al., 
2006; Lavoie & Sigmund, 2003; Kaschina & Unger, 2003], which would annul potential maternal 
adverse effects. Indeed, an increase of AT2 receptor expression during adult life has been only 
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observed under pathological conditions [Kaschina & Unger, 2003]. Interestingly, activation of RAS, 
namely activation of AT1 receptor, was been related with development of pre-eclampsia [Zhou et al., 
2008]. So, hypothetically, the use of an AT2 receptor antagonist during pregnancy could activate 
preferably AT1 receptor and induce pre-eclampsia. However, it was recently described that angio-
tensin receptor binding was undetectable in normal and pre-eclamptic pregnant uterine placental 
bed. Thus, placental bed does not express AT2 receptor, which annuls a possible development of 
pre-eclampsia induced by AT2 receptor antagonist.
In the nitrofen-induced CDH model, in vivo antenatal AT2-antagonist (PD-123319) treat-
ment improved the key determinants of mortality associated with CDH, namely lung hypoplasia 
and PH. In CDH neonates, despite the presence of mechanical forces that compress lungs, 
AT2-antagonist increased lung growth by promoting distal lung development and, consequently, 
induced partial recovery of lung hypoplasia (a recover of 11.4%). The potential clinical relevance 
of this effect should be emphasized, since such an increase in lung parenchyma can be deter-
minant in providing a better adaptation of CDH fetus to extra-uterine life. Furthermore, maternal 
PD-123319 administration ameliorated indirect parameters of PH (pulmonary arterial structural 
abnormalities and molecular markers of PH), which suggest that PD-123319 might reduce pul-
monary vascular reactivity, and the risk of postnatal persistent PH observed in CDH neonates. 
Moreover, maternal PD-123319 administration improved lung function and survival time of CDH 
pups. Actually, the increase of lung growth enhanced pulmonary gas exchange and peripheral 
O2 delivery, as demonstrated by significant improvement of acidosis, hypercapnia, hypoxia and 
lactate concentration that characterizes CDH fetuses. Furthermore, this enhancement on lung 
function had important consequences on neonatal survival. Thus, the discovery of RAS as a new 
regulator of fetal lung growth allowed the establishment of AT2 receptor antagonist (PD-123319) 
as a putative antenatal therapy for pathologies characterized by fetal lung hypoplasia, such as 
CDH. These results open the perspectives for future pre-clinical studies.
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Conclusions
Having in the mind the aims of the present dissertation, namely the discovery of novel physiological 
regulators of lung development and their use as therapeutic targets for CDH, main achievements 
derived from this dissertation are listed below.
i. IL-6 is constitutively expressed in pulmonary epithelium throughout fetal lung develo-
pment, presenting highest levels of expression during pseudoglandular stage. Moreover, IL-6 
enhances fetal lung explants branching, most likely involving p38-MAPK intracellular pathway. 
Thus, endogenous IL-6 has a physiological role on pulmonary branching mechanisms.
ii. LIF and its subunit receptor LIFRα are constitutively expressed during fetal lung develop-
ment and they have an inhibitory physiological role on fetal lung branching.
iii. The effect, on lung development, of cytokines signaling through gp130 homodimers is oppo-
site to gp130 heterodimers. Indeed, cytokines signaling through gp130 homodimers (IL-6 and IL-11) 
stimulate lung branching, whereas cytokines acting in a gp130 heterodimer receptor (LIF and OSM) 
inhibit lung growth. This specificity of gp130-type cytokines might represent a regulatory mechanism 
of lung morphogenesis, intrinsic to this family of cytokines, in order to achieve the correct lung growth.
iv. We demonstrated that nitrofen-induced hypoplastic explants have the ability to grow in 
vitro at higher rates than control explants. Thus, hypoplastic fetal lungs are able to recover from 
growth retardation through a way that resembles the catch-up growth phenomenon, which sug-
gests the presence of an intrinsic mechanism of lung growth regulation. Moreover, we showed 
that IL-6 might be involved in the mechanisms underlying this phenomenon.
v. There is a local and physiologically active RAS during lung morphogenesis. In fact, all 
components of RAS (renin, ACE, angiotensinogen, AT1 and AT2 receptors) are constitutively ex-
pressed in the lung throughout gestation. Moreover, ANG II induces a stimulatory effect on lung 
branching, mediated by AT1 receptor, through p44/42 and Akt phosphorylation. 
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vi. The selective inhibition of AT2 receptor is a putative antenatal treatment for pathologies cha-
racterized by fetal lung hypoplasia, such as CDH. In fact, in nitrofen-induced CDH model, antenatal 
PD-123319 (an AT2 receptor antagonist) treatment increased neonatal lung growth, ameliorated 
indirect parameters of PH, improved lung function and survival, without maternal or fetal delete-
rious effects.
In summary, in this PhD thesis, according to the proposed aims, we have identified two novel 
physiological regulators of fetal lung development: gp130 family of cytokines and local lung RAS. 
Moreover, we demonstrated that fetal lung has the intrinsic ability to regulate its growth in order 
to achieve the expected size. Finally, we showed that selective inhibition of AT2 receptor is a puta-
tive antenatal therapy for pathologies characterized by lung hypoplasia, such as CDH. 
Regarding future perspectives, it is our perception that this thesis naturally leads to three 
fields of research:
i. The description of the role of gp130 family of cytokines on lung development, namely an 
opposite effect induced by homodimers and heterodimers receptors, arouse a new hypothetical 
explanation for inflammation effects on lung growth and maturation. The beneficial effect of a 
mild inflammatory context and the deleterious effect of a severe inflammatory context on these 
processes might not rely on the dose-effect of each cytokine, but instead on the balance between 
agonists of homodimers vs. heterodimers receptors. Thus, this hypothesis should be clarified 
not only in context of prematurity, but also in lung diseases, repair and fibrosis. The role of the 
most recently gp130 cytokines described, IL-27 and neuropoietin, needs also to be investigated. 
Moreover, a possible crosstalk between gp130 dependent family of cytokines and other cytokines 
with relevant roles on preterm birth (IL-1a, IL-8, TNF-a) should be elucidated. Furthermore, the 
study of the role of these other inflammatory mediators as lung growth regulators (and not only 
maturation regulators) might be important. Indeed, increasingly, to the classic inflammatory me-
diators have been assigned non-immune roles, namely developmental and morphogenetic roles. 
ii. As we demonstrated that fetal lung has the intrinsic ability to regulate its growth, we pro-
posed a model for regulation of correct lung size and growth. Nonetheless, future studies are ne-
cessary to clarify this regulatory loop and its mediators, namely the sensors of lung size, afferent 
mediators, other effectors (efferent mediators) and signaling pathways involved in compensatory 
growth. Moreover, the possible involvement of systemic loops needs to be investigated. 
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iii. The establishment of AT2 receptor antagonist (PD-123319) as a putative antenatal the-
rapy for pathologies characterized by fetal lung hypoplasia, such as CDH, open the perspectives 
for future pre-clinical studies.
 At this time, for someone who believes that basic research is the keystone for clinical re-
search and progression, which has technical laboratorial abilities and concern about congenital 
lung diseases, these fields of research would be the key of future investigation.
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